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This chapter introduces the concept of the adenosine receptor as a G protein-
coupled receptor. The therapeutic potential of the adenosine A1 receptor is 
highlighted and the investigated effects of the most well-known adenosine A1 
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General Introduction 
Communication within the mammalian body is essential for the regulation of all manner of 
different physiological functions. The exchange of information from the extracellular 
environment into the cell is often conducted by membrane receptors. The largest class of cell-
surface receptors are the Guanylyl-nucleotide-binding protein-coupled receptors, otherwise 
known as G protein-coupled receptors or GPCRs. The GPCRs are activated by a diverse 
assortment of ligands, including peptides, ions, photons and hormones,1 and is the largest 
group of current drug targets.2 This super-family of receptors consists of amino acid chains 
which are arranged into seven transmembrane (7TM) helices traversing the cell-membrane, 
linked by intra- and extracellular loops (Figure 1.1).  Upon activation of the receptor by the 
signalling molecule, the G protein binds and provokes a further signal through its association 
and subsequent dissociation from the receptor. The G protein itself consists of three subunits, 
α, β and γ. In the inactive state, the Gα subunit 
has guanosine diphosphate (GDP) in its binding 
site, when the receptor is activated, a change in 
the structure occurs causing GDP to leave and be 
replaced by its triphosphate cousin (GTP). The 
GTP activates Gα causing it to dissociate from 
Gβγ. The final effect of this cascade of events is 
conducted through the activation (or inactivation) 
of an effector protein, e.g., adenylate cyclase and 
phospholipase C.3  
The GPCR super-family of receptors can be classified into a number of different categories 
depending on similar structural features.4 The largest of these categories is Class A (also 
called Family 1) characterised by the conservation of certain amino acids.4,5 Individual 
examples of Class A receptors are the dopamine receptors, the serotonin receptors and the 
adenosine receptors.  
Adenosine Receptors 
The adenosine receptors, hence their name, are subject to activation by the endogenous ligand 
adenosine (Figure 1.2). In extracellular space adenosine is 
formed by the breakdown of adenosine triphosphate 
(ATP). In the body, adenosine has an extremely short half-
life (approximately 1 second)6 and is thus produced when 
and where it is deemed necessary, acting as a local 
hormone. There are four categories of adenosine receptor, 
the A1, A2A, A2B, and the A3.7,8 The nomenclature in 
current use is based on that proposed by Van Calker et 
al.,7 who defined the A1 receptor as being inhibitory to 
adenylate cyclase and the A2 receptor as consequently 
Figure 1.1 The seven transmembrane 





















Figure 1.2 Adenosine 
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stimulatory to this effector protein. Further categorisation of the A2 receptor was a result of 
experimental findings describing high and low affinity binding sites.9,10 The A3 adenosine 
receptor was discovered in a ‘reversed’ manner, where the receptor was first cloned and 
sequenced before its function and endogenous ligand were discovered.11 As molecular 
biological techniques evolved and improved in the early-to-mid 1990s, the receptors were 
individually cloned and identified for a number of species. The human adenosine A1 receptor 
was first characterised in 1992.12,13 It was revealed to have an amino acid sequence of 326 in 
length and hold a 95 % sequence homology to the rat, and 94 % to the dog and bovine A1 
receptors.12 As would be expected, the sequence homology between the different adenosine 
receptors is quite low, with only the A2A and the A2B receptors retaining more than 60% 
similarity (73% in the transmembrane domain).14 
The different adenosine receptors can be found distributed widely in varying levels 
throughout the physiological system,15,16 and for this reason, the effects of adenosine are so 
wide and varied. For example, high expression of the A1 receptor can be found in such tissue 
as the brain, the spinal cord and the atria; the A2A receptor is found in good levels of 
expression in the striatum, the spleen, blood platelets, and in the lung; the A2B receptors are 
present in fair quantities in tissue such as the bladder and colon, and the A3 receptors are 
expressed in somewhat lower levels in human liver and kidney tissues.15 Although higher 
levels of expression of certain receptors are found in certain organs, the presence of one 
particular receptor is not usually exclusive to that organ. As such, highly selective compounds 
targeted at specific receptors are very much desired. 
Having mentioned the almost omnipotent presence of adenosine receptors in the physiological 
system, the pharmaceutical benefits of compounds targeted at the receptors should be 
addressed. The two traditional divisions are the agonists and antagonists. Agonists are species 
that can activate a receptor in its natural state, and replace the need for the presence or 
generation of the endogenous ligand. Many adenosine receptor agonists have been developed, 
and most of these mimic the natural ligand closely in terms of structure. Traditionally, the 
presence of the purine ring and the necessity of the intact ribose moiety (Figure 1.2) allow 
agonistic properties to prevail, in conjunction, of course, with good affinity for the adenosine 
receptors. Very recently, agonists have been developed which do not mimic the natural 
ligand, in that they do not possess the purine ring structure, nor do they contain the ribose 
group.17-19 Partial agonism may be desired to overcome side-effects associated with the full 
agonism of receptors by highly potent compounds. Like most of the full agonists, most partial 
agonists are adenosine derivatives and created by either substitution at the purine or the sugar 
group.20-25  
Antagonists are compounds that occupy the receptor, preventing the binding and thus the 
action of the endogenous ligand. More recently, the theory that a receptor possesses an 
intrinsic level of activity has been researched. This has led to a new category of compounds, 
namely inverse agonists, ligands that lower the level of activity of the receptor. One example 
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is the well-known adenosine receptor ligand 1,3-dipropyl-8-cyclopentyl xanthine (DPCPX), 
this was long thought of as being a pure antagonist but it can in fact act as an inverse 
agonist.26 No doubt there are many more adenosine receptor ‘antagonists’ which could be 
reclassified as inverse agonists.  
The Therapeutic Potential of the Regulation of the Adenosine A1 Receptor 
The adenosine A1 receptor is, as mentioned in the previous section, widely distributed in 
varying levels of expression about many different tissues in the human body, ranging from the 
colon to the brain.15,16 The therapeutic potential of regulating this receptor is thus sizeable. 
The great expectancy laid upon such a therapeutically attractive target has generated a vast 
quantity of scientific literature dedicated specifically towards this receptor. Some of the more 
highlighted aspects that regulation of the adenosine A1 receptor induce are described below.27 
The high presence of adenosine A1 receptors in atrial tissue, suggests its cardiovascular role. 
To date, the only adenosine-related medicine available is adenosine itself. It is injected 
directly in cases of supraventricular tachycardia (abnormal heart rhythm) to return to normal 
sinus rhythm.28 Other functions that activation of the A1 receptor preclude are injuries caused 
by myocardial ischæmia (restriction of blood from the myocardium) and subsequent 
reperfusion (restoration of blood to an ischæmic area).29  
One very promising area of research has been the investigation into the use of A1 receptor 
antagonists in the treatment of renal disorders in congestive heart failure patients.30-33 Patients 
with congestive heart failure often have raised levels of adenosine in the kidneys. The 
activation of the A1 receptor in the kidneys mediates vasoconstriction, reducing the 
glomerular filtration rate (the rate at which the blood is filtered) and thus resulting in fluid 
retention in the patient.31 The use of antagonists thus blocks the effect of adenosine and has 
been shown to increase the urine flow, preventing renal failure.  
In the central nervous system (CNS), the activation of the A1 receptor leads to sedation, 
decreased locomotor activity, neuroprotection and anticonvulsant effects.34-36 Although the A1 
and A2A receptors are both present in the brain, the distribution of the two receptors is very 
different. The A1 receptors are found in almost all parts of the brain, with higher levels of 
expression present in the hippocampus and the cerebral cortex.37 The A2A receptors, in 
contrast, are located in greater quantities in more specific areas such as the striatum, where 
dopamine is readily produced.38  
The depth and levels of sleep were found to be dependent on the amount of adenosine present 
in the brain and it has become well accepted that the effects of adenosine are mediated 
through the A1 receptors,39 although some recent experiments indicate a role for the A2A 
receptors too.40 Adenosine and A1 agonists have been shown in in vitro models of cerebral 
ischæmia (reduced/inadequate blood flow in the brain) to reduce neuronal damage, providing 
perhaps hope of its use in such neurological conditions as Parkinson’s Disease and 
Huntington’s Disease.41 At peripheral and spinal sites, activation of the A1 receptor has also 
been shown to produce antinociceptive (painkilling) effects.42 In contrast, compounds that are 
Chapter 1 
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able to block the receptor from receiving its endogenous ligand in the CNS may be beneficial 
in terms of counteracting the sedation and negative locomotor effects. Antagonists have been 
found to induce cognition enhancement, leading to a general improvement in memory 
performance.34-36 This is potentially useful in the treatment of neurological disorders such as 
Alzheimer’s disease.  
Caffeine 
The potential of adenosine A1 receptor antagonists as neurological drugs explains the high 
interest in this type of compound. Undoubtedly the best known and archetypical example is 
caffeine. The official name of caffeine according to IUPAC convention is 1,3,7-trimethyl-3,7-
dihydropurine-2,6-dione and it is also known as trimethylxanthine (Figure 
1.3). It is the most widely consumed drug in the world and is found in many 
forms, from our daily beverages of tea, coffee, soft drinks, to food 
(chocolate) to formulations of over-the-counter painkillers and coldcures.40 
The average intake of caffeine from tea and coffee for certain regions in the 
world is displayed below. These statistics were calculated in the same 
manner as described by Fredholm et al.40 from data published by the UN for 
2002 (Table 1.1 and Figure 1.4). It is interesting to note that the average caffeine intake from 
coffee and tea sources in Europe, a non-tea and coffee producing region, is higher than any 
other world region. In Europe itself, the caffeine-intake, mostly from coffee, is greatest in 
northern Europe where filtered coffee rules the hot beverage kingdom. The extraction process 
and the coffee beans generally used means filtered coffee contains the greatest content of 
caffeine per mL.43 The ‘average’ caffeine content of a cup of coffee is often given as 100 mg 
implying that the ‘average’ coffee drinker in Finland, Sweden or the Netherlands consumes at 
least 5 cups of coffee a day, accounting somewhat for the non-coffee drinkers.  
At the levels of normal ingestion, the effects of caffeine are a result of its blockade of the 
adenosine receptors.44 The affinity of caffeine for the A2B and A3 receptors is not particularly 
high (Ki(hA2B) = 10.4 µM,45 Ki (rA3) > 10 µM)46 and moreover, the distribution of these two 
receptors in the CNS is low.15 Thus, although the affinity of caffeine for the A1 and A2A 
receptors is also relatively low (Ki(rA1) = 8.5 µM, Ki(rA2A) = 25 µM),45 the sheer levels of 
expression of these receptors in the brain mean that the well-known psychostimulant 
properties of caffeine are an effect of the antagonism of the adenosine A1 and A2A receptors.40 
The most well-known effect of caffeine is its power to banish sleepiness.47 It is also reputed to 
facilitate cognitive activity, learning, memory and attention span.48 
Derivatives of caffeine have been made in an attempt to improve the affinity for the individual 
receptors. However, despite achieving this, compounds based on the xanthine-structure (that 
caffeine possesses) have been beset by problems, including low solubility and thus bio-
availability, and also its ability to interact with other bodily processes, e.g., as an inhibitor of 
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Table 1.1 Caffeine intake from tea and coffee consumption in selected 
countries and continents in 2002. 
Statistics generated as described by Fredholm et al.: caffeine content of coffee taken as 1.6% and the extraction 
efficiency as 95%; caffeine content of tea taken as 3% and the extraction efficiency as 50%.40  Source data 























































Asia 3,775,948 1360 0.36 15 2061 0.55 22 37 
Africa 832,089 522 0.63 26 301 0.36 15 41 
Australasia 31,844 84 2.64 110 18 0.57 23 133 
Europe 727,019 2793 3.84 160 456 0.63 26 186 
N. & C. America 500,749 1615 3.23 134 168 0.34 14 148 
South America 357,329 565 1.58 66 860 2.41 99 165 
Belgium 10,296 44 4.27 178 1 0.10 4 182 
China 1,302,307 40 0.03 1 511 0.39 16 17 
Finland 5,197 57 10.97 457 1 0.19 8 465 
France 59,850 335 5.60 233 16 0.27 11 244 
Germany 82,414 539 6.54 272 26 0.32 13 285 
Italy 57,482 306 5.32 222 6 0.10 4 226 
Netherlands 16,067 142 8.84 368 19 1.18 49 417 
Norway 4,514 42 9.30 387 1 0.22 9 397 
Spain 40,977 169 4.12 172 3 0.07 3 175 
Sweden 8,867 87 9.81 409 2 0.23 9 418 
UK 58,287 143 2.45 102 134 2.30 94 197 

























































































The Scope and Content  
The previous sections have outlined the high therapeutic potential of compounds able to 
regulate the adenosine A1 receptor. There have been numerous non-xanthine ligands that have 
been synthesised as antagonists for the adenosine A1 receptor with varying levels of affinity 
and selectivity. The diversity of the compounds is quite astounding, but the application of 
such molecules for medicinal purposes is still lacking. The still relatively limited knowledge 
of GPCRs and thus the understanding of the active site of the A1 receptor in terms of size, 
shape and functionality, contributes to the lack of actual drugs. The potential therefore, for 
developing novel ligands specifically targeted at this receptor derived from new and different 
perspectives is still boundless. Thus, the focus of this thesis is the reassessment of the design 
and development of A1 receptor ligands with an eye to developing a new understanding of the 
adenosine A1 receptor. 
In the following chapters, the state of affairs is established with a review of the current 
literature and the subsequent development of several novel series of ligands for the adenosine 
A1 receptor is presented. The basis of this thesis was to generate a pharmacophore by studying 
computational models of some of the most highly effective ligands. Stemming from this, a 
novel series of compounds was synthesised and evaluated at the adenosine receptors. The 
capacity of adenosine receptor ligands as medicines targeted at the CNS requires the 
incorporation, or at least the consideration, of certain physical molecular characteristics. This 
is undertaken by taking into account the polar surface area of a compound. Using the initial 
pharmacophore, a further set of compounds conforming to the set limits was produced. 
Further refinement of the model was investigated resulting in a new perspective on a familiar 
ring system. Using the results from this refinement and from the initial two series, consistent 
sub-nanomolar affinity was produced in a following series. As a consequence of the very 
recent discovery that non-adenosine compounds could also be agonists of the adenosine 
receptor, a series of pyridine-3,5-dicarbonitriles with selectivity for the A1 receptor was 
investigated. This series of non-adenosine, non-xanthine ligands was shown to display both 
agonistic and antagonistic behaviour.  
A general discussion and a look to the future of adenosine receptor research follow, 
concluding this thesis. 
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Naturally occurring caffeine and theophylline are the most well-known adenosine 
receptor antagonists. These and other xanthine derivatives have enjoyed a long 
history of development and investigation into their structure and ability to bind to 
the adenosine A1 receptor. However, xanthine-derived compounds have a number 
of disadvantages and development issues, including the limited creative 
possibilities about such a rigid core. The scope of non-xanthine ligands as 
adenosine A1 receptor antagonists is much broader and also offers more 
possibilities for exploring and defining the active site of the receptor. This chapter 
systematically charts the considerable amount of research that has been performed 
into non-xanthine moieties over the past 25 years since the potential of regulating 
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2.1 The Design of Adenosine A1 Receptor Antagonists 
Significant and intensive scientific interest into the adenosine A1 receptor and its potential as 
a drug target seemed to be sparked a little more than two decades ago with the publication of 
a paper by Daly.1 This was the result of the field-defining publications by Londos et al.2 and 
Van Calker et al.3 at the end of the 1970s, and the recent search for adenosine receptor ligands 
by Bruns.4 At that stage, research into adenosine receptor antagonists only just proffered 
several non-selective xanthine derivatives, e.g., the naturally occurring compound caffeine 
(which has an affinity at the rat A1 receptor of 44 µM)5 and 8-phenyltheophylline with an IC50 
value of 1 µM in guinea pig brain.6 As for non-xanthine derivatives, no systematic study had 
yet been undertaken, although some research programmes had identified such compounds as 
etazolate (2.37) to be antagonists of the adenosine A1 receptors.7 
Since then, a whole host of compounds has been made and tested as antagonists of the 
adenosine A1 receptor. Many have been based on the well-documented xanthine-structure that 
accounts for compounds such as caffeine and theophylline. The associated problems of the 
xanthine-based compounds, as mentioned in Chapter 1 - poor selectivity over the other 
receptors (namely A2(A) in the early days), poor solubility and bio-availability encouraged the 
search for non-xanthine-like compounds. The early papers describe screening programmes to 
identify potential non-xanthine leads with some success.8,9 In the mid-1980s rationale was 
brought into the design process by focussing on the numerously available agonists and their 
behaviour towards the A1 receptor.10,11 This was followed by a flurry of papers in the late 
1980s when many of the larger parties in the pharmaceutical industry published their findings 
in SAR at the adenosine receptors.12-14 This also coincided appropriately with the growth of 
computational power (both in the availability of mass-marketed PCs and workstations, and in 
the computing capacity of these machines), to result in the first models of the A1 receptor.15,16 
A very good summary of these models was written by Poulsen and Quinn in 1998.17 
Developments in molecular modelling of the A1 receptor since the Poulsen and Quinn review 
include a 3-D model of the human A1 adenosine receptor by Biannucci et al. using a 
bacteriorhodopsin template.18 In this paper, the His 7.43 residue was proposed to be of great 
importance for agonist binding to the receptor, confirming earlier biological data.19 In a return 
to the ligand-based approach, Doytchinova and Petrova20 proposed a refinement of the ‘N6-
C8’ model as proposed by Peet et al. in 1990.21 The ‘N6-N7’ model suggested a slight shift in 
the superimposition of the xanthine and the agonist would give a better electrostatic and steric 
‘fit’.  
Rivkees et al. took into account results from mutagenesis experiments and created a model for 
the A1 receptor based on mammalian rhodopsin, and demonstrated the importance of TM 3 
and 7 for ligand binding.22 Since then, developments in the field of GPCRs have seen the 
structural determination of mammalian rhodopsin (the first and only detailed crystal structure 
of a GPCR to date).23 Incorporating the co-ordinates of rhodopsin, molecular modelling has, 
of late, been focussed on the protein, creating a binding site and docking known ligands at this 
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proposed structure. Unfortunately, although the adenosine receptors are categorised in the 
same class (Class A) of GPCRs as rhodopsin, the structural similarities are likely to be very 
limited, based on the function of the receptor, the (lack of) amino acid sequence homology, 
and the differences in the native ligand. Molecular modelling of the protein based on the 
rhodopsin template in the search of the agonist binding site, and the docking of agonists in 
proposed binding sites of models based on the rhodopsin template, must also be viewed with 
some candour due to the fact that the published structure details an inactive form of 
rhodopsin.  
More recently, Da Settimo et al. crossed both regions of molecular modelling in 2001.24 A 
series of ligands that was synthesised towards the benzodiazepine receptor was identified as 
being structurally similar to adenosine A1 receptor ligands and biological testing confirmed 
their affinity for the bovine A1 receptor. Analysing these ligands using molecular modelling 
techniques showed that they were superimposable with a number of existing adenosine A1 
receptor antagonists and a pharmacophore was developed. This pharmacophore identified 
three lipophilic regions, and three hydrogen-bonding domains. To rationalise the SARs of the 
ligands, a model of the bovine A1 adenosine receptor was built using frog rhodopsin as a 
template.  
Bondavalli et al.25 designed a series of pyrazolo[3,4-b]pyridine derivatives with good affinity 
and selectivity towards bovine A1 adenosine receptors. The resulting computational studies 
took eleven structurally different A1 antagonists from literature and derived a pharmacophoric 
model. For each conformer selected by the system an electrostatic picture was created and 
analysed. To confirm these results a second computational system was utilised and the 
resulting maps pointed to a pharmacophore that comprised of several main features deemed to 
be necessary for adenosine A1 receptor antagonists. The first was the presence of a hydrogen-
bond acceptor atom in the ligand to correspond with a donor site in the protein, the second 
alluded to two hydrophobic centres in the bi-cyclic planar nucleus of the antagonist, the next a 
third hydrophobic domain and lastly another hydrogen-bond acceptor site. The generation of a 
pseudoreceptor to match this phamacophore was performed by choosing appropriate amino 
acid residues from information derived from site-directed mutagenesis experiments, and the 
primary amino acid sequence of the rat A1 adenosine receptor. The results of this study were 
in agreement with the proposals by Da Settimo et al. although a slight disagreement in the 
size of one of the pockets of the receptor surfaced.  
The receptor was again investigated by Giordanetto et al.26 in 2003, and a model was built for 
the human A1 receptor based on the structure of bovine rhodopsin using a set of 22 agonists. 
The results of several site-directed mutagenesis studies were also taken into account, and the 
importance of the interactions of synthetic agonists with a number of amino acid residues was 
confirmed. The docking experiments highlighted the 2-chloro substituent on the purine ring as 
being especially beneficial for binding to the A1 receptor. In addition, substitution at the N6 
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was suggested to fit both TM 3-5 and TM 5-6-7 lipophilic domains, though more emphasis on 
the former pocket is vital for good binding affinity.  
Bovine rhodopsin was again the basis of a molecular model by Gutiérrez-de-Terán et al.,27 
focussing in particular at the A1 adenosine receptor and its agonist binding site. In this paper, 
the transmembrane region was the subject of focus, due to the very low homology between 
the human A1 adenosine loops and those of bovine rhodopsin. The docking of the natural 
ligand was performed by searching for a suitable polar binding site for the ribose moiety. The 
conclusions drawn from this study suggest that certain residues (Ser 1.46, Asp 2.50, His 7.43, 
and Ser 7.46) are important for receptor activation.  
One last area to mention, where very limited attention has been given in adenosine receptor 
research, is the field of pharmacognosy and phytotherapy. Despite the naturally occurring 
xanthine derivatives, caffeine and theophylline, which can be found in good quantities in our 
daily beverages, there is just a handful of papers focussing on products derived from natural 
sources.28-30 The active components described in these papers are essentially very different 
from the (chemically) ‘designed’ ligands. They are generally structures without nitrogen 
atoms (see Section 2.3.2.2) and as such offer the possibility of a much more varied and 
expansive library of non-xanthine adenosine receptor antagonists. The first and most 
interesting compound discussed in this category was isolated from a traditional Chinese 
medicine which had been widely used in the treatment of acute myocardiac infarction and 
angina.30 The surprisingly high affinity (10 nM at human A1 receptors) for a compound 
possessing very different characteristics from the traditional non-xanthine ligand is an 
indication of the variety and diversity available in the ‘natural’ world.  
A variety of phytochemicals, amongst which the flavonoids featured, was the focus of a 
screening programme in 1996.28 Flavonoids are natural products that are in large abundance 
in fruit and vegetable matter and have reputed biological properties in all manner of different 
medical needs, from hypertension and diabetes to allergies and cancers.31 The most active 
compounds (e.g., 2.76) at the adenosine receptors were unfortunately only in the sub-
micromolar range, but further optimisation or derivatisation may provide a more selective and 
active compound.  
As a result of the early screening programmes, the computational investigations, molecular 
biological techniques and the pure intuitiveness of medicinal chemists, the vast selection of 
differing structural types of adenosine A1 receptor antagonist is bewildering. This assortment 
of compounds has been in the past reviewed a little haphazardly according to the latest 
developments as new types of ligands have been made and tested. In this examination, these 
compounds are categorised according to the size and type of their central structure. Although 
there are very many solitary structures that have been shown to have some moderate affinity 
(usually in the µM range), especially from the screening programmes, only those compounds 
that have been taken on and developed with clear structure-activity relationships are discussed 
in detail in this review. There are also very many compounds that have been developed in 
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industry. Many of these have only been published in patent literature, and as is common in 
patents, structure-activity relationships and full biological data are scarcely available. As 
such, this review is based upon only standard scientific literature. Relevant compounds from 
the patents, which have some biological data or have outstandingly novel structures, will be 
mentioned briefly. This discussion splits the published material into three sections depending 
on the size of the heteroaromatic core of the compounds, i.e., into mono-, bi-, and tri-cyclic 
(fused) heteroaromatic systems. We begin logically with the mono-cyclic heteroaromatic 
cores and continue in an increasing order of magnitude, attempting to show how each series 
was developed historically as more information became available. Early papers test new 
compounds at the A1 and what were then known as the A2 receptors from a variety of different 
species, including dog, sheep, bovine and rat, the latter being the most common. As 
pharmacology and molecular biology developed and the (human) A2A and A3 receptors were 
identified and made available, these receptors were tested too. The A2B receptor is still an 
exception in the field; the low affinity nature of the receptor accounts for the lack of good 
selective ligands and thus, the only recent, existence of appropriate radioligands (e.g., 
[3H]MRS 175432 and [3H]MRE 2029-F2033) still excludes its broad assessment in 
conventional procedures. In the tables, the most recent data is given and selectivity ratios are 
shown where appropriate. 
2.2. Mono-cyclic Heteroaromatic Rings (Non-Fused Rings) 
Mono-cyclic heteroaromatic rings are relatively rarely found in adenosine A1 receptor 
antagonism. In fact, recent reviews by Hess34 and by Müller35,36 state quite clearly that the 
different structural classes for A1 adenosine receptor antagonists are bi- and tri-cyclic 
heterocyclic compounds. The few classes of compounds in this category consist of a bare 
handful of papers. Mono-cycles were amongst a variety of different compounds screened 
early on in adenosine receptor research, in the paper by Davies et al.9 The few compounds 
that could be classed as pyridine, pyrazole, or pyrimidine showed no favourable effects as 
adenosine receptor antagonists. In 1985, a selection of barbiturates (pyrimidine-2,4,6-triones) 
were investigated at the A1 adenosine receptor37 and although reportedly selective antagonists 
of the A1 receptor they only showed affinity in the micromolar range. A screening by Siddiqi 
et al.38 showed two pyridine derivatives to have micromolar affinity at the A1 receptor with 
slightly more affinity for the A3 receptor. In 1997 Biagi et al.39 compared analogous 
pyrimidines to their 8-azaadenine series and found them to be of much lower activity, and 
thus concluded that the bi-cyclic aromatic system was necessary for good affinity at the 
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More recently, an investigation by Van Muilwijk-Koezen et al. highlighted the general low 
affinity of mono-cyclic compounds.40 The exceptions to this were two 5-membered 
heterocycles, namely thiazoles and thiadiazoles (Figure 2.1), which were modified to give 
compounds with affinities in the lower nM range (Table 2.1, compounds 2.1-2.8) at the A1 
receptor with reasonable selectivity.40,41 A phenyl group was placed at the 3-position of the 
thiadiazole in consequence to previously investigated quinolines and quinazolines,42 and at 
the 5-position a substituted amido-group was present. Variation of this amido- function 
resulted in some very potent compounds. The phenyl-substituted compound 2.1 was an 
encouraging lead with an affinity at the A1 receptor of 31 nM and a degree of selectivity over 
the A2A and A3 receptors. Further substitution of this phenyl group resulted in the discovery of 
the 4-hydroxy moiety (2.2), which showed a gain in affinity over the unsubstituted phenyl 
group at 7 nM though with a slight loss in selectivity. To assess the interaction of the 4-
hydroxy substituent with the receptor, cis- and trans- 4-hydroxy-cyclohexyl derivatives were 
tested. Interestingly, the trans- substituent (2.5) showed a better (2-fold) level of affinity 
compared to the cis- analogue (2.4). These 4-hydroxycyclohexyl analogues were less potent 
than their 4-hydroxyphenyl counterpart, but this was matched by a gain in selectivity for the 
A1 receptor over both the A2A and A3 receptors.  






Ki [nM a)] 
Compound X R R1 
A1 A2A A3 
A2A/A1 A3/A1 Ref. 
2.1 N Ph Ph 31a) 4400b) 410c) 142 13 [40] 
2.2 N 4-HOPh Ph 7a) 570b) 130c) 81 19 [40] 
2.3 N cC6H11 Ph 1400a) >10000b) 16000c) >7 11 [40] 
2.4 N cis-HO-cC6H10 Ph 42a) >10000b) 2700c) >238 64 [40] 
2.5 N transHO-cC6H10 Ph 20a) >10000b) 1900c) >500 95 [40] 
2.6 CH Ph 2-Py 1700a) 8700b) 3400c) 5 2 [40] 
2.7 CH Ph Ph 39a) >10000b) >1000c) >256 >26 [41] 
2.8 CH 4-ClPh Ph 18a) >10000b) >1000c) >556 >56 [41] 
a)Displacement of specific [3H]DPCPX binding in rat brain cortical membranes. b)Displacement of specific 
[3H]ZM 241385 binding in rat striatal membranes. c)Displacement of specific [125I]AB-MECA binding in HEK 
293 cell membranes expressing the human adenosine A3 receptor. 
At the thiazoles,41 a similar substitution pattern was executed, aromatic substitution next to 
the nitrogen ring (in the 4-position) and amido-substitution between the sulfur and nitrogen 
atoms (the 2-position) (Figure 2.1). A 2-pyridyl group as the aromatic moiety in the 4-position 
was an attempt to provide a hydrogen-bond donor at a similar position to the N-2 moiety of 
the thiadiazoles (2.6). The poor results in comparison to the analogous phenyl-thiadiazole 










unsubstituted phenyl moiety of the thiazole (2.7) however, was much more promising with a 
Ki value of 39 nM at the A1 receptor. Further variation at the 5-amido-group resulted in a 2-
fold increase in affinity at the A1 receptor with a 4-chlorophenyl moiety (2.8), retaining 
selectivity for the A1 receptor.  
There are several publications to note in patent literature, which also deal with mono-cyclic 
(non-fused) heteroaromatics. Although these compounds have very little biological data 
present and specific A1 receptor antagonism is often not mentioned, the core heterocycles are 
as follows (Figure 2.2): pyrazole derivatives (2.9) have been claimed by Eisai;43 pyrimidines 
(2.10) by Fujisawa;44,45 Boehringer Ingelheim  has a series of triazine derivatives (2.11) under 
patent,46 and Novartis has laid claims on a diaryl thiazole core (2.12)47,48 although the latter 









Figure 2.2 Mono-cyclic compounds under patent: pyrazoles (2.9), pyrimidines (2.10), triazines (2.11) 
and thiazoles (2.12). 
2.3. Fused Bi-cyclic Heteroaromatic Systems 
2.3.1 The 6:5 Fused Nitrogen-Containing Heteroaromatic Systems 
The 6:5 fused nitrogen-containing heteroaromatic compounds make up by far the largest 
group of published non-xanthine adenosine A1 receptor antagonists. In this section the core 
bi-cyclic compounds are discussed in ascending order with respect to the number of nitrogens 
in the core structure.  
2.3.1.1 The 6:5 Fused Heteroaromatic Systems Possessing Two Nitrogen Atoms 
Pyrazolo[1,5-a]pyridines (2.13-2.24), imidazo[1,2-a]pyridines (2.25) and benzimidazoles 
(2.26) (Figure 2.3) make up the compounds of this category of nitrogen heteroaromatics. By 
far the most investigated core structure of this class is the pyrazolo[1,5-a]pyridine with a 
number of publications  from 1996 to 2001 by the Japanese pharmaceutical concern Fujisawa, 
detailing the medicinal chemistry of variously substituted compounds.49-53 The papers 
describe substitution at the 3-position. Modification at the core, namely at the pyridine ring, 
creating pyrazolo-pyrimidines and pyrazolo-quinolines, and some variation at the 2-position 
has also been reported in patent literature, although with little biological data.54,55 
FK 453 (Figure 2.4, Table 2.2, 2.13) was one of the most promising of the earlier 
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position and the α,β-unsaturated amide motif at the 3-position. Following SAR studies and 
crystal structural determination of this compound, it was determined that the acryloyl moiety, 
adopting a cis form (the positioning of the carbonyl bond with respect to the double bond (as 






Figure 2.3 The 6:5 Fused Bi-cyclics Possessing Two Nitrogen Atoms: Pyrazolo[1,5-a]pyridines (2.13-
2.24); imidazo[1,2-a]pyridines (2.25) ; benzimidazoles (2.26). 
It was reasoned that replacement of this group with rigid heteroaromatics would retain the 
affinity of FK 453 whilst preventing isomerisation of the double bond. This led to the 
discovery of a highly potent 2-substituted 3-oxo-2,3-dihydropyridazin-6-yl group (which 
incidentally was a fragment of one of the compounds screened by Siddiqi et al. in 1996 that 
showed some affinity for the adenosine receptors)38 (Figure 2.4, 2.14-2.24). Subsequently, 
variation at the 2-position of the pyridazinyl group with a number of different functional 
hydrophilic features resulted in improved affinity and selectivity for the A1 receptor over the 
A2A receptor. In Table 2.2 a selection of ligands with varying substitution is shown with their 
determined affinities. Although the initial lead compound FK 453 already showed good 
affinity coupled with a good selectivity over the A2 receptor, there were vast improvements 










Figure 2.4. FK 453 (2.13); 3-(2-substituted-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-
a]pyridines (2.14-2.24). 
Substitution with a carboxylic acid group (FK 838, 2.14)50 reduced the affinity for the A1 
receptor, and also increased the affinity for the A2A receptor significantly. Further 
manipulation of the dihydropyridazinyl moiety with (2-substituted) cyclohexene derivatives 
(2.15-2.19) was in consequence to the six-membered (2-substituted) piperidine of FK 453. 
The differing functional groups all performed particularly well in the A1 receptor binding 































a)IC50 - Inhibition of [3H]CHA specific binding to rat cortical membranes. b)IC50 - Inhibition of [3H]NECA 
specific binding to rat striatal membranes. c)Ki - Inhibition of specific [3H]DPCPX binding in CHO cell 
membranes expressing the human adenosine A1 receptor. d)Ki - Inhibition of specific [3H]CGS 21680 binding in 
CHO cell membranes expressing the human adenosine A2A receptor. 
The carboxylic acid derivatives, which to some extent combine features from both FK 453 
and FK 838 performed slightly worse in terms of affinity (2.18), or in terms of selectivity over 
the A2A receptor (2.19). However, in the search of ‘better’ physical properties, compound 2.18 
showed more than a 20-fold improvement in the water-solubility compared to FK 838 (2.14). 
The last paper of the series details a number of functional groups attached with methylene 
spacers to the dihydropyridazinyl group. They all show remarkably high affinity for the A1 
receptor (2.20-2.22), indeed three out of the four shown here have subnanomolar affinity, with 
compound 2.20 being the most potent. Considering the therapeutic target of adenosine A1 
receptor antagonists, these compounds were also investigated for their ability to permeate 
brain tissue after oral administration. It was concluded that amino substitution (2.22-2.24) was 
most beneficial for blood-brain barrier permeation and compound 2.24 in particular showed 






2.13 (FK 453) - - - 17a) 11000b) 650 [52] 
2.14 (FK 838) (CH2)3CO2H 
 













CONMe2 - 2a) 530b) 310 [52] 
2.18 (FR166124)  
 
 






- 4a) 100b) 25 [51] 
2.20 CH2COR1 iPr - 0.03c) 140d) 4700 [53] 
2.21 CH2CR1R2OH Me Me 0.4c) 160d) 400 [53] 
2.22 CH2CONHR1 iPr - 0.3c) 490d) 1600 [53] 
2.23 (CH2)2NR1 -(CH2)5- - 2c) >1000d) >400 [53] 
2.24  
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favourable properties leading to its nomination for further pharmacological evaluations. 
Imidazopyridines (2.25) and benzimidazoles (2.26) (Figure 2.3) have only been described in 
patent literature.57,58 Along with the reported selective adenosine A1 antagonistic properties, 
the imidazopyridines are described as being p38 inhibitors useful in the treatment of 
inflammatory diseases (2.25).57 An interesting feature to note is the presence of the  
2-substituted 3-oxo-2,3-dihydropyridazin-6-yl motif seen in an analogous position to that of 
the pyrazolopyridines described by Fujisawa. The limited biological data describes efficacy at 
less than 0.01 µM, with  functional antagonism in an IC50  range of 1-100 nM. In  addition,  the 
selectivity over A2A was 500 fold, and >1000-fold over A2B and A3. The benzimidazoles 
alluded to are covered by an earlier Japanese patent issued to Toa Eiyoo KK in 1998.58 In this 
patent the compounds are said to be A1 selective with the best in the region of 10 nM. 
2.3.1.2 The 6:5 Fused Heteroaromatic Systems Possessing Three Nitrogen Atoms 
The bi-cyclic cores containing three nitrogen atoms can be divided into three main categories, 
namely the 7H-pyrrolo[2,3-d]pyrimidines (also known as the 7-deazapurines),59-63 the 5-H-
pyrrolo[3,2-d]pyrimidines, and the 1H-pyrazolo[3,4-b]pyridines (Figure 2.5). Amino 
substitution at the 4-position of the first category, the 7-deazapurines, renders further 
classification of this series to 7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, also known as the 7-
deazaadenines. It is this series of compounds that have been most widely explored of the bi-
cyclics with three N-atoms with publications on this topic spanning more than a decade 
(Table 2.3). Daly et al. published the first biological results from this series, and showed 





Figure 2.5 The 6:5 Fused Bi-cyclics Possessing Three Nitrogen Atoms: 7H-pyrrolo[2,3-d]pyrimidines 
(also known as the 7-deazapurines) (2.27-2.34) ; 5H-pyrrolo[3,2-d]pyrimidines (2.36); 1H-
pyrazolo[3,4-b]pyridines (2.37-2.43). 
paper was the importance of the phenyl group in the 7-position of the ring. Further 
investigations of the 7-phenylpyrrolo[2,3-d]pyrimidin-4-ylamines revealed that a phenyl 
group in the 2-position was also beneficial (2.29).60 Modifying the 7-phenyl group to a chiral 
moiety showed that the (R)-enantiomer (2.30) was much preferred to the (S) (2.31).60 
Incorporating these features also improved the selectivity for A1 receptors over the A2(A) 
receptors dramatically. Synthetic ease dictated the presence of a dimethyl substitution at 
positions 5 and 6, but the only compound evaluated without this di-substitution pattern 
showed considerable benefits with an almost 6-fold increase in affinity at the A1 receptor to 
its analogous dimethyl substituted equivalent (2.27 vs. 2.28). Changing the position of the 





















did not change the affinity for the A1 receptor significantly, but did improve selectivity 
dramatically (2.32). Campbell et al.62 synthesised a library set of pyrrolo[2,3-d]pyrimidines 
which included the most significant features as described previously by Müller et al.,60 
varying only at the exocyclic N. The findings here were tested at the human adenosine 
receptors and showed compounds in the nanomolar range, although with a loss in selectivity 
(2.33). In the most recent publication in the series the phenyl group was varied at position 2- 
of the pyrrolopyrimidine ring for different heterocycles, e.g., the 2-, 3-, or 4-pyridyl, 2-thienyl 
and 2-furyl.63 Of these, the substitution which retained the highest affinity was the 4-pyridyl 
species (2.34).     










2.27 H H H H Ph 3100a) 17000b) 5 [59] 
2.28 H H Me Me Ph 18000a) 123000b) 7 [60] 
2.29 Ph H Me Me Ph 36a) 14000b) 400 [60] 
2.30 Ph H Me Me (R)- MeCHPh 5a) 3700b) 740 [60] 
2.31 Ph H Me Me (S)- MeCHPh 165a) 80000b) 490 [60] 
2.32 Ph  (R)-MeCHPh Me Me H 7a) >30000b) >4300 [61] 
2.33 Ph -CH2CH2-NHAc Me Me H 12c) 23d) 2 [62] 
2.34 4-Py H Me Me (R)- MeCHPh 9e) 1300f) 140 [63] 
a)Inhibition of [3H]PIA specific binding to rat cortical membranes. b)Inhibition of [3H]NECA specific binding 
to rat striatal membranes. c)Inhibition of [3H]DPCPX in yeast cells transformed with human A1 receptor. 
d)Inhibition of [3H]CGS 21680 in membranes from HEK293 cells stably expressing the human A2A receptor. 
e)Inhibition of [3H]CCPA in human recombinant A1 adenosine receptors expressed in CHO cells. f)Inhibition of 
[3H]CGS 21680 specific binding in rat striatal membranes. 
The 5H-pyrrolo[3,2-d]pyrimidines64 (Figure 2.5) mentioned here are not strictly 
pyrrolopyrimidines, but are actually pyrrolopyrimidine diones. They are xanthine derivatives, 
and are also otherwise known as 7-deazaxanthines (Table 2.4). Similarly, 9-deazaxanthines 
(2,4-dione variations of the 7H-pyrrolo[2,3-d]pyrimidines) have also been made and tested for 
A1 receptor affinity. The obvious resemblance with the xanthine template affords the logical 
development of these two series and because of their status as xanthine derivatives only the 
affinity of the two most promising compounds of each series are shown here. The  
7-deazaxanthine derivative (2.35) has no great affinity for the A1 receptor with a Ki value in 
the µM range, whilst the 9-deazaxanthine compound (2.36) shows considerable improvement 
with an affinity of 13 nM and 35-fold selectivity for the A1 receptor over the A2A receptor 
(although the lengthening of the alkyl groups at the 1- and 3- positions may also influence the 
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            Ki [nM] Ref. 
 
R1 R2 R3 R4 R5 
 rA1 rA2 
A2A/A1 
 
2.35      7-deazaxanthine Me Me H Ph H 3100a) 12000b) 4 [64] 
2.36      9-deazaxanthine Pr Pr H Ph H 13a) 450b) 35 [64] 
a)Inhibition of [3H]R-PIA specific binding in rat brain cortex. b)Inhibition of [3H]NECA specific binding in rat 
striatum.    
The last class of tri-nitrogen bi-cyclic derivatives discussed here are the 1H-pyrazolo[3,4-b]-
pyridines (Figure 2.5). They were first mentioned in connection to the adenosine receptors as 
early as 1981 in the guise of the putative anxiolytic agents etazolate, cartazolate and 
tracazolate (2.37-2.39, Table 2.5).7,65 Development of these compounds by Shi et al. 
exploring mostly substitution at the exocyclic amine resulted in only just sub-micromolar 
affinity towards the A1 receptor (2.40), although selectivity was improved somewhat.65 New 
developments at the exocyclic amine and some further variation at the 1-and 6-positions have 
been detailed only recently by Schenone et al.66,67 and Bondavalli et al.,25 and offer 
improvements on the previously reported pyrrolopyridines. 






    Ki  [nM]  R1 R2 R3 
A1 A2A A3 
A2A/A1 Ref. 
2.37    etazolate H N=CMe2 Me 3400a) 1200b) - 0.4 [65] 
2.38   cartazolate H Bu Et 460a) 1400b) - 3 [65] 
2.39   tracazolate Et Bu Et 710a) 1500b) - 2 [65] 
2.40 H cC5H9 Me 310a) 5300b) - 17 [65] 
2.41 H Pr CH2CH(Cl)Ph 100c) >10000d) >10000e) >100 [66] 
2.42 H 1-pyrrolidinyl CH2CH(Cl)Ph 98c) >10000d) >10000e) >100 [66] 
2.43 H -CH2CH2Ph CH2CH(Cl)Ph 50c) >10000d) >10000e) >200 [66] 
a)Inhibition of specific [3H]CHA binding to rat cerebral cortical membranes. b)Inhibition of specific [3H]CGS 
21680 binding in rat striatal membranes. c)Displacement of specific [3H]CHA binding in bovine cortical 
membranes. d)Displacement of specific [3H]CGS 21680 binding in bovine striatal membranes. e)Displacement of 































At the 1-position, a styryl moiety and a chlorophenyl substituent were attempted, of these 
only the derivatives possessing the chlorophenylethyl substituent gave a positive result.25 
Although no mention of its reactivity is made, this relatively free and reactive halide may 
possibly react with the receptor (or other materials present in the system) rather than mere 
covalent interaction with the receptor.  At the exocyclic amine, a wider range of substitutions 
were acceptable, e.g, Pr (2.41), pyrrolidinyl (2.42), and 2-phenylethyl (2.43).66,67 Though 
these compounds are fairly well tolerated at the A1 receptor, no affinity is seen at either the 
A2A or the A3 receptors. Substitution at the 6-position with a methylthio-group in analogy to 
already published material on the pyrazolo[3,4-d]pyrimidines (Section 2.3.1.3) did not lead to 
improvements in affinity.67  
2.3.1.3 The 6:5 Fused Heteroaromatic Systems Possessing Four Nitrogen Atoms 
The three main categories of the four-nitrogen bi-cyclic rings are 9H-purine, 8,8a-Dihydro-
imidazo[1,2-a][1,3,5]triazine, and 1H-pyrazolo[3,4-d]pyrimidine (Figure 2.6). 
We begin with the series that holds the greatest resemblance with the endogenous ligand, the 
purine-based moiety. As perhaps the most logical derivative to be synthesised as antagonists 
due to its similarities to adenosine itself, this is also one of the series with one of the longest 
continuing histories in non-xanthine adenosine antagonist research (Table 2.6). Early attempts 
involved variation at the exocyclic amino group of adenine, along with substitution at the  
9-position of the ring. Ukena et al. showed that N6 cyclopentyl was most favourable over 
other ring systems (phenyl, pyridyls, thienyls).68 At the 9-position a methyl group showed 
distinct advantages over the unsubstituted form (2.44). In 1991, Thompson et al. further 






Figure 2.6 The 6:5 Fused Bi-cyclics Possessing Four Nitrogen Atoms: 9H-purine (2.44-2.53);  
8,8a-Dihydro-imidazo[1,2-a][1,3,5]triazine (2.54-2.56); 1H-pyrazolo[3,4-d]pyrimidine (2.57-2.61). 
In addition, the 9-ethyl derivatives gave a slight improvement over the 9-methyladenines, and 
2-chloro substitution of the ring was not detrimental for affinity (2.45, 2.46). In a paper by 
Peet et al. in 1992, chiral substituents at the N6 position were investigated, the R- and the S- 
configurations of 1-(hydroxymethyl)-2-phenylethyl were tested and it seems that the binding 
pocket of the adenosine receptor has a preference for the (S) isomer (2.47).70 In 1998 further 
investigations into the adenines were undertaken by Camaioni et al., systematically placing 
large substituents at each of the 2-, 6-, and 8-positions of the ring.71 Though these ligands 
were generally more effective at the A2A receptor, the paper showed that a large substituent is 
reasonably well tolerated at the 2-position of the adenine ring at the A1 receptor with a 


































          Ki [nM] 
 
R1 R2 R3 R4 
A1 A2(A) A3 
A2A/ A1 Ref. 
2.44 H cC5H9 H Me 540a) 11000b) - 20 [68] 
2.45 H cC5H9 H Et 440a) 17000b) - 40 [69] 
2.46 Cl cC5H9 H Me 530a) 9300b) - 18 [69] 
2.47 OPr *) H Ph 96a) 5600b) - 60 [70] 
2.48 O(CH2)2Ph H H Et 170c) 120d) 45000e) 0.7 [70] 
2.49 Ph cC6H11 H CH2Ph 9f) >10000g) - >1000 [72] 
2.50 H H Ph Et 27h) 360i) 3300i) 13 [73] 
2.51 H cC5H9 NMeiPr Me 8j) - 14000k) - [74] 
2.52 H cC6H11 H  
 
4800l) 160000m) - 30 [75] 




24l) 3680n) - 150 [76] 
a)Inhibition of specific [3H]PIA binding in rat brain membranes. b)Inhibition of specific [3H]NECA binding in 
rat striatum. c)Inhibition of specific [3H]DPCPX binding in CHO cell membranes expressing the human 
adenosine receptor. d)Inhibition of specific [3H]CGS 21680 binding in CHO cell membranes expressing the 
human adenosine receptor. e)Inhibition of specific [125I]ABMECA binding in CHO cell membranes expressing 
the human adenosine receptor. f)Inhibition of specific [3H]CHA binding in bovine brain cortical membranes. 
g)Inhibition of specific [3H]CGS 21680 binding in bovine brain striatal membranes. h)Inhibition of specific 
[3H]CCPA binding in CHO cell membranes expressing the human adenosine receptor. i)Inhibition of specific 
[3H]NECA binding in CHO cell membranes expressing the human adenosine receptor. j)Displacement of 
specific [3H]DPCPX binding from CHO-A1++ membranes. k)Displacement of specific [125I]IBMECA from HEK 
293-A3 membranes. l)Inhibition of specific [3H]DPCPX binding to rat brain membranes. m)Inhibition of specific 
[3H]NECA binding to solubilised A2(A) receptors of human platelet membranes. n)Inhibition of specific [3H]CGS 
21680 binding to rat striatal membranes. *) (S)-1-(hydroxymethyl)-2-phenylethyl 
Bianucci et al. described yet more variations at the 4-amino and 9-positions and discovered 
that a benzyl group at the 9-position improved affinity significantly over the 9-alkyl-
adenines.72 Cyclopentyl at the N6 position was still found to be positive, but the cyclohexyl 
group showed slightly more affinity (2.49). 2- and 8-substitution of 9-ethyladenines was the 
subject of a recent study by Klotz et al., 8-substitution proved more favourable towards A1 
receptor binding and in particular the 8-phenyl derivative (2.50).73 The most recent addition to 
this series of compounds retains the N6-cyclopentyl group and the N9-methyl adduct as 
described by Ukena et al. (2.44), and explores the 8-position with amino-derivatives.74 The 
most promising compound (2.51) in terms of affinity at the A1 adenosine receptor possesses 
an isopropylmethylamine substituent at the C8 position. Since the ribose ring has been found 
necessary for agonistic activity, modification of this moiety results in compounds with a range 
















properties of 2',3'-dideoxy-N6-cyclohexyl adenosine, and showed it to possess antagonistic 
properties (2.52).75 More significantly, Van Calenberg et al. demonstrated nanomolar affinity 
with ribose modified compounds.76 Cyclopentyl adenosine (CPA) was altered at the  
3' position with various amide derivatives. The compounds which showed the most affinity 
were the 3,4-disubstituted-benzamides, and in particular the 3,4-dimethyl-benzamide (2.53) 
with an affinity of 24 nM at the A1 receptor. 
   Table 2.7 Biological data of compounds 2.54-2.56 
Ki [nM]  R1 R2 




2.54 cC5H9 Me 41  4100  2250 100 55 [77] 
2.55 CO-cC5H9 Me 4 4300  410 1000 100 [77] 
2.56 CO-cC5H9 Et 3  2600 20 870 7 [77] 
a)Displacement of specific [3H]CHA binding in bovine cortical membranes. b)Displacement of specific [3H]CGS 
21680 binding in bovine striatal membranes. c)Displacement of specific [125I]AB-MECA binding in bovine 
cortical membranes. 
The 8,8a-Dihydro-imidazo[1,2-a][1,3,5]triazines (Figure 2.6, Table 2.7, 2.54-2.56) have only 
recently been discovered and exploited as adenosine receptor antagonists.77 The compounds 
were designed according to a pharmacophore reported in an earlier paper.24 In consequence to 
the discoveries in the adenine series, a phenyl group in the 2-position is retained, and an exo-
cyclic amine is present in the 4-position of the ring. Substitution at the 4-amino group with a 
cycloalkyl group had a positive influence upon the binding affinity of the species towards the 
A1 receptor (2.54). Inserting a CO spacer between the heterocyclic ring and the cycloalkyl 
group further enhanced affinity for the A1 receptor (2.55), and subsequent lengthening of the 
alkyl moiety at the 7-position was yet more positive for A1 affinity (2.56). However, this also 
had a generally beneficial effect on the binding affinity at the A2A and A3 receptors, and thus 
lowered the overall selectivity of the compounds for the A1 receptor.  
Pyrazolo[3,4-d]pyrimidines (Figure 2.6, Table 2.8, 2.57-2.61) were examined early on in 
adenosine receptor research. In 1983 Davies et al. identified pyrazolo[3,4-d]pyrimidines as 
having affinity to the adenosine A1 receptor (2.57).78 The 1992 paper by Peet et al. 
investigating chiral substituents also looked at pyrazolopyrimidines and showed affinity for 
both the A1 and A2 receptors without much selectivity (2.58).70 Quinn and co-workers 
followed up on the discoveries by Davies and Peet to systematically explore the pyrazolo[3,4-
d]pyrimidines, explaining in detail the effects of varying the substituents at the adenosine A1 
and A2A receptors.79-85 The initial lead (2.57) was quickly dissected at the 4- and 6-positions. 
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the 6-substituent was essential for good binding affinity at the A1 receptor.79 Following this, 
variation of the thio-substituent at the 4-position with an amino moiety incorporating the 
essence of the discovery by Davies et al. improved affinity significantly (2.59),80 and further 
modification of the 6-substituent with a branched alkyl chain introduced a 16-fold 
improvement to sub-nanomolar affinity (2.60).83 











   Ki [nM] Ref. 
 




2.57 SCHMeCONH2 SCHMeCONH2 H 370a) - -   [9] 
2.58 OPr NH*) Ph 350a) 370b)          1   [70] 
2.59 SCH2CONHEt NH2 Ph 12a) 131c) 11 [80] 
2.60 SCH(Bu)CONH2 NHMe Ph 0.8a) 247c) 300 [82] 
2.61 NHCH(Me)CONH2 NH2 Ph 49a) 648c) 13 [85] 
2.62 - 39d) - - [86] 
a)Displacement of specific [3H]PIA bound to rat membranes. b)Inhibition of specific [3H]NECA binding in rat 
striatum. c)Inhibition of specific [3H]CGS 21680 binding to rat brain striatum membranes. d)Inhibition of 
specific [3H]CHA binding in rat brain membranes. *) (R)-1-(hydroxymethyl)-2-phenylethyl 
Later variations of the 6-thio substituent for an amino-analogue displayed less though still 
good and selective affinity for the A1 receptor (49 nM, 13-fold selectivity over A2A) (2.61).85 
Also of note to mention here are the related structures of the pyrazolo[4,3-d]pyrimidin-7-ones. 
The most interesting compound to note is that published by Hamilton et al., which showed a 
Ki of 39 nM at the A1 receptor vs. [3H]CHA (2.62).86   
3-Deaza-8-azaadenines (1H-[1,2,3]triazolo[4,5-c]pyridines) were examined recently by Biagi 
et al. in relation to the 8-azaadenines (see Section 2.3.1.4).87 It seems that this variant of the 
adenine ring can also show good affinity for the A1 receptor depending upon its substituents. 
A norbonyl moiety was the most positive with a Ki of 11 nM at the A1 receptor (2.63, Table 
2.9). 
2.3.1.4 The 6:5 Fused Heteroaromatic Systems Possessing Five Nitrogen Atoms 
The five-nitrogen bi-cyclic rings have been explored in detail by Biagi et al. A whole 
selection of 1H-[1,2,3]triazolo[4,5-d]pyridazines and 3H-[1,2,3]triazolo[4,5-d]pyrimidines 
have been published over the past decade. Early work on the [1,2,3]triazolo[4,5-d]pyridazines 



















substituted exocyclic amino group was shown yet again to be the most beneficial variation on 
the bi-cyclic core (2.64).88,89 Modification at the 1-benzyl group resulted in 30-70 nM 
affinity.90 Swapping the benzyl group for a methyl-thienyl moiety (2.65) retained a similar 






Figure 2.7 The 6:5 Fused Bi-cyclics Possessing Five Nitrogen Atoms: 1H-[1,2,3]triazolo[4,5-
d]pyridazines (2.64-2.65); 3H-[1,2,3]triazolo[4,5-d]pyrimidines (8-azapurines) (2.66-2.71). 





  Ki [nM]  X Y R1 R2 R3 R4 
 A1 A2A 
A2A/A1 Ref. 
2.63 C C H Ph norbornyl CH2Ph  11a) >1000b) >90 [87] 
2.64 N C OH - 3-tolyl CH2Ph 7c) 3000d) 430 [88] 
2.65 N C OH - c-C5H9 CH22-thienyl 47a) 895b) 19 [91] 
2.66 C N - Ph c-C5H9 CH2Ph 11c) >1000d) >90 [92] 
2.67 C N - H c-C5H9 CH2(4-FPh) 11a) 3422b) 300 [93] 
2.68 C N - Ph c-C5H9 erythro- 
CH(Hex)CH(OH)Me 
4a) >1000b) >250 
[94] 
2.69 C N - Ph H erythro- 
CH(Hex)CH(OH)Me 
3a) >1000b) >300 
[94] 
2.70 C N - Ph (trans-4-HO-cC6H11) CH2Ph 3a) >1000b) >300 [95] 
2.71 C N - Ph c-C5H9 (S)-CH2CH(OH)Me  2a) >1000b) >500 [95] 
a)Displacement of specific [3H]CHA binding in bovine cortical membranes. b)Displacement of specific [3H]CGS 
21680 binding in bovine striatum. c)Displacement of specific [3H]CHA binding in sheep cortical membranes. 
d)Displacement of specific [3H]CGS 21680 binding in rat striatal membranes. 
The 1,2,3-triazolo[4,5-d]pyrimidines (8-azapurines) (Figure 2.7, Table 2.9) were mentioned 
early on by Escher et al.96 They constitute a series based upon the experiences of Quinn et al. 
in the area of the pyrazolo[3,4-d]pyrimidines.79,97 However, the same substitution pattern 
imposed upon the [1,2,3]triazolo[4,5-d]pyrimidines did not result in a similar potency. Further 
exploration of this series seems to have been abandoned by the Australian group. In the mid-
1990s the series was picked up on with much more success by Biagi and co-workers.  A large 
number of publications from 1994-2003 detail the exploration of various positions. Fairly 
early on in their endeavours an exocyclic amino group in the 7-position was found to be 
beneficial for adenosine receptor affinity. At this exocyclic amine a cyclopentyl substituent 
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group in the 5-position of the ring brought about good binding affinity to the A1 receptor too 
(2.66),92 although compound 2.67, without this substituent, also displayed good affinity.93 
Substitution at the 3-position of the heterocyclic ring seemed also to be of importance for 
affinity,93,98 the first variants being substitutions on the benzyl moiety (2.67). More recently, a 
number of different substituents have been attempted to show the stereoselective nature of the 
A1 receptor and in the pursuit of water solubility. An erythro-CHRCH(OH)Me group (R = 
alkyl) was shown to retain the good binding affinity of the azaadenines, though in this case 
the unsubstituted exocyclic amino variant was the best compound - showing a lack of 
additivity in substitution (2.68-2.69).94 To attain better water solubility several hydroxyl-
variants were made, both at the exocyclic amino group and at the 3-positions.95 Compounds 
2.70 and 2.71 both show very good selective affinity for the A1 receptor and water solubility. 
2.3.2 Other Fused Bi-cyclic Heteroaromatic Systems 
2.3.2.1 Other Nitrogen-containing Heteroaromatic Systems 
1,8-Naphthyridine derivatives consist of two 6:6 fused rings. With regard to the adenosine 
receptors, the first publication by Müller et al. came about based on its similarities to the 
adenines.99 Substitution in the 3-position and 4-amino positions only yielded micromolar 
affinities with not much selectivity over the A2(A) receptors (Figure 2.8, Table 2.10, 2.72). 
Siddiqi et al. screened many compounds and found some affinity for naphthyridine 
derivatives.38 More recently, Ferrarini et al. published more lucrative substitution about the 
1,8-naphthyridine ring.100 At the 7-position a number of halides were used, showing an almost 
equal effect across the board. At the 4-position, an amino group was favourable, as was a 
mono-substituted amine. A chloro-substituent had very little effect, and a hydroxy moiety was 
the most positive. The compound with the highest affinity for the A1 receptor was 7-chloro-4-
hydroxy-2-phenyl-1,8-naphthyridine at 0.15 nM at the bovine A1 receptor (2.73). Further 
examination of the compound and its derivatives showed that the hydroxyl function on the 
heterocycle was necessary to allow ring tautomerism, resulting in the availability of a 
hydrogen-bond donor and acceptor adjacent at the 1- and 8-positions of the ring (Figure 2.8). 
Although the amino acid sequence homology for the A1 adenosine receptors is more than 90% 
between a number of different mammalian species, a subsequent paper by Ferrarini et al. 
highlights the great differences in affinity achieved by compounds at the human and bovine 
receptors.101 7-Chloro-4-hydroxy-2-phenyl-1,8-naphthyridine (2.73) has a Ki value of 300 nM 
at the human adenosine A1 receptor, and also reports a drop in selectivity over the A2A 
receptor.  
Other nitrogen-based heteroaromatic fused ring systems have generally a low affinity, mainly 
in the micromolar range. For the sake of completeness they are mentioned only briefly here. 
Another 6:6 fused nitrogen heterocyclic system are the pyridopyrimidines (Figure 2.8, 2.74).99 
They were investigated by Müller et al. in conjunction with the 1,8-naphthyridines mentioned 
previously. The pyridopyrimidines have a xanthine-like structure in the sense of the 
pyrimidinone moiety of the system, but show better affinity and selectivity for the A1 receptor 
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compared to the prototypic caffeine and theophylline. Two examples were made and tested, 
and both showed better affinity and selectivity than the 1,8-naphthyridines featured in that 
particular publication. Substitution of these pyridopyrimidines in a similar manner to the 
Ferrarini naphthyridines may also have a positive influence on the affinity. 
An example of a 5:7 fused nitrogen heterocycle that has been synthesised and tested as 
adenosine receptor antagonists are the imidazodiazepinediones (Figure 2.8, 2.75).102 As with 
many of the earlier publications they are again xanthine-like derivatives, incorporating the 7-
membered ring in the place of the 6-membered ring of xanthine. 1-Benzyl substitution was 
seen to be essential for affinity to the adenosine receptors and substitution at the N4- and N7- 
positions with Pr groups (analogous to DPCPX) gave rise to the best compound in terms of 
affinity.  
2.3.2.2 Nitrogen-Free Heteroaromatic Systems 
This class of ligands contains the compounds isolated from natural products. There are just 
two categories of natural products that have been explored with respect to adenosine receptor 
research, namely the benzofuran derivatives and the flavonoids. The former category was 
derived from the extraction and isolation of an active component of a natural product used 
frequently in traditional Chinese medicine (TCM). The dried root of Salvia miltiorrhiza 
Bunge (Danshen) has been widely used in TCM to treat coronary heart disease, particularly 
angina pectoris and myocardial infarction, and has been a subject of great interest throughout 
the 20th century.103 It has been reported to have a host of medicinal properties, ranging from 
antibacterial to anti-inflammatory  activity,  and more than 40 separate  components  have 
been isolated.30,103,104 The compound of interest to the adenosine receptor field was reported 
in 1991 (Figure 2.8, Table 2.10, 2.76).103 It was the first nitrogen-free ligand to show good 
affinity to the adenosine A1 receptor with an IC50 of 17 nM. Some subsequent variations and 
derivatives have been reported, but the original compound remains the most attractive.105 
Unfortunately, no further investigations have been undertaken and the exploration of similar 
phytomaterials may warrant further attention. 
The identification of the flavonoids came as a result of a report that showed 5,7-dihydroxy-4’-
hydroxyisoflavone to have an affinity of 5 µM at the adenosine A1 receptor.106 Flavonoids are 
plant pigments ubiquitous to green plant cells. They are highly diverse and the daily intake is 
estimated to be 1-2 g of a normal human diet.31 Following the publication mentioned above, a 
broad screening effort of phytochemicals ensued and identified the potential of several 
flavones.28 However, the highest affinity attained was only in the sub-micromolar range 
(2.77). Some sporadic reports of further flavones have been reported since, an affinity of 3 µM 
(at the rat A1 receptor) was published in 1997 for an extract of Microtea debilis, a plant from 

























Figure 2.8 Other Fused Bi-cyclic Heteroaromatic Systems. 1,8-Naphthyridines (2.72-2.73), 
pyridopyrimidines (2.74), imidazodiazepinediones (2.75), benzo[b]furan derivatives (2.76), flavones 
(2.77), tetrahydrobenzothiophenone (2.78). 
Table 2.10 Biological data of compounds 2.72-2.78 (see Figure 2.8) 
               Ki [nM] 
 
A1 A2A A3 
A2A/A1 A3/A1 Ref. 
2.72 7500a) 44000b) - 6 - [99] 
2.73 300c) 450d) 2100e) 1.5 7 [100,101] 
2.74 1800a) 18900b) - 11 - [99] 
2.75 11000f) 52000g) - 5 - [102] 
2.76 17h)*) - - - - [30] 
2.77 509a) 6450i) 1210j) 13 2 [28] 
2.78 567a) >10000b) - >18 - [108] 
a)Displacement of specific [3H]R-PIA binding in rat brain cortical membranes. b)Displacement of specific 
[3H]NECA binding in rat striatal membranes. c)Displacement  of specific [3H]DPCPX binding to human brain 
cortical membranes. d)Inhibition of specific [3H]CGS 21680 binding to human striatal membranes. e)Inhibition 
of specific [3H]R-PIA binding to rat testis membranes in the presence of 150 nM DPCPX. f)Inhibition of specific 
binding of 1 nM [3H]R-PIA to rat cerebral cortical membranes. g)Inhibition of 1 nM [3H]NECA specific binding 
to rat striatal membranes. h)Inhibition of [3H]R-PIA binding to bovine cerebral cortical membranes. 
i)Displacement of specific [3H]CGS 21680 binding in rat striatal membranes. j)Displacement of specific 
[125I]AB-MECA binding at human A3 receptors expressed in HEK-293 cell membranes.*)IC50   
In 2000, the leaves of Senna siamea, a widely used plant in Thailand were extracted and its 
components were isolated and tested at the adenosine A1 receptor. One compound, luteolin, 
was shown to have an affinity for the rat A1 receptor of 1 µM.29 However, the compounds 

















































phytochemicals.28 Although there are (probably) many flavonoids still to be examined, the 
only moderate activity and the lack of any distinct structure-activity relationship for those that 
have been studied does not encourage an extensive search. 
The last non-nitrogen series to mention are the tetrahydrobenzothiophenones. Following up 
on a lead generated by the screening programme by Siddiqi et al.,38 the 
tetrahydrobenzothiophenones (Figure 2.8, 2.78) were explored further by Van Rhee et al.108 
Although reasonable selectivity for the A1 receptor was achieved, the best compound only just 
displayed micromolar affinity. 
2.4. Fused Tri-cyclic Heteroaromatic Systems 
2.4.1 The 6:6:5 Fused Heteroaromatic Systems 
The 6:6:5 fused nitrogen heteroaromatics can be grouped together to form the largest 
collection of the tri-cyclic antagonists (Figure 2.9). They are in fact a collection of chemically 
very different structures, with either three or four nitrogens in the rings, different substitution 
patterns and very different methods of synthesis. However, as ligands towards the adenosine 
A1 receptors, they have a remarkable number of similarities and some are just further 
developments on the bi-cyclic heteroaromatics described previously. 
The main similarities between the different classes of 6:6:5 fused nitrogen heteroaromatic 
systems are: 1) the peripheral 6-membered ring (as opposed to the sandwiched 6-membered 
ring) contains no heteroatoms; 2) the position of the rings in relation to each other; 3) the 
patterns of substitution in the most favourable compounds (numbered positions 2- and 8- for 
the majority); and 4) an exocyclic amino group (numbered as the 4-position of the ring for the 
majority of the structures). Another similarity of the most potent examples is the favourable 
presence of a cyclopentyl group at this exocyclic amine. The difference between all these 
structures can be considered as the number and the arrangement of the nitrogen atoms about 
the 5-membered ring. 
The first compound in the table (Table 2.11, 2.79) is an example of an 1H-imidazo[4,5-
c]quinolin-4-amine (Figure 2.9). It was designed and synthesised by Van Galen et al.109 
according to a predicted pharmacophore.15 The 2- and 4-amino positions were explored with 
the hypothesis that hydrophobic substituents would enhance affinity. The most potent and 
selective compound incorporated a cyclopentyl group at the 4-amino-group and a phenyl 
substituent at the 2-position, showing a 10 nM affinity at the rat A1 receptor and 45-fold 
selectivity over the A2(A) receptor. These substituents were regio-specific in terms of the 
affinity for the adenosine receptors; when the position of the cyclopentyl and phenyl groups 
were swapped, a drastic drop in affinity was observed (2.80). 
The next two series to mention with three nitrogen atoms in the fused tri-cyclic system are the 
pyrazolo[3,4-c]quinolines (2.81-2.82) and the imidazo[1,2-a]quinoxalines (2.83-2.85) 
published by Colotta et al. and Ceccarelli et al. The pyrazoloquinolines were explored at the 
2-position with a number of substituted phenyl groups; at the 4-position with amino-
derivatives or a hydroxyl-function; and at the 8-position with a chloro-moiety.110 The most 
Non-Xanthine Antagonists of the Adenosine A1 Receptor 
 
 39
effective compound (2.81) at the A1 receptor consisted of a 4-cyclopentylamino group, an 
unsubstituted 2-phenyl moiety and no substitution at the 8-position. Selective A3 affinity 
could also be attained with this type of structure by the inclusion of a carbonyl moiety at the 










Figure 2.9 The 6:6:5 Fused Tri-cyclic Systems; 1H-imidazol[4,5-c]quinolines (2.79-2.80), 2H-
pyrazolo[3,4-c]quinolines (2.81-2.82), imidazo[1,2-a]quinoxaline (2.83-2.85), pyrazolo[1,5-a]-
quinoxaline (2.86), imidazo[1,5-a]quinoxaline (2.87-2.88), [1,2,3]triazolo[1,5-c]quinazoline (2.89-
2.90), [1,2,4]triazolo[4,3-a]quinoxaline (2.91-2.92), 2H-[1,2,4]triazolo[4,3-a]quinoxalin-1-one (2.93-
2.95), [1,2,4]triazolo[1,5-a]quinoxaline (2.96-2.98). Atom numbering about the rings are as given for 
compounds 2.79-2.80, except where stated. 
Imidazoquinoxalines were explored briefly by Colotta et al. in 1995,111 these compounds 
however, only just displayed sub-micromolar affinity and were not pursued further. In this 
paper they showed that C2 phenyl substitution was beneficial for A1 affinity and that the 
presence of the amino group was also necessary for A1 receptor affinity (2.83). Ceccarelli et 
al. revisited this series and showed that cycloalkyl substitution at the 4-amino group was 
attractive and that variation at the 7- and 8-positions of the fused phenyl ring was possible 
whilst retaining affinity (2.84).112 In a further variation, a methyl moiety at the 1-position 
resulted in an improvement in affinity to low nanomolar values (2.85). 
The Colotta group in 1995 also investigated two more types of fused tri-cyclic structures 
containing three nitrogen atoms, namely pyrazolo[1,5-a]quinoxalines and imidazo[1,5-
a]quinoxalines.111 Of the former structure, only one example was given (2.86), and this 
showed only micromolar affinity. The two examples of the imidazo[1,5-a]quinoxalines both 
incorporated the 2-phenyl group, and the 4-amino moiety was also present. Cyclopentyl 
substitution at the 4-amino group did not improve the affinity over the unsubstituted form for 
the A1 receptor, but affinity for the A2A receptor did drop off significantly (2.87-2.88). 
The largest sub-section of the fused tri-cyclic category is that with four nitrogen atoms 
incorporated into the rings. Francis et al. showed the triazoloquinazolines to be adenosine 
receptor antagonists as early as 1988,12 in consequence to the discovery of CGS 15943 (2.89) 









































material which indicated these compounds as substances to treat depression and fatigue.113 
Substitution with an aromatic group in the 2-position in analogy to CGS 15943 showed that 
the 2-furyl substituent was the most effective, and some selectivity for the A1 receptor was 
obtained with alkyl-substitution at the 4-amino group (2.90).  
Also in 1988 Trivedi and Bruns published the triazolo[4,3-a]quinoxalines as selective A1 
receptor antagonists.13 Several alkyl groups were investigated at the exocyclic amine, and the 
 








        Ki [nM]  X Y R1 R2 
A1 A2A A3 
A2A/A1 A3/A1 Ref. 
2.79 CPh N cC5H9 H 10a) 450b) - 45 - [109] 
2.80 C(cC5H9) N Ph H 230a) >1000b) - >4 - [109] 
2.81 NPh CH cC5H9 H 3c) 849d) 61e) 300 20 [110] 
2.82 NPh CH COPh H >20000c) >20000d) 2e) - - [110] 
2.83 CPh CH H H 230f ) 720g) - 3 - [111] 
2.84 CH CH cC5H9 Cl 24a) >2500g) >10000e) >100 >400 [112] 
2.85 CH CMe cC5H9 H 8a) 2500g) >10000e) 300 >1250 [112] 
2.86 CH N H H 3050f) 3000g) - 1 - [111] 
2.87 N CPh H H 130f) 310g) - 2 - [111] 
2.88 N CPh cC5H9 H 810f) >10000g) - >12 - [111] 
2.89 C(2-furyl) N H Cl 21f )*)  3b)*) - 0.3 - [12] 
2.90 C(2-furyl) N iPr Cl 22f )*) 179b)*) - 8 - [12] 
2.91 N CCF3 cC5H9 H 7f) 1000b) - 140 - [13] 
2.92 N CCF3 cC5H9 Cl 36h)    710i) - 20 - [14,114] 
2.93 NPh CO cC5H9 H 0.4c) 986d) 55j) 2500 140 [115] 
2.94 NPh CO H Cl 
(6-NO2) 
0.2c) 256d) 112e) 1300 560 [116] 
2.95 NPh CO cC5H9 NO2 0.4c) >20000d) 212e) >50000 530 [117] 
2.96 CPh N H Cl 50f) 161g) - 3 - [111] 
2.97 C(2-F-Ph) N H Cl 13f) >10000g) - >770 - [111] 
2.98 C(2-thienyl) N H Cl 12f) >10000g) - >800 - [111] 
a)Displacement of specific [3H]DPCPX binding in rat brain cortical membranes. b)Displacement of [3H]NECA 
in rat striatal membranes. c)Displacement of specific [3H]CHA binding in bovine brain membranes. 
d)Displacement of specific [3H]CGS 21680 binding in bovine striatal membranes. e)Displacement of specific 
[125I]AB-MECA binding at human A3 receptors expressed in CHO cells. f)Displacement of specific [3H]CHA 
binding in rat cerebral cortex membranes. g)Displacement of specific [3H]CGS 21680 binding in rat striatal 
membranes. h)Inhibition of specific binding of 1.1 nM [3H]CHA to A1 receptors in guinea pig forebrain 
membranes. i)Inhibition of specific [3H]NECA binding in the presence of 50 nM CPA in rat striatal membranes. 
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cyclopentyl was shown as the most beneficial substituent. At the 2- and 3-positions of the ring 
were situated cyclic nitrogen atoms, thus the only possible place of variance was explored 
with short alkyl derivatives, with the most effective being the trifluoromethyl moiety (2.91). 
In consequence to this set of compounds, Sarges et al.14 showed further development 
describing another 138 derivatives. The variations involved mainly new 4-amino substituents 
and new substitutions at the 6-, 7- and 8-positions of the fused phenyl ring. The most effective 
compound (2.92) possessed chloro-substitution at the 8-position on the fused phenyl ring, an 
analogy to the series published by Francis et al. (2.89, 2.90). The reported value in Table 2.11 
is the Ki as reported by Suzuki et al.114 
A variation of the triazolo[4,3-a]quinoxalines by Trivedi and Bruns and Sarges et al. 
incorporates a carbonyl oxygen in the 1-position allowing for substitution in the 2-position. 
These compounds were first reported by Colotta et al. in 2000, and were shown to be very 
effective at the A1 receptor (2.93).115 Further development in 2003 showed that the 
cyclopentyl group was not necessary for good affinity at the A1 receptor, when compensated 
with 6- and 8- substitution at the fused phenyl ring (2.94).116 The most recent developments of 
this series re-incorporate the cycloalkyl group at the 4-amino moiety and also incorporate the 
substitutions at the 6- and 8- positions.117 The most effective compound in terms of overall 
affinity and selectivity has cyclopentyl as the 4-amino-substituent and a nitro group in the  
8-position (2.95). 
The [1,2,4]triazolo[1,5-a]quinoxalines as reported by Colotta et al. in 1995111 investigated the 
receptor pocket that allows 2-substitution of these 6:6:5 fused tri-cyclic systems. Leaving the 
4-amino-group unsubstituted, good affinity was obtained with a 2-phenyl moiety (2.96). 
Replacing this with a 2-fluorophenyl moiety (2.97) gave improvements in both affinity and 
selectivity over the A2A receptor and a 2-thienyl group showed slightly better affinity for the 
A1 receptor (2.98). 
Another variation of the four-nitrogen tri-cyclic fused rings incorporates a hydroxyl function 
at the 4-position in the place of the exocyclic amino group. Tautomerism dictates that this 
moiety exists also in the amido form, and substitution at the (5-)nitrogen locks the molecule in 
this form. The first compounds to mention are the triazolo[4,3-a]quinoxalin-1-ones with this 
moiety in place. They were published in 2003 by Colotta et al. in analogy to the 4-NH2 
series.116 No substitutions were shown at the N5 group, and as such these compounds could 
also exist in the iminol form. The affinity and selectivity was not better than the 4-amino-






Figure 2.10 The 6:6:5 Fused Tri-cyclic Systems; [1,2,3]triazolo[1,5-a]quinoxaline (2.99-2.101), 4H-

















[1,2,3]Triazolo[1,5-a]quinoxalines  are a relatively new series of compounds which have been 
reported by Bertelli et al. and Biagi et al.118,119 The 4-hydroxy variants were reported first and 
display good affinity with the A1 receptor, especially where the N5-position was left 
unsubstituted (Figure 2.10, Table 2.12, 2.99 vs. 2.100). An ethoxy-carbonyl group was found 
in the 3-position of the system, and substitution of the fused phenyl ring at the 7-position 
favoured a methoxy- group. In the second paper of this series, some other variations at the 3- 
and 5-positions were attempted, but these led to a complete loss of affinity for the A1 receptor. 
The 4-hydroxy function was also exchanged for an amino group, again leading to a significant 
loss of affinity at 5 µM (2.101).119  









    Ki [nM] Ref. 
 




2.99 H MeO H CO2Et 29 >1000 >35 [118] 
2.100 Me MeO H CO2Et 389 >1000 >3 [118] 
2.101 MeCHPh H H CO2Et 5139 >10000 >2 [119] 
2.102 H H Cl Ph 148 >10000 >70 [120] 
2.103 H H H Ph 239 >10000 >40 [120] 
a)Displacement of specific [3H]CHA binding in bovine brain membranes. b)Displacement of specific [3H]CGS 
21680 binding in bovine striatal membranes. 
The last in this series of four-nitrogen tri-cyclic fused aromatics we report on are the 
[1,2,3]triazolo[1,5-a]quinazolines (Figure 2.10, Table 2.12).120 They show great similarities 
with the above [1,2,3]triazolo[1,5-a]quinoxalines, but differ in the position of the nitrogen 
atom in the central 6-membered ring. In analogy to the triazoloquinoxalines, the 4-hydroxy 
group showed the best biological results, however substitution in the 3-position with the 
ethoxy-carbonyl group was not beneficial to this ring system and a 3-phenyl group was found 
to be much more potent (2.102). Exchange of the 4-hydroxy for a 4-amino group again led to 
a drop in affinity at the A1 receptor (2.103). 
2.4.2 The 6:5:6 Tri-cyclic Heteroaromatic Systems  
These compounds published by Müller et al. are derivatives of the deazapurine series (Section 
2.3.1.2).59 The fusion of a 6-membered ring at the 7- and 8-positions of the deazapurine gives 
rise to this series. Two varieties were explored, involving a partially saturated and an 
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derivatives published in 1990, showed the signature exocyclic 4-amino moiety, and a phenyl 
group at the 9-position (Figure 2.11, Table 2.13, 2.104). Follow-up work on this series was 
reported in 2000 and substitution at the 2-position was explored, the most effective of which 






Figure 2.11 Tri-cyclic deazapurine derivatives (2.104-2.107). 
Where a benzene ring was fused onto the deazapurine, the initial lead (2.106) contained a 
hydroxyl group at the 4-position (tautomerism with purinone structure). This compound had 
very little selectivity over the A2A receptor.60 Later work showed the 4-amino group to be 
favourable, with the inclusion of an aromatic substituent at the 2-position and a chiral moiety 
at the N9 position (2.107). 61  
The last compound in this class to mention is also based on the tri-cyclic deazapurine moiety. 
The difference is at the 4-amino domain, a chiral substituent attaches this in a 5-membered 
ring formation to the N1 of the purine ring (Table 2.13, 2.108).70  
                            Table 2.13 Biological data of compounds 2.104-2.108 
 





         Ki [nM]  R1 R2 R3 
A1 A2A A3 
A2A/A1 A3/A1 Ref. 
2.104 NH2 H Ph 3240a) 10900b) - 3 - [60] 
2.105 NH2 4-Py Ph 600c) >10000d) - >17 - [63] 
2.106 OH H Ph 880a) 1440b) - 2 - [60] 
2.107 NH2 Ph (R)-MeCHPh 3a) 6200b) >1000e 2000 >330 [61] 
2.108 CH2Ph OPr Ph 620a) >100000b) - >160 - [70] 
a)Inhibition of [3H]PIA specific binding to rat cortical membranes. b)Inhibition of [3H]NECA specific binding to 
rat striatal membranes. c)Inhibition of specific [3H]CCPA binding in human recombinant A1 adenosine receptors 
expressed in CHO cells. d)Inhibition of [3H]CGS 21680 specific binding in rat striatal membrane. e)Inhibition of 
specific [3H]NECA binding in human recombinant receptors expressed in CHO cell membranes. 
 A very different 6:5:6 heterocycle was proposed and investigated by Da Settimo et al.24 
These were the aryl[1,24]triazino[4,3-a]benzimidazol-4-(10H)-ones and were first reported as 



























adenosine receptor antagonists. Substitution was seen in two positions about the main ring; at 
N10 – the nitrogen in the central 5-membered ring; and in the 3-position. The most effective 
compound incorporated phenyl substituents at these two positions and had an affinity of 18 
nM at the A1 receptor with very good selectivity over the A2A and A3 receptors (Figure 2.12, 
Table 2.14, 2.109). Some tri-cyclic xanthine derivatives also fall into the class of 6:5:6 fused 
ring systems. These were published by Geis et al. in 1995, and are direct derivatives of 
theophylline, with the third fused ring formed about the N7 and C8 atoms.121 
 The compounds in general only showed micromolar affinity at the A1 receptor with poor 
selectivity over the A2(A) adenosine receptors (as for theophylline). One example however, 
displayed a 15-fold selectivity for the A1 over the A2(A) receptor. Along with the theophylline 
base, the fused 6-membered ring formed a tetrahydro-pyrimidin-4-one, and further 
substitution at the nitrogen accounted for the selectivity (2.110).  
2.4.3 The 5:6:5 Tri-cyclic Heteroaromatic Systems  
Some other tri-cyclic xanthine derivatives of note feature in patent literature and have been 
developed by Boehringer Ingelheim. The first to mention has a linear arrangement of the three 
rings, and can be thought of as a xanthine with a third 5-membered ring fusing at the N1-C2 
bond. The most potent example consists of a cyclopentyl group substituted at C8 (2.111).122 
The two last tri-cyclic xanthine derivatives mentioned here have the third fused ring between 
C2 and N3 of the xanthine core. The first example is a fairly compact molecule in the sense 
that the most effective example has small alkyl subsituents about the tri-cyclic core (2.112).123 
The second example contains a larger phenyl substituent on the third fused ring and also sees 
substitution at the C8 position (2.113).124 
Table 2.14 Biological data for Compounds 2.109-2.118 (Figure 2.12) 
             Ki [nM] Ref. 
 A1 A2A A3 
A2A/A1 A3/A1 
 
2.109 18a) >10000b) >1000c) 550 55 [24] 
2.110 17000d) >250000e) - >15 - [121] 
2.111 1f) 422g) - 400 - [122] 
2.112 2f) - - - - [123] 
2.113 2f) - - - - [124] 
2.114 283h) 420i) - 1.5 - [125] 
2.115 90h)  1370i) - 15 - [126] 
2.116 47h) >20000i) - >425 - [126] 
2.117 240h) 2960i) - 12 - [126] 
2.118 84h) 2280i) - 27 - [127] 
a)Displacement of specific [3H]CHA binding in bovine brain membranes. b)Displacement of specific [3H]CGS 
21680 binding in bovine striatal membranes. c)Displacement of specific [125I]AB-MECA binding in bovine 
cortical membranes. d)Inhibition of [3H]PIA specific binding to rat cortical membranes. e)Inhibition of 
[3H]NECA specific binding to rat striatal membranes. f)tested in radioligand binding assays at the human A1 
receptor, further details (e.g., radioligand) not given. g)tested in radioligand binding assays at the rat A2A 
receptor, further details (e.g., radioligand) not given. h)Displacement of specific [3H]CHA binding in rat 
cerebral cortex membranes. i)Inhibition of [3H]CGS 21680 specific binding in rat striatal membrane. 
 

































Figure 2.12 Other Fused Tri-cyclic Systems: [3,10]diphenyl-10H-benzo[4,5]imidazo[2,1-c] 
[1,2,4]triazin-4-one (2.109), 1,3-dimethyl-8-[3-(4-methylpiperazin-1-yl)-propyl]-5,6-dihydro-[1H,8H-
1,3,4b,8,9]-pentaaza-fluorene-2,4,7-trione (2.110), 6-benzyl-2-cyclcopentyl-4-ethyl-3,4-dihydro- 
[1,2,4]triazolo[1,5-a]purin-9-one (2.111), 2-ethyl-4-propyl-4H,8H-[1,2,4]triazolo[5,1-b]purin-5-one 
(2.112), 7-t-butyl-4-ethyl-2-(4-methoxybenzyl)-4H,8H-[1,2,4]triazolo[5,1-b]purin-5-one (2.113),  
1-(3-methoxyphenyl)-3-methyl-1H-chromeno[2,3-c]pyrazol-4-one (2.114), 1-(3-aminophenyl)- 
6-methoxy-3-methyl-1H-chromeno[2,3-c]pyrazol-4-one (2.115), 3-methyl-1-(3-nitrophenyl)- 
1,9-dihydro-pyrazolo[3,4-b]quinolin-4-one (2.116), 1-(3-nitrophenyl)-1H-imidazo[4,5-b]quinoxaline 


































































2.4.4 The 6:6:5 Tri-cyclic Heteroaromatic Systems  
In 1993 Colotta et al. reported on a novel mixed heteroatomic tri-cyclic system in the search 
of A2A selective ligands.125 These were the benzopyrano[2,3-c]pyrazolo-4-ones, and although 
on the whole more selective for the A2A receptor, some derivatives showed favour, albeit very 
slightly, for the A1 receptor (2.114). Development of the series in 1995 with further 
substitution at the fused benzo-ring increased the affinity and selectivity for the A1 receptor 
(2.115).126 In a variation of this, the oxygen was replaced with a nitrogen atom creating  
1,9-dihydro-pyrazolo[3,4-b]quinolin-4-ones. Improved selectivity for the A1 receptor over the 
A2A receptor was achieved with the amino substitution at the non-fused phenyl ring (2.116).126 
The third series in this paper is another 6:6:5 fused tri-cyclic nitrogen heteroaromatic system. 
It is an imidazo[4,5-b]quinoxaline and of the three examples that were synthesised and tested 
only one showed sub-micromolar affinity at the A1 receptor (2.117).125 The last compound to 
mention is actually a fused bicyclic compound, but is included in this section due to its logical 
development from the 6:6:5 compounds 2.114-2.115. Instead of a fused phenyl ring on the 
heterocyclic system, the phenyl ring was placed in the 1- or the 2-positions.127 The most 
positive influence was the phenyl in the 1-position (2.118), attaining better or comparable 
affinity and better selectivity than compounds 2.114 and 2.115. 
2.5 Summary 
This review of the current state of non-xanthine A1 adenosine receptor antagonists shows that 
research in this area has been highly active and imaginative, despite the restrictions of general 
GPCR research, i.e., the lack of a fully disclosed binding site.  
Although there are numerous ligands with reportedly good potencies and selectivity for the A1 
receptor, many of them may still lack a complete data set. Those made in the 1980s and early 
1990s only document binding data at the A1 and A2(A) receptors, making suggestions of 
selectivity highly speculative. In addition, although the cloning of the human adenosine A1 
receptor was reported in 1992, many even very recently developed compounds have not been 
tested at this receptor. One particularly relevant and very recent example are the 
naphthyridines reported by Ferrarini et al.100,101 The quoted 94% amino-acid homology 
between the human and bovine A1 receptors concealed the discrepancies in affinity that was 
experienced by these compounds. At the bovine adenosine A1 receptor, the most potent 
compound possessed an affinity of 0.15 nM, but retesting this at the human adenosine A1 
receptor resulted in a Ki value of 300 nM. To be thoroughly consistent and comprehensive, all 
previously reported compounds should be tested at all human adenosine receptors. However, 
the value of the data available should not be underestimated and despite the discrepancies and 
the absent information, we can still draw on the general themes and conclusions offered by 
over two decades of research. 
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2.6 Concluding Remarks 
This large collection of non-xanthine adenosine A1 receptor antagonists is the result of more 
than twenty years of intensive research. The most developed and only openly available (non-
selective) adenosine receptor antagonists on the market are xanthine derivatives, e.g., 
theophylline and enprofylline used in the treatment of asthma, or caffeine widely used 
(recreationally) for its cognition enhancing properties. Although the therapeutic potential of a 
highly selective and potent adenosine A1 receptor antagonist is great, we still seem to be some 
way off this goal. Thus the scope of research into non-xanthine ligands remains a broad and 
(almost) infinite field.  
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Chapter 3  
 
Substituted Pyrimidines as a New Class of Selective 
Adenosine A1 Receptor Antagonists  











Adenosine receptor antagonists usually possess a bi- or tri-cyclic heteroaromatic 
structure at their core with varying substitution patterns to achieve selectivity 
and/or greater affinity. Taking into account molecular modelling results from a 
series of potent adenosine A1 receptor antagonists, a pharmacophore was derived 
from which we show that a monocyclic core can be equally effective. As a result, 
a novel series of 4-amido-2,6-diphenyl-pyrimidines was synthesised. The 
compounds were all tested at the human A1, A2A, and A3 receptors, showing in 
many cases low nanomolar affinity for the adenosine A1 receptor.  In particular, 
compound 3.16 (LUF 5764) displayed, in terms of both affinity (Ki = 9 nM) and 
selectivity (displacement of the radioligand at the A2A and A3 receptors at 1 µM 
<32% and <39%, respectively), some of the most favourable characteristics. 
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3.1 Introduction 
The widespread purpose and presence of adenosine has led to substantial research into the 
individual adenosine receptors as pharmaceutical targets. Over the years, there have been 
many attempts to design and develop adenosine receptor antagonists, and over the past 
decade, the search for ligands that show selectivity towards individual receptors has 
intensified as the role of the receptors in many therapeutic areas expands.1 As detailed in 
Chapter 2, there have been many ligands developed for the adenosine A1 receptor. These 
compounds have been identified as a result of serendipity, screening programmes, rational 
design and computer models.  
One of the first computer-derived models for the adenosine A1 receptor binding site was 
published by Van Galen et al. in 1990.2 This was based on the superimposition of 
theophylline and the endogenous agonist adenosine. The ‘best’ orientation of the xanthine, in 
terms of better electrostatic fit with respect to adenosine was suggested to be at a rotation 180º 
about the longer axis of the molecule (Figure 3.1). This was subsequently labelled as the 
‘flipped’ model.  In this same paper, certain features were highlighted to form the basis of a 
pharmacophore for adenosine A1 receptor antagonists (Figure 3.2). The overlap of a selection 
of ligands suggested that one of the most important features was a large Y-shaped area of 



















Figure 3.1. a) adenosine, b) above the standard depiction of theophylline and below the ‘flipped’ 
depiction of theophylline, c) the N6-C8 model, and d) the ‘flipped’ model. 
 
(c) ‘N6-C8’ model 






























































Two further areas of relatively positive electrostatic potential were also suggested. Months 
later, a different model was proposed by Peet et al. which suggested that N6 of the purine 
derivative was more compatible with the C8 position of the xanthine derivative, hence the 
model acquiring the name N6-C8 (Figure 3.1).3 An analysis of these models by Van der 
Wenden et al.4 suggested that the latter model was more appropriate based on better spatial 
compatibility. However, the suggested pharmacophore by Van Galen et al.2 describes only 
adenosine A1 receptor antagonists and thus the relevancy of the ‘flipped’ vs. the ‘N6-C8’ 
models is negligible. This pharmacophore noted the start of a number of structurally very 
different compounds, encompassing a variety of bi- and tri-cyclic heteroaromatic systems. 
Analysis of these compounds in subsequent reviews revealed that they almost all fulfill 
certain criteria: they possess (i) a planar central structure, (ii) aromatic or π-electron rich and 











Figure 3.2. Depiction of the pharmacophore as described by Van Galen et al.2 The 6:5 fused 
heteroaromatic core gives rise to areas of negative electrostatic potential, seen as (-) in the diagram. 
Two common areas of positive electrostatic potential (+) are also described.  
Further modelling studies based on the superimposition of the antagonist with the agonist7,8 
have been published and more recently the protein itself has been modelled, identifying the 
potential importance of specific amino acids (see Chapter 2). However, actual suggestions 
that update the criteria mentioned above have been lacking, despite the identification of new 
compounds that no longer conform, e.g., the 6:6 fused naphthyridines9 and the mono-cyclic 
thiazoles/thiadiazoles.10,11 
In this chapter, molecular modelling of a number of ligands further refined the criteria for 
ligands that act as adenosine A1 receptor antagonists. Subsequent appraisal of this model was 
performed by the development of a set of ligands that fulfilled the requirements, yet were 
































Figure 3.3. The 15 A1 adenosine receptor antagonists modelled in this study. Of the two areas marked 
on each molecule, the left ellipse signifies electronically rich regions corresponding to hydrogen-bond 
accepting regions. The area marked with the right-hand ellipse on each molecule depicts electron-poor 
regions corresponding to hydrogen-bond donating regions. a Ki(rA1) = 7.3 nM;12 b IC50(rA1) = 22 
nM;13 c Ki(rA1) = 5 nM;14 d Ki(rA1) = 10 nM;15 e Ki(rA1) = 130 nM;16 f Ki(rA1) = 12 nM;16 g Ki(rA1) = 
3 nM;17 h Ki(rA1) = 0.8 nM;18 i Ki(sA1) = 7 nM;19 j Ki(sA1) = 29 nM;20 k Ki(rA1) = 8 nM;21 l Ki(hA1) = 

























































































3.2 Results and Discussion  
3.2.1 Molecular Modelling.  
Molecular modelling work was conducted on a number of ligands with high affinity and 
selectivity for the A1 adenosine receptor as shown in Figure 3.3. These compounds were 
selected, based on the available literature at the end of 2000 and their diversity with respect to 
each of their central cores, with the only repetition being examples c and l, which possess 
very different substituents about the central structure. The actual ligand depicted and used in 
the modelling was that which displayed the most affinity for the A1 receptor of each series. 
The molecules were drawn in the SPARTAN24 molecular modelling package, minimised, and 
only the lowest energy conformer was taken into consideration. This conformer was then 
subjected to surface calculations from which an electrostatic potential energy was drawn, and 
upon which the electron density was mapped. Relatively electronegative and electron-poor 
regions were denoted by colour-coded regions. These areas were mapped upon each of the 
compounds shown in Figure 3.3. It became clear that each molecule had in common an 
electron-rich and poor area at the ‘bottom’, as denoted by the ellipses in Figure 3.3. These 
areas correspond to hydrogen-bond accepting and donating regions, respectively. 
Superimposition of the compounds using these regions as a basis resulted in the illustration 
seen in Figure 3.4a. Figure 3.4b shows the electron density mapped upon the electrostatic 












Figure 3.4. a) The 15 compounds mapped upon the adjacent electron-rich and electron-poor regions at 
the ‘bottom’ of each molecule, b) The inclusion of just one electrostatic potential map (of compound f) 
typical of this selection of compounds to illustrate the relative degrees of electronegativity seen in the 
molecular modelling study. 
This resulting pharmacophore derived from the molecular modelling is illustrated with a 
schematic diagram in Figure 3.5. The criteria to create ligands with good affinity at the 
adenosine A1 receptor seem to include the following aspects: a requirement for neighbouring 
electronically rich and poor regions at the ‘bottom’ of the molecule (labelled regions A and B 
in Figure 3.5), corresponding to hydrogen-bond accepting and donating regions, respectively. 
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At the ‘top’ of the figure (region C) there is a requirement for another hydrogen-bond 
acceptor. Furthermore, three lipophilic entities about the central planar core, labelled L1, L2 







Figure 3.5. Schematic diagram of the resulting pharmacophore attained from the modelling study. A 
and B represent H-bond accepting and donating regions at the ‘bottom’ of the molecule, respectively. 
An H-bond acceptor is denoted by C. Three lipophilic domains are represented by L1, L2 and L3. 
Since the design of this pharmacophore, several papers have been published which draw 
similar conclusions. A model for the bovine A1 adenosine receptors was published by Da 
Settimo et al. to rationalise the SARs of a set of aryl-triazino-benzimidazolones.25 This model 
was further exploited by the same group to provide a series of imidazotriazines with good 
affinity for the bovine A1 receptor.26 In 2002, Bondavalli and co-workers27 carried out some 
computational work on a collection of eleven different A1 antagonists using different methods 
to achieve a similar pharmacophore to that of Da Settimo et al. These models however were 
all based on bi- and tri-cyclic heteroaromatic cores, fuelling new antagonists which were 
again bi-cyclic - the pyrazolopyridines of Bondavalli, or tri-cyclic – the triazinobenzimidazo-
les by Da Settimo. In our case, the model proposed only suggests an aromatic core with the 
given characteristics, to be substituted accordingly to fill the lipophilic pockets. Thus, it 
seemed that to fulfil the requirements of this model, a singular non-fused heterocycle as the 
central core would be sufficient. Singular non-fused heterocycles have seldom been seen as 
adenosine receptor antagonists as detailed in Chapter 2. Of the few exceptions to this were the 
thiazoles and thiadiazoles as published in 2001.10,11 Examining the model in more detail, a 
single aromatic group containing a nitrogen atom would fit the hydrogen-bond accepting 
region. An amido group in an adjacent position would fulfil hydrogen-bond donating and 
accepting regions B and C. The two lipophilic pockets L1 and L3 could be ‘filled’ with 
phenyl groups to give an almost symmetric core, leaving the pocket L2 to be explored 
thoroughly. Thus the 2,6-diphenyl-4-amido-pyrimidines were conceived.  
3.2.2 Chemistry 
The pyrimidinone ring was created by the reaction of the commercially available β-ketoester, 
ethyl benzoate, with benzamidine hydrochloride in the presence of a base (3.1). The first 
attempts to achieve the condensation using sodium ethoxide rendered only poor yields; 
changing the base to sodium hydroxide in accordance to a script by De Valk and Van der 
Aromatic 
 A    B
 
   C
      L1 




Plas28 improved the reaction significantly, resulting in a yield of 59%. Displacement of the 
hydroxide function was achieved with an excess of phosphoryl chloride, containing 
phosphorous pentachloride, according to a preparation by Brown et al.29 Subsequent 
substitution with ammonia in a sealed vessel gave the key 4-amino-2,6-diphenyl pyrimidinyl 
intermediate (3.3). The final step to give compounds 3.4-3.20 involved the formation of the 
amide bond. Attempts using the carboxylic acid with standard coupling agents, for example 
EDC and HOBt, gave poor or no yields. As an alternative, the amine was reacted with acid 














Scheme 1. Synthetic route to the 4-amido-2,6-diphenyl-pyrimidines. (a) NaOH, EtOH; (b) POCl3, 
PCl5; (c) NH3, EtOH; (d) RCOCl, Et3N, 1,4-dioxane. 
3.2.3 Structure Activity Relationships 
The results of the binding assays are represented in Table 3.1. There are distinct and vital 
differences in affinity for the compounds across the receptors, thus highlighting the variation 
in the electronic and spatial requirements necessary to create good ligands for the adenosine 
receptors. In consequence to previously published material by our group,30 the first amides 
prepared were phenyl derivatives based on the Topliss system of substitution,31 and assumed 
the L2 pocket to be similar to L1 and L3 in size and shape (Figure 3.5) . The initial compound 
(the unsubstituted phenyl derivative) shows fair affinity for the A1 adenosine receptor at 670 
nM with a two-fold selectivity over the A3 receptor (Ki = 1300 nM). Substituting following 
the Topliss system gave little or no improvement in affinity, with only 4-methoxyphenyl 
derivative 3.6 showing a very slight gain in affinity at the A3 receptor, in agreement with our 
previous publications. With the alkyl amides, significant improvements were made over the 
phenyl substituents at the L2 pocket. In the straight-chained alkyls, from methyl to pentyl 
(3.7-3.10) a distinct optimum is apparent for a two-carbon chain (compound 3.8) at the A1 
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Table 3.1. Affinities of the 4-Amido-2,6-Diphenyl-Substituted-Pyrimidines 3.4-3.20 in Radioligand 









 aKi ± SEM (n = 3), % displacement (n = 2). bDisplacement of specific [3H]DPCPX binding in CHO cell 
membranes expressing human adenosine A1 receptors or % displacement of specific binding at 1 µM 
concentrations. cDisplacement of specific [3H]ZM 241385 binding in HEK 293 cell membranes expressing 
human adenosine A2A receptors or % displacement of specific binding at 1 µM concentrations. dDisplacement of 
specific [125I]AB-MECA binding in HEK 293 cell membranes expressing human adenosine A3 receptors or % 
displacement of specific binding at 1 µM concentrations.  
This pattern is repeated at the A2A receptor, with a Ki of 82 nM (3.8). At the A3 receptor 
however, the methyl-substituted derivative (3.7), with an affinity of 7 nM was far and away 
the better compound. In terms of selectivity, compound 3.7 was 5-fold more selective for the 
A3 receptor than for the A1 receptor, whilst in a slight reversal of 
this compound 3.8 showed a 2-fold selectivity in favour of the A1 adenosine receptor over the 
A3 receptor. Better selectivity for the A1 adenosine receptor came with the n-propyl derivative 
(3.9) with an almost 7-fold better affinity over the A2A receptor (Ki = 17.6 nM vs. Ki = 124 
nM) and by almost a factor of ten with the A3 adenosine receptor (Ki = 167 nM). From these 
results, it seems that the lipophilic pocket (L2) is not quite as ‘deep’ for the A1 adenosine 
receptor as expected. 
To explore the ‘breadth’ versus ‘depth’ hypothesis of the L2 pocket thrown up by the results 
of the straight-chained alkyls, a number of branched alkyl derivatives (3.11-3.15) were made. 
Though all showed good to fair affinity across the adenosine receptors, the overall bias was 
Ki (nM)  or % displacementa  
 
R 
A1b A2Ac A3d 
3.4 Ph 671 ± 110 17% 1300 ± 300 
3.5 4-Cl-Ph 35% 0% 33% 
3.6 4-MeO-Ph 30% 0% 1170 ± 150 
3.7 Me 38 ± 8 489 ± 140 6.9 ± 2 
3.8 Et 9.5 ± 5 82 ± 14 22 ± 9 
3.9 Pr 18 ± 5 124 ± 17 167 ± 51 
3.10 Bu 109 ± 15 48% 392 ± 65 
3.11 iPr 11 ± 6 376 ± 76 267 ± 39 
3.12 2-MePr 15 ± 3 157 ± 42 447 ± 62 
3.13 1-EtPr 6.4 ± 0.4 381 ± 33 57% 
3.14 (LUF 5767) 1-MePr 2.2 ± 1 899 ± 130 147 ± 22 
3.15 tBu 28 ± 6 18% 49% 
3.16 (LUF 5764) 2,2-diMePr 8.8 ± 4 32% 39% 
3.17 c-Pr 7.6 ± 1 189 ± 44 25 ± 2 
3.18 c-Bu 6.5 ± 2 179 ± 58 178 ± 57 
3.19 (LUF 5740) c-Pent 2.1 ± 0.1 196 ± 66 170 ± 60 








towards the A1 receptor. The isopropyl compound (3.11) showed a 24-fold selectivity for the 
A1 receptor over the A3 with an affinity of 11 nM vs. 267 nM. Improving upon this, the 
isopentyl (3.13) showed a Ki value of 6 nM at the A1 receptor, whilst losing a significant 
amount of affinity at the A3 receptor. Compound 3.14 was overall the best of the branched 
alkyl group in terms of affinity to the A1 receptor with an affinity of 2.2 nM. The large, 
sterically hindered t-butyl group only seems to be tolerated at the A1 receptor with compounds 
3.15 and 3.16 showing little affinity for either the A2A or the A3 receptors, making these 
compounds highly selective for the A1 adenosine receptor.  
The cycloalkyl derivatives (3.17-3.20) were made to combine and confirm the length and 
breadth hypothesis of the L2 pocket of the A1 receptor drawn from the branched and straight 
alkyl derivatives. It is notable that the cyclopentyl compound (3.19) shows the best affinity 
with a Ki of 2.1 nM at the A1 receptor, suggesting an optimal two-three carbon chain length of 
the pocket. It can also be compared favourably to the isopropyl, isobutyl, and isopentyl in 
terms of the width. The affinity of the compounds at the A2A and A3 adenosine receptors were 
only fair (the only exception being the good affinity of the cyclopropyl derivative, Ki = 25 nM 
for the A3 receptor), and thus showing an overall marked selectivity for the A1 receptor. It is 
notable that the cyclopentyl group occurs more frequently as the compound in a series with 
the highest affinity for the A1 receptor; namely, in the structurally different compounds of the 
imidazoquinolines,15 the imidazoquinozalinamines,21 the triazoloquinoxalines,12 and the 
xanthines (DPCPX).32 This is however, the first thorough examination of this particular area 
of the receptor site in such a manner. We have found that in agreement with Da Settimo et 
al.25 the L2 pocket is relatively small and compact. This hypothesis was disputed by the 
Bondavalli group27 due to the good affinity at the bovine A1 receptor of one of their 
compounds, which incorporated a rather large side chain. We can see clearly in our results 
that there is some affinity for a phenyl substituent, i.e., that the pocket can accommodate a 
phenyl ring, but that this is not optimal.   
It is also interesting to note the different requirements across the receptors. Although it has 
not been optimised in this paper, there is a distinct trend to be seen in the results at the A2A 
and A3 receptors. Affinity at the A2A peaked with a relatively short narrow chain - the ethyl 
group at this pocket, and the A3 affinity increased with the very smallest substituents, namely 
the methyl and the cyclopropyl groups.  
3.3 Conclusion 
Presented in this chapter is a novel series of adenosine receptor antagonists which have been 
designed and synthesised on the basis of a pharmacophore derived from the modelling of a 
number of previously published ligands. The idea of a mono-cyclic heteroaromatic core as the 
basis of an antagonist has been proven to be compatible with the adenosine receptor site, and 
one of the proposed lipophilic pockets of the site has been thoroughly investigated in terms of 
spatial requirements. 
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3.4 Experimental Section  
3.4.1 Molecular Modelling 
Molecular modelling work was performed with the SPARTAN molecular modelling package version 5.0 
(Wavefunction Inc.)24 running on a Silicon Graphics O2 workstation. Default values in the Merck Force Field 
were used in Molecular Mechanics minimisations. Conjugate gradient energy minimisations were continued 
until the rms energy derivative was less than 0.001 kcal·mol-1Å-1. The conformers were generated using the 
systematic search method. The energy and molecular electrostatic potential was calculated using the semi-
empirical molecular orbital program AM1. The electrostatic potentials were sampled over the entire accessible 
surface of the molecules (equal to a Van der Waals contact surface). The most negative electrostatic potential is 
depicted as red and the most positive as blue. 
3.4.2 Chemistry 
Materials and Methods 
All reagents used were obtained from commercial sources and all solvents were of an analytical grade. 1H and 
13C NMR spectra were recorded on a Bruker AC 200 (1H NMR, 200 MHz; 13C NMR, 50.29 MHz) spectrometer 
with tetramethylsilane as an internal standard. Chemical shifts are reported in δ (ppm) and the following 
abbreviations are used: s = singlet, d = doublet, dd = double doublet, t = triplet, m = multiplet, br = broad and ar 
= aromatic protons. Melting points were determined on a Büchi melting point apparatus and are uncorrected. 
Elemental analyses were performed by the Leiden Institute of Chemistry and are within 0.4% of the theoretical 
values unless otherwise stated. Reactions were routinely monitored by TLC using Merck silica gel F254 plates.  
2,6-Diphenyl-3H-pyrimidin-4-one (3.1). 
Benzamidine hydrochloride (3.0 g, 19.2 mmol) was dissolved in a minimal amount of H2O (10 
mL), to this was added NaOH (0.8 g, 19.2 mmol, 1 eq.) dissolved in H2O (2 mL), followed by 
ethylbenzoate (3.5 mL, 20.2 mmol, 1.05 eq.). Ethanol was then added until a clear solution was 
obtained. The reaction mixture was allowed to stir at room temperature overnight yielding a thick 
suspension, which was filtered to give a white solid. After washing with diethyl ether to remove 
unreacted/excess β-ketoester the solid was dried in vacuo to give 59% of the desired product. 1H NMR δ 
(DMSO-d6): 8.31-8.18 (m, 5H, phenyl-H), 7.60-7.54 (m, 5H, phenyl-H), 6.92 (s, 1H, pyrimidine-H). 
4-Chloro-2,6-diphenyl-pyrimidine (3.2). 
Phosphorous oxychloride (9.30 mL, 99.8 mmol, 7.5 eq.) was added dropwise to 2,6-diphenyl-3H-
pyrimidin-4-one (3.3 g, 13.3 mmol) in a vigorous reaction. To this mixture was added cautiously 
and portionwise phosphorous pentachloride (2.77 g, 13.3 mmol, 1 eq.) and the reaction mixture was 
stirred at reflux for 3 hours. The reaction mixture was quenched by pouring into ice-water, and 
extracted with ethyl acetate (3  x  150 mL). The combined organic layers were washed with water, 
dried (MgSO4) and then concentrated to give a yellow solid. This was recrystallised from ethanol to give fine 
white needles (65%). 1H NMR δ (CDCl3): 8.60-8.18 (m, 5H, phenyl-H), 7.63 (s, 1H, pyrimidine-H), 7.51-7.57 
(m, 5H, phenyl-H). 
2,6-Diphenyl-pyrimin-4-ylamine (3.3). 
Ethanol (50 mL) was saturated with NH3(g) at 0 °C and added to 4-chloro-2,6-diphenyl-pyrimidine 
(2.30 g, 8.63 m mol) in a sealed vessel. This was stirred at 140 °C for 24 h. Upon cooling and 
concentrating, the residue was extracted with hot chloroform (3 x 50 mL) and the solvent 
evaporated in vacuo. The crude product was purified by column chromatography on SiO2 eluting 
with CH2Cl2 to give an off-white solid (80%).  1H NMR δ (DMSO-d6): 8.47-8.42 (m, 2H, phenyl-
H), 8.16-8.13 (m, 2H, phenyl-H), 7.57-7.5 (m, 6H, phenyl-H), 7.02 (br s, 2H, NH2), 6.88 (s, 1H, pyrimidine-H). 
General Procedure for the Preparation of 4-Amido-2,6-diphenylpyrimidines (3.4-3.20). 
To a solution of 4-amino-2,6-diphenylpyrimidine (0.202 mmol, 1 eq.) in 1,4-dioxane (5 mL) was 
added triethylamine (0.223 mmol, 1.1 eq.), followed by the appropriate acid chloride (0.304 
mmol, 1.5 eq.). This was then stirred at reflux until no starting material was visible by TLC. 
Upon completion, the reaction mixture was separated between ethyl acetate (20 mL) and water 
(20 mL). The aqueous layer was further extracted with ethyl acetate (2 × 20 mL) and the 
combined organics washed with water. After drying over MgSO4 and evaporation under reduced pressure, the 
crude product was purified by column chromatography, eluting with a petroleum ether-ethyl acetate or a 
dichloromethane-methanol solvent system. Recrystallisation from ethanol or petroleum ether-ethyl acetate gave 
the corresponding amide in crystalline form. 
N-(2,6-Diphenyl-pyrimidin-4-yl)-benzamide (3.4). Yield 48%; white solid; mp 120-123 °C; 1H NMR 
δ(CDCl3): 8.78 (br s, 1H, N-H), 8.72 (s, 1H, pyrimidine-H), 8.58-8.54 (m, 2H, phenyl-H), 8.34-8.29 (m, 2H, 
phenyl-H), 7.99-7.96 (m, 2H, phenyl-H), 7.64-7.48 (m, 9H, phenyl-H). 13C-NMR δ(CDCl3): 166.2, 165.9, 164.0, 
158.4, 137.3, 137.1, 133.4, 132.6, 130.8, 130.7, 128.9, 128.7, 128.3, 128.1, 127.4, 127.2, 103.3. MS (ES+): 
















4-Chloro-N-(2,6-diphenyl-pyrimidin-4-yl)-benzamide (3.5). Yield 57%; white solid; mp 182 °C; 1H NMR  
δ(CDCl3): 8.70 (br s, 1H, N-H), 8.68 (s, 1H, pyrimidine-H), 8.57-8.52 (m, 2H, phenyl-H) 8.33-8.28 (m, 2H, 
phenyl-H), 7.93-7.89 (m, 2H, aromatic-H), 7.56-7.49 (m, 8H, phenyl-H). 13C-NMR δ(CDCl3): 165.2, 164.0, 
158.3, 157.1, 139.2, 137.1, 136.2, 131.9, 131.0, 130.9, 129.3, 128.9, 128.8, 128.7, 128.5, 128.2, 127.5, 127.2, 
103.4. MS (ES+): 385.85, 407.9 Da. Anal. (C23H16ClN3O) C, H, N. 
N-(2,6-Diphenyl-pyrimidin-4-yl)-4-methoxy-benzamide) (3.6). Yield 12%; white solid; mp 155-156 °C;  
1H NMR δ(CDCl3): 8.73 (s, 1H, pyrimidine-H), 8.67 (br s, 1H, N-H), 8.59-8.54 (m, 2H, phenyl-H) 8.34-8.29 (m, 
2H, phenyl-H), 8.00-7.96 (m, 2H, aromatic-H), 7.55-7.51 (m, 6H, phenyl-H), 7.06-7.02 (m, 2H, aromatic-H), 
3.91 (s, 3H, CH3). MS (ES+): 381.85 Da. Anal. (C24H19N3O2.0.4H2O) C, H, N. 
N-(2,6-Diphenyl-pyrimidin-4-yl)-acetamide (3.7). Yield 43%; white solid; mp 140 °C; 1H NMR δ(CDCl3): 
8.54-8.49 (m, 3H, phenyl-H + pyrimidine-H) 8.45 (s, 1H, N-H), 7.55-7.49 (m, 6H, phenyl-H), 2.20 (s, 3H, CH3).  
13C-NMR δ(CDCl3): 165.9, 158.1, 154.3, 140.7, 130.74, 130.68, 128.7, 128.4, 128.0, 127.4, 103.0, 35.7. MS 
(ES+): 289.89 Da. Anal. (C18H15N3O.0.5EtOH) C, H, N. 
N-(2,6-Diphenyl-pyrimidin-4-yl)-propionamide (3.8). Yield 77%; white solid; mp 125-126 °C; 1H-NMR 
δ(CDCl3): 8.58 (s, 1H, pyrimidine-H), 8.55-8.50 (m, 2H, phenyl-H), 8.36 (br s, 1H, NH), 8.30-8.25 (m, 2H, 
phenyl-H), 7.54-7.49 (m, 6H, phenyl-H), 2.41(q, 2H, J= 7.3 Hz, CH2CH3), 1.23 (t, 2H, -CH2CH3). 13C-NMR 
δ(CDCl3): 173.2, 165.8, 163.9, 137.3, 137.0, 130.7, 128.7, 128.0, 127.4, 121.5, 103.1, 30.7, 8.87. MS (ES+): 
303.8 Da. Anal. calc. for C19H17N3O (C 75.23; H 5.65; N 13.85) found (C 75.32; H 6.23; N 14.04) %. 
N-(2,6-Diphenyl-pyrimidin-4-yl)-butyramide (3.9). Yield 45%; white solid; mp 102-103 °C; 1H-NMR 
δ(CDCl3): 8.60 (br s, 2H, pyrimidine-H + NH), 8.56-8.51 (m, 2H, phenyl-H), 8.31-8.26 (m, 2H, phenyl-H), 7.45-
7.50 (m, 6H, phenyl-H), 2.29 (t, 2H, J = 7.48 Hz, CH2CH2CH3), 1.71 (sextet, 2H, J = 7.39 Hz, CH2CH2CH3), 
0.95 (t, 3H, J = 7.30 Hz, CH2CH2CH3). 13C-NMR δ(CDCl3): 172.9, 165.8, 163.8, 158.5, 137.4, 137.0, 130.8, 
130.7, 128.6, 128.4, 128.1, 127.3, 103.3, 39.2, 18.3, 13.5. MS (ES+): 317.87 Da. Anal. (C20H19N3O. 0.1H2O) C, 
H, N. 
Hexanoic acid (2,6-diphenyl-pyrimidin-4-yl)-amide (3.10). Yield 53%; white solid; mp 40 °C; 1H-NMR 
δ(CDCl3): 8.53 (s, 1H, pyrimidine-H), 8.52-8.49 (m, 2H, phenyl-H,) 8.30-8.23 (m, 3H, phenyl-H  + N-H), 7.55-
7.47 (m, 6H, phenyl-H), 2.43 (t, 2H, J = 7.30 Hz, CH2CH2CH2CH2CH3), 1.82-1.67 (m, 2H, 
CH2CH2CH2CH2CH3), 1.41-1.21 (m, 4H, CH2CH2CH2CH2CH3), 0.96-1.89 (m, 3H, CH2CH2CH2CH2CH3).  
13C-NMR δ(CDCl3): 172.8, 165.9, 164.0, 158.4, 137.4, 137.1, 130.8, 128.6, 128.4, 128.1, 127.4, 103.2, 37.2, 
31.1, 24.6, 22.2, 13.8. MS (ES+): 345.88, 690.58 Da Anal. (C22H23N3O. 1.7 H2O) C, H, N.  
N-(2,6-Diphenyl-pyrimidin-4-yl)-isobutyramide (3.11). Yield 39%; white solid; mp 116-117 °C; 1H-NMR 
δ(CDCl3): 8.59 (s, 1H, pyrimidine-H), 8.55-8.50 (m, 2H, phenyl-H), 8.30-8.25 (m, 2H, phenyl-H), 8.05 (br s, 
1H, NH), 7.54-7.49 (m, 6H, phenyl-H), 2.64 (septet, 1H, J = 6.85 Hz, CH(CH3)2), 1.33 (d, 6H, J = 6.94 Hz, 
CH(CH3)2). 13C-NMR δ(CDCl3): 176.5, 165.8, 158.3, 137.4, 137.1, 130.7, 128.7, 128.4, 128.0, 127.4, 103.4, 
36.8, 19.2, 19.1. MS (ES+): 317.94, 634.75 Da. Anal. (C20H19N3O.0.1H2O) C, H, N. 
 N-(2,6-Diphenyl-pyrimidin-4-yl)-3-methyl-butyramide (3.12). Yield 52%, white solid; mp 127°C; 1H-NMR 
δ(CDCl3): 8.59 (s, 1H, pyrimidine-H), 8.56-8.51 (m, 2H, phenyl-H), 8.35 (br s, 1H, NH), 8.31-8.26 (m, 2H, 
phenyl-H), 7.56-7.49 (m, 6H, phenyl-H), 2.25-2.24 (m, 3H, CH2CH(CH3)2), 1.02-0.99 (d, 6H, CH2CH(CH3)2). 
13C-NMR δ(CDCl3): 172.1, 165.9, 158.2, 137.4, 137.1, 130.7, 130.6, 128.6, 128.4, 128.0, 127.4, 113.5, 103.2, 
46.8, 25.8, 22.3ppm. MS (ES+): 331.8 Da. Anal. (C21H21N3O) C, H, N.  
N-(2,6-Diphenyl-pyrimidin-4-yl)-2-ethyl-butyramide (3.13). Yield 66%, white solid; mp 137-138 °C; 1H-
NMR δ(CDCl3): 8.64 (s, 1H, pyrimidine-H), 8.55-8.50 (m, 2H, phenyl-H), 8.31-8.26 (m, 2H, phenyl-H), 8.09 (br 
s, 1H, NH), 7.54-7.49 (m, 6H, phenyl-H), 2.23-2.11 (m, 1H, CH(CH2CH3)2), 1.86-1.56 (m, 4H, CH(CH2CH3)2), 
0.99 (t, 6H, J = 7.31 Hz, CH(CH2CH3)2). 13C-NMR δ(CDCl3): 175.8, 165.9, 158.3, 130.8, 130.7, 128.7, 128.4, 
128.1, 127.4, 121.6, 103.2, 52.2, 25.5, 11.8. MS (ES+): 345.86, 690.56 Da. Anal. (C22H23N3O. 0.1H2O) C, H, N.  
N-(2,6-Diphenyl-pyrimidin-4-yl)-2-methyl-butyramide (3.14), Yield 89%, white solid; mp; 102 °C; 1H-NMR 
δ(CDCl3): 8.71 (br s, 1H, N-H), 8.67 (s, 1H, pyrimidine-H), 8.59-8.54 (m, 2H, aromatic-H), 8.33-8.28 (m, 2H, 
aromatic-H), 7.53-7.50 (m, 6H, aromatic-H), 2.29-2.19 (m, 1H, CH), 1.82-1.86 (m, 1H, 0.5*CH2), 1.55-1.41 (m, 
1H, 0.5*CH2), 1.16 (d, J=6.58Hz, 3H, CH3), 0.90 (t, J=7.30Hz, 3H, CH3). 13C-NMR δ(CDCl3): 176.4, 165.9, 
163.9, 158.5, 137.4, 137.1, 130.8, 130.7, 128.7, 128.4, 128.1, 127.4, 103.3, 44.0, 27.0, 16.9, 11.6. MS (ES+): 
331.8 (MH+) Da. Anal. (C21H21N3O) C, H, N.  
N-(2,6-Diphenyl-pyrimidin-4-yl)-2,2-dimethyl-propionamide (3.15). Yield 66%, white solid; mp 52 °C;  
1H-NMR δ(CDCl3): 8.63 (s, 1H, pyrimidine-H), 8.58-8.51 (m, 2H, phenyl-H), 8.30-8.27 (m, 2H, phenyl-H), 8.21 
(s, 1H, N-H), 7.54-7.51 (m, 6H, phenyl-H), 1.40 (s, 9H, CH3). 13C-NMR δ(CDCl3): 178.0, 165.8, 163.8, 158.4, 
137.3, 137.1, 130.7, 130.6, 128.6, 128.3, 128.1, 127.4, 103.2, 40.0, 27.2. MS (ES+): 331.92 Da. Anal. 
(C21H21N3O) C, H, N. 
N-(2,6-Diphenyl-pyrimidin-4-yl)-3,3-dimethyl-butyramide (3.16). Yield 62%, white solid; mp 134 °C;  
1H-NMR δ(CDCl3): 8.73 (br s, 1H, N-H), 8.64 (s, 1H, pyrimidine-H), 8.55-8.50 (m, 2H, aromatic-H), 8.32-8.27 
(m, 2H, aromatic-H), 7.54-7.49 (m, 11H, aromatic-H), 2.20 (s, 2H, CH2), 1.08 (s, 9H, 3*CH3). 13C-NMR 
Substituted Pyrimidines as Adenosine A1 Receptor Antagonists. Part I. 
 63
δ(CDCl3): 171.7, 165.9, 163.9, 158.4, 137.4, 137.1, 130.8, 130.7, 128.7, 128.4, 128.2, 127.4, 103.2, 51.0. 31.2, 
30.0. MS (ES+): 367.6 (MNa+), 345.9 (MH+) Da. Anal. (C22H23N3O) C, H, N. 
Cyclopropanecarboxylic acid (2,6-diphenyl-pyrimidin-4-yl)-amide (3.17). Yield 86% white solid; mp 127- 
128 °C; 1H-NMR δ(CDCl3): 8.99 (br s, 1H, NH), 8.58 (s, 1H, pyrimidine-H), 8.56-8.52 (m, 2H, phenyl-H), 8.29-
8.24 (m, 2H, phenyl-H), 7.53-7.49 (m, 6H, phenyl-H), 1.47-1.43 (m, 1H, -CHCH2CH2-), 1.11-1.05 (m, 2H, -
CHCH2CH2-), 0.86-0.76 (m, 2H, -CHCH2CH2-). 13C-NMR δ(CDCl3): 173.5, 165.7, 163.8, 158.4, 137.4, 137.0, 
130.7, 130.6, 128.6, 128.3, 128.0, 127.2, 113.5, 103.2, 58.2, 15.7, 8.84. MS (ES+): 315.8 Da. Anal. (C20H17N3O) 
C, H, N. 
Cyclobutanecarboxylic acid (2,6-diphenyl-pyrimidin-4-yl)-amide (3.18). Yield 90% white solid; mp; 121- 
122 °C; 1H-NMR δ(CDCl3): 8.62 (s, 1H, pyrimidine-H), 8.56-8.51 (m, 2H, phenyl-H), 8.32-8.27 (m, 3H, phenyl-
H + N-H), 7.54-7.48 (m, 6H, phenyl-H), 3.13 (pentet, 1H, -CHCH2CH2CH2-), 2.45-1.90 (m, 6H, -
CHCH2CH2CH2-). 13C-NMR δ(CDCl3): 174.6, 165.8, 163.9, 158.4, 137.1, 130.7, 128.7, 128.4, 128.0, 127.4, 
103.2, 86.9, 40.7, 24.9, 17.9. MS (ES+): 329.7 Da. Anal. (C21H19N3O. 0.1H2O) C, H, N. 
Cyclopentanecarboxylic acid (2,6-diphenyl-pyrimidin-4-yl)-amide (3.19). Yield 69%; white solid; mp 126.5-
127 °C. 1H-NMR δ(CDCl3): 8.60 (s, 1H, pyrimidine-H), 8.56-8.51 (m, 2H, phenyl-H), 8.32-8.26 (m, 3H, phenyl-
H + NH), 7.53-7.50 (m, 6H, phenyl-H), 2.77-2.65 (m, 1H, -CHCH2CH2CH2CH2-), 1.98-1.60 (m, 8H, -
CHCH2CH2CH2CH2-). 13C-NMR δ(CDCl3): 175.9, 165.8, 158.4, 137.4, 137.1, 130.7, 130.6, 128.7, 128.4, 128.0, 
127.4, 103.2, 46.8, 30.2, 25.9. MS (ES+): 343.7 Da. Anal. (C22H21N3O. 0.1H2O) C, H, N. 
Cyclohexanecarboxylic acid (2,6-diphenyl-pyrimidin-4-yl)-amide (3.20). Yield 87%; white solid; mp 142- 
143 °C. 1H-NMR δ(CDCl3): 8.60 (s, 1H, pyrimidinel-H), 8.57-8.52 (m, 2H, phenyl-H), 8.34 (br s, 1H, NH), 
8.30-8.25 (m, 2H, phenyl-H), 7.53-7.49 (m, 6H, phenyl-H), 2.31-2.18 (m, 1H, -CHCH2CH2CH2CH2CH2-), 1.97-
1.30 (m, 10H, -CHCH2CH2CH2CH2CH2-). 13C-NMR δ(CDCl3): 175.7, 165.8, 163.8, 158.4, 137.1, 130.7, 130.6, 
128.6, 128.3, 127.3, 113.6, 103.2, 46.4, 29.2, 25.3. MS (ES+): 357.7, 358.7 Da. Anal. (C23H23N3O. 0.2H2O) C, H, 
N.  
3.4.3 Biology  
Materials and Methods  
[3H]DPCPX and [125I]AB-MECA were purchased from Amersham Biosciences (NL). [3H]ZM241385 was 
obtained from Tocris Cookson, Ltd. (UK). CHO cells expressing the human adenosine A1 receptor were 
provided by Dr. Andrea Townsend-Nicholson, University College London, UK. HEK 293 cells stably expressing 
the human adenosine A2A and A3 receptor were gifts from Dr. Wang (Biogen, USA) and Dr. K.-N. Klotz 
(University of Würzburg, Germany), respectively. All compounds made were tested in radioligand binding 
assays to determine their affinities at the human adenosine A1, A2A and the A3 receptors. 
Adenosine A1 Receptor 
Affinity at the A1 receptor was determined on membranes from CHO cells expressing the human receptors, using 
[3H]DPCPX as the radioligand. Membranes containing 40 µg of protein were incubated in a total volume of 400 
µL of 50 mM Tris/HCl (pH 7.4) and [3H]DPCPX (final concentration 1.6 nM) for 1 h at 25 °C in a shaking water 
bath. Non-specific binding was determined in the presence of 10 µM CPA. The incubation was terminated by 
filtration over Whatman GF/B filters under reduced pressure with a Brandell Harvester. Filters were washed 
three times with ice-cold buffer and placed in scintillation vials. Emulsifier Safe (3.5 mL) was added, and after 2 
h radioactivity was counted in an LKB rack β scintillation counter. 
Adenosine A2A Receptor 
At the A2A receptor, affinity was determined on membranes from HEK 293 cells stably expressing this receptor, 
using [3H]ZM 241385 as the radioligand. Membranes containing 25-30 µg of protein were incubated in a total 
volume of 200 µL of 50 mM Tris/HCl (pH 7.4) and [3H]ZM 241385 (final concentration 2.0 nM) for 2 h at 25 
°C in a shaking water bath. Non-specific binding was determined in the presence of 100 µM CPA. The 
incubation was terminated by filtration over Whatman GF/B filters under reduced pressure with a Brandell 
Harvester. Filters were washed three times with ice-cold buffer and placed in scintillation vials. Emulsifier Safe 
(3.5 mL) was added, and after 2 h radioactivity was counted in an LKB rack β scintillation counter. 
Adenosine A3 Receptor 
The affinity at the A3 receptor was measured on membranes from HEK 293 cells stably expressing the human A3 
receptor, using [125I]AB-MECA as the radioligand. Membranes containing 20-40 µg of protein were incubated in 
a total volume of 100 µL of 50 mM Tris/HCl, 10 mM MgCl2, 1 mM EDTA, 0.01% CHAPS (pH 7.4), and 
[125I]AB-MECA (final concentration 0.10 nM) for 1 h at 37 °C in a shaking water bath. Non-specific binding 
was determined in the presence of 100 µM R-PIA. The incubation was terminated by filtration over Whatman 
GF/B filters under reduced pressure with a Brandell Harvester. Filters were washed three times with ice-cold 







Ki values were calculated using a non-linear regression curve-fitting program (GraphPad Prism, GraphPad 
Software Inc., San Diego, CA, USA). KD values of the radioligands were 1.6 nM, 1.0 nM and 5.0 nM for 
[3H]DPCPX, [3H]ZM 241385 and [125I]AB-MECA, respectively. 
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Chapter 4  
 
 
Substituted Pyrimidines as a New Class of Selective 
Adenosine A1 Receptor Antagonists 




Adenosine mediates a number of responses in the central nervous system (CNS) 
via cell membrane receptors. The four known adenosine receptors are present in 
varying degrees throughout the human body, and A1 and A2A receptors are 
particularly prevalent in the brain. The blockade of adenosine A1 receptors in the 
brain may be useful in therapeutic areas such as cognition enhancement and sleep 
disorders. Designing a selective compound that is able to cross the blood-brain 
barrier is therefore of great importance. In this chapter a restriction is proposed in 
relation to the polar surface area of a compound in the quest to design and 
synthesise an adenosine A1 receptor antagonist that may act at the CNS. We show 
that a novel series of 2-amido-4,6-diphenyl-pyrimidines are selective A1 
antagonists with a polar surface area within the desired range for a compound to 
be able to cross the blood-brain barrier. In particular, compound 4.23 (LUF 5735) 
shows excellent affinity (Ki = 4 nM) and selectivity (displacement of the 
radioligand at the A2A and A3 receptors at 1 µM <7% and <38% respectively), and 
has a polar surface area of 53 Å2. 
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4.1 Introduction 
As described in Chapter 1, adenosine receptors are localised throughout the human body in 
varying levels of expression and facilitate different reactions in accordance to physiological 
needs. Adenosine A1 receptors are in abundance in the mammalian brain,1 and the role that 
they play in important functions, such as in the modulation of neurotransmitter release, sleep 
regulation and cognition enhancement, has been thoroughly investigated.2-4 For this reason it 
is essential that a compound targeted at these therapeutic areas is able to cross the blood-brain 
barrier (BBB). Research into the BBB and the ability of a compound to cross it has become a 
highly investigated topic in recent years. A recent review5 highlighted some ‘rules of thumb’ 
which have emerged from numerous research articles from the past few years. Amongst these 
was the almost qualitative example that the sum of the nitrogen and oxygen atoms in a 
molecule should be five or less for that molecule to have a greater chance of entering the 
brain.6 Of the more quantitative prediction techniques, the rule that for good brain permeation, 
as for good intestinal absorption, the polar surface area (PSA) of a molecule should be below 
a certain limit has been very thoroughly investigated.7-11 The PSA is defined as the surface 
area of a molecule occupied by nitrogen and oxygen atoms, and hydrogen atoms that are 
attached to these atoms.11 It has become one of the most convenient and reliable parameters to 
calculate, and the limits for brain penetration according to research, e.g., by Kelder et al.9 
have been proposed to be in the region of 60-70 Å2. 
In the preceding chapter, the design and synthesis of a series of pyrimidines as a new class of 
A1 adenosine antagonists was described. With the notion of the importance of the BBB in 
mind, we performed PSA calculations on this series, and realised that the compounds are 
within the limits described by Kelder et al.9 This chapter describes the verification of our 
methods of calculating the PSA and the development of a new series of ligands related to that 
in Chapter 3 displaying similar levels of affinity and a notable increase in selectivity for the 
A1 adenosine receptor over the A2A and A3 receptors, whilst conforming to the PSA limits 
detailed above.  
4.2 Results and Discussion  
4.2.1 Polar Surface Area Calculations  
The polar surface area values of the molecules were calculated using Spartan 5.0 for SGI,12 in 
combination with an in-house developed application called PolSurf 1.0. [A copy of PolSurf 
and its (C) source code can be obtained via the author]. First Spartan was used to build the 
molecule, optimise its 3D-structure and calculate its property data; subsequently PolSurf was 
applied to convert the raw data from the Spartan "input" and "proparc" files into the polar 
surface area of the molecule. The resulting PSA values were verified by comparison with data 
already available in literature for calculations based on a single conformer and based upon 
Van der Waals surface areas (R2 = 0.98 for 75 compounds, Figure 4.1), as described by 
Clark.7,8 In the initial study,7 Clark took a training set of 20 compounds as described by Palm 
et al.,11 and showed that the use of a single-conformer based calculation was sufficient for 
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determining molecules that were likely to exhibit poor intestinal absorption. In further 
investigations, 74 drugs were taken, the PSA values calculated and compared to experimental 
percentage fractional absorption data, and the ‘rule-of-five’.13 He concluded that poor passive 
intestinal absorption occurred when a molecule has a PSA value of ≥ 140 Å2. Likewise, 
Kelder et al.9 published a similar paper stating that orally active drugs, when transported 














Figure 4.1. PSA values as calculated by Polsurf vs. values from Clark.7,8 
Furthermore, the Kelder investigation also studied BBB penetration, and concluded that by 
limiting the PSA to 60-70 Å2, brain penetration could be achieved. As in our calculations, 
both parties use Van der Waals surface areas, and only consider the heteroatoms N, O and any 
hydrogens that may be attached to them. This significant value of 60-70 Å2 was therefore 
proposed as the relevant limit for PSA to favour brain penetration. 
The PSA values of the compounds described in the previous chapter were calculated to be 
under the set limit, with a range of 49 (R = tBu) - 60 (R = Me) Å2. With reference to the 
preceding chapter, the current set of ligands was prepared with the model and PSA limits in 
mind.  
Again, the hydrogen-bond accepting and donating regions at the ‘bottom’ of the model can be 
satisfied by an aromatic nitrogen atom and an amido-hydrogen atom, respectively. At the 
‘top’ of the model a carbonyl oxygen will account for the hydrogen-bond accepting region 
(see Figure 4.2). This ‘fulfilment’ of the requirements leads directly to the concept of 2,4,6-
substituted pyridines, especially considering the benefits to PSA of only 4 atoms to include in 
the calculations (the two N atoms, the O atom and the hydrogen atom attached to amide 
nitrogen). One example, namely N-(4,6-diphenyl-pyridin-2-yl)-benzamide (PSA = 40 Å2) was 
made and tested, yielding an affinity at the human A1 adenosine receptor of 657 nM and 
displacement of the radioligand of 16% and 38% for the hA2A and hA3 receptors at 1 µM 
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(3.4) in Chapter 3 (Ki(hA1) = 670 nM, hA2A = 17% displacement at 1 µM, Ki(hA3) = 1700 
nM; PSA = 50 Å2), and similar substitution at the amide with small alkyl groups would have 
no doubt improved affinity dramatically. However, synthetic ease directed further 
developments towards the 2-amido-4,6-disubstituted pyrimidines. For this type of compound, 
the calculated PSA values are almost identical to the series described in Chapter 3, and thus 
within the 60-70 Å2 limit proposed earlier. The distinction between the 2-amido-4,6-
disubstituted pyrimidines and the 4-amido-2,6-disubstituted pyrimidines can be most simply 









Figure 4.2 The fulfilment of the various hydrogen-bonding regions of the pharmacophore       
described in Chapter 3.  
The two lipophilic groups described as L1 and L3 in the model were initially set again as 
phenyl groups in analogy to the previous series, and the exploration of the L2 pocket deemed 
to be of most importance. Some further investigation into the L1 and L3 pockets was realised 
with the synthesis of compounds with various substituted phenyl groups at the 4- and 6- 
positions of the 2-amido-pyrimidines. Two non-aromatic examples were also made.  
4.2.2 Chemistry 
The pyrimidines 4.14-4.43 were synthesised according to the route depicted in Scheme 4.1. 
The chalcones 4.1-4.4 were synthesised in a single step via an aldol condensation in the 
presence of TiCl414 whilst the other chalcones used were commercially available. Guanidine 
was freed from its hydrochloride salt form with NaOH(aq.) and reacted with the appropriate 
chalcone according to a method described by Al-Hajjar and Sabri.15 The primary amines 4.5-
4.13 were obtained in 15-51% yields. This 2-aminopyrimidine was reacted with the respective 
acid chlorides in the presence of triethylamine to give the desired 2-amido compounds (4.14-
4.19, 4.21-4.43). These were obtained in 13-98% yields, where the reaction conditions for 
each substrate were not optimised. The formamide derivative (4.20) was synthesised 
according to a preparation by Krein and Lowary using formic acid and acetic anhydride.16  
4.2.3 Structure Activity Relationships 
Table 4.1 summarises the results of the binding assays. The (substituted) benzamides were the 
first compounds to be prepared and tested. We found that the unsubstituted compound (4.14) 
showed relatively good affinity at the A1 receptor. In consequence to the Topliss17 system of 
substitution, the 4-position of the phenyl ring was varied first. This generally lowered the 
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affinity of the pyrimidines at all the adenosine receptors. In previous publications, it has been 
shown that the A3 adenosine receptor requires a 4-methoxy substitution to increase 
affinity.18,19 However, in this series of benzamides the 4-chloro substituent (4.15) showed the 
highest potency. The only 3-substituent (4.19) we made showed only fair affinity at the A1 










Scheme 4.1. Synthetic route to the 2-amido-4,6-diphenyl-pyrimidines 4.14-4.43. (a) TiCl4, Et3N; (b) 
NaOH, EtOH, H2O; (c) R1COCl, Et3N, 1,4-dioxane; (d) benzaldehyde, NaBH(OAc)3. 
As with the 4-amido-2,6-diphenyl-pyrimidines (Chapter 3), the alkyl substituents caused a 
substantial increase in affinity when compared to the phenyl counterparts, suggesting perhaps 
that these molecules bind in a similar way (at the A1 receptor), albeit with a different 
electronic pattern in the central heterocyclic core. At an affinity of 4 nM, compound 4.23 
(LUF 5735) with an n-propyl substituent, was the most active ligand. 
The A3 receptor is favoured by the smaller methyl and ethyl derivatives, improving on the 
affinity achieved by the 4-chlorobenzamide derivative substantially.  The extent of this 
resulted in a two-fold selectivity for A3 over A1; compound 4.21 Ki (hA1) = 480 nM  vs Ki 
(hA3) = 240 nM.  
The branched alkyl derivatives (4.26-4.29) showed a remarkably high selectivity for the A1 
receptor over the A2A and the A3 receptors. With Ki values ranging between 9-30 nM for most 
of these derivatives, it can be said that they are very well suited as ligands for the A1 
adenosine receptor.  
The cycloalkyl analogues were similarly good at the A1 receptor, with the cyclopentyl 
substituent (4.32, LUF 5751) having an affinity of 11 nM and good selectivity over the other 
two receptors. Like the small methyl and ethyl derivatives (4.21, 4.22), the smallest 
cycloalkyl group (4.30) had the best affinity to the other two receptors. The formamide 
derivative (4.20) displayed good affinity and surprisingly good selectivity for the A1 receptor, 
showing that although small substituents are more suitable for the A2A and A3 receptors, the 
lack of a substituent at this position does not favour these receptors.  
In an attempt to explore the maximal size and any specific hydrogen-bonding aspects of the 
two lipophilic areas labelled L1 and L3 in Figure 4.2, some phenyl derivatives were made, 
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displayed a drastic loss in their affinity to bind to the A1 receptor. This was, however, 
matched by a general increase in the affinity of the compounds to bind to the A3 receptor, 
culminating in the oft-predicted 4-methoxyphenyl substituent (4.36 and 4.39). The 
symmetrical nature of this series of molecules prevents our knowing whether the singularly 
substituted phenyl resides in the L1 or the L3 pocket.  
Table 4.1. Affinities and PSA values of the 2-amido-4,6-disubstituted-pyrimidines 4.14-4.43 in 








Ki (nM) or % displacementa  
 




(Å2) A1b A2Ac A3d 
4.14 Ph Ph Ph 53 309 ± 73 5% 38% 
4.15 4-Cl-Ph Ph Ph 53 0% 0% 3280 ± 1700 
4.16 4-MeO-Ph Ph Ph 64 31% 45% 41% 
4.17 4-Me-Ph Ph Ph 53 37% 0% 13% 
4.18 3,4-diCl-Ph Ph Ph 53 0% 0% 30% 
4.19 3-Cl-Ph Ph Ph 53 368 ± 66 22% 41% 
4.20 H Ph Ph 53 20 ± 2 21% 0% 
4.21 Me Ph Ph 53 483 ± 90 31% 237 ± 150 
4.22 Et Ph Ph 53 46 ± 3 893 ± 160 547 ± 47 
4.23 (LUF 5735) Pr Ph Ph 53 3.7 ± 2 7% 38% 
4.24 Bu Ph Ph 53 28 ± 10 0% 23% 
4.25 Pent Ph Ph 52 28% 0% 24% 
4.26 (LUF 5737) iPr Ph Ph 51 8.9 ± 4 44% 45% 
4.27 tBu Ph Ph 50 224 ± 120 0% 4% 
4.28 2-MePr Ph Ph 51 25 ± 7 42% 23% 
4.29 1-EtPr Ph Ph 51 27 ± 6 11% 27% 
4.30 c-Pr Ph Ph 52 25 ± 5 228 ± 95 676 ± 120 
4.31 c-Bu Ph Ph 53 107 ± 36 33% 18% 
4.32 (LUF 5751) c-Pent Ph Ph 51 11 ± 2 11% 39% 
4.33 c-Hex Ph Ph 51 119 ± 42 31% 9% 
4.34 Ph 4-ClPh 4-ClPh 49 2% 0% 6630 ± 1350 
4.35 Ph 4-MePh 4-MePh 51 0% 6% 36% 
4.36 Ph 4-MeOPh 4-MeOPh 73 6% 2% 1030 ± 308 
4.37 Ph 4-ClPh Ph 51 0% 15% 2110 ± 1310 
4.38 Ph 4-MePh Ph 51 6% 0% 1090 ± 340 
4.39 Ph 4-MeOPh Ph 62 7% 16% 825 ± 36 
4.40 Me 4-MeOPh Ph 64 314 ± 54 11% 73 ± 10 
4.41 Ph cHex Ph 53 34% 0% 30% 
4.42 Ph iPr Ph 53 19% 0% 30% 
4.43 Ph Ph H 53 8% 0% 2% 
aKi ± SEM (n = 3), % displacement (n = 2). bDisplacement of specific [3H]DPCPX binding in CHO cell 
membranes expressing human adenosine A1 receptors or % displacement of specific binding at 1 µM 
concentrations. cDisplacement of specific [3H]ZM 241385 binding in HEK 293 cell membranes expressing 
human adenosine A2A receptors or % displacement of specific binding at 1 µM concentrations. dDisplacement of 
specific [125I]AB-MECA binding in HEK 293 cell membranes expressing human adenosine A3 receptors or % 











However, there is a clear distinction in the benefits of substitution at just one of the phenyl 
groups for the A3 receptor, e.g., 4.34 (Ki = 6.6 µM) vs. 4.37 (Ki = 2 µM); 4.35 (36% 
displacement at 1 µM) vs. 4.38 (Ki = 1 µM); 4.36 (Ki = 1 µM) vs. 4.39 (Ki = 0.8 µM). 
Combining this single 4-methoxyphenyl substituent with the ‘best’ R1 substituent (Me), in 
terms of affinity for the A3 receptor, led to our most potent compound at this receptor (4.40), 
possessing also a more favourable selectivity for the A3 over the A1 receptor than compound 
4.21. There is certainly great potential to optimise this series to provide better ligands for the 
A3 receptor.  
To check the necessity of an aromatic substituent in either the L1 or the L3 pocket (Figure 
4.2), a cyclohexyl variety was synthesised (4.41). The loss of affinity with this compound 
suggests that either the lipophilic pocket is relatively narrow or that the π-electrons form 
favourable interactions with the amino acids of the receptor and thus increasing the affinity of 
the compound significantly. The further drop in affinity when a much smaller isopropyl group 
is introduced in this position (4.42), suggests that the π-electron interaction is very important, 
although some steric obstruction may still occur. The complete removal of one of the two 
groups, i.e. compound 4.43 shows that the dramatic loss in affinity results from the lack of π-






Figure 4.3 Two possible tautomers of the amide-bond (a) the amide-form; (b) the iminol form. 
If we assume that this set of ligands binds to the A1 receptor in the same manner as the 4-
amido-2,6-diphenylpyrimidines (Chapter 3) based on the comparably good affinities, there is 
one major difference between the two series of compounds that must therefore account for the 
enhanced selectivity. This is the position of the nitrogens in the ring with respect to the amide 
bond. The positioning of both nitrogen atoms adjacent to the amide functionality now 
highlights the issue of electronic interaction between the pyrimidine ring and the amide group. 
The close proximity of the two systems may lead to a forced conformation of the amide 
substituent, twisting the carbonyl group out of plane with the ring. This of course assumes 
that the molecule sits in the normally energetically more favourable amide form. It is also 
possible that there is a shift in electrons/protons forcing a preferred iminol-tautomer (see 
Figure 4.3), leaving the substituent still in the plane of the ring. This tautomerism may also be 
relevant to the 4-amido-2,6-diphenyl-pyrimidines of the preceding chapter, but due to the 
close proximity of not only one, but two nitrogen atoms (from the pyrimidine ring) to the 
amide group, we believe that it is of much more importance to the current series. This type of 
tautomerism question has been dealt with previously in our group on a set of isoquinolines.20 
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as that of the isoquinoline might contribute to conjugation, promoting the iminol form. In the 
1H NMR (CDCl3) spectra, a signal seen in the 16 ppm region was attributed to the iminol-
form and a peak present in the 10 ppm region to the amide form. This was further 
corroborated with IR spectral evidence using the presence or the absence of the characteristic 
carbonyl shift in the 1600-1700 cm-1 region. The IR spectra of the solid compounds showed 
that the compounds were primarily in the amide form. The similarities of the isoquinolines to 
the pyrimidines with respect to the positioning of the amide group adjacent to the nitrogen of 
the heterocycle led us also to examine the spectroscopic data of one representative compound 
in more detail. Compound 4.26 (LUF 5737) was chosen as the representative ligand due to its 
high affinity and good selectivity for the A1 adenosine receptor. Although the phenyl-
substituted compounds (4.14-4.19) are more similar to the isoquinoline derivatives, these 
were not examined in further detail due to their relatively poor affinities. The 1H NMR 
(CDCl3) of compound 4.26 showed clearly a signal in the 8 ppm region which corresponds to 
the N-H of the traditional amide form of the molecule. The use of the more polar DMSO as a 
NMR solvent gave a comparable spectrum. The ligand was further examined with IR 
spectroscopy, where a sharp carbonyl signal was present at 1680 cm-1 in the solid phase, 
shifting to a broader signal at 1683 cm-1 in chloroform. Examining compound 4.26 in silico, 
the molecules were drawn in Spartan, minimised and conformers were then generated using 
the systematic search method. To determine a representative and comparable energy of each 
tautomer, the lowest energy conformer was subjected to ab initio calculations using 3-21G* 
as the basis set. The resulting ∆G between the lowest energy conformers of the two 
tautomeric forms was 17 kcal·mol-1 in favour of the amide.  It is therefore proposed that the 
alkyl-substituted 2-amido-pyrimidines reside in the amide tautomeric form.  It should be 
noted though, that the receptor-bound conformation could still be different despite the 
unambiguous experimental and computational evidence for the amide tautomer. The ability of 
this particular hydrogen in question to shift between the heteroatoms, causing the molecule to 
adopt different tautomers, may also be a key reason why the 2-amido- or indeed the 4-amido-
pyrimidines possess a high affinity for the adenosine A1 receptor. 
The compounds designed, synthesised and tested in this chapter show PSA values within the 
proposed limits for BBB penetration by Kelder.9 To relate our compounds to examples of 
adenosine A1 antagonists that already display CNS activity, we calculated the PSA of two 
well-documented molecules (see Figure 4.4). The first example was caffeine, an adenosine 
antagonist with well-known CNS effects, and was calculated by our methods to have a PSA 
value of 59 Å2. Another xanthine, which was published with thorough in vivo data, is KFM 19 
(the more active S(-) enantiomer is known as ampaxifylline).21 This was administered orally 
to a number of different species and found to demonstrate good bioavailability. Moreover, its 
pharmacological profile suggested a high therapeutic potential for dementia and other 
cognitive deficits. We calculated the PSA value of KFM 19 to be 82 Å2. Since the PSA values 
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for the ligands detailed in this paper lie within or under these two values we believe that this 








Figure 4.4 a) Caffeine (PSA = 59 Å2), b) KFM 19 (PSA = 82 Å2) 
4.3 Conclusion 
Presented here is a new series of ligands with good affinity at the adenosine A1 receptor and 
excellent selectivity over the A2A and A3 adenosine receptors. Moreover, they have a PSA of 
approximately 60 Å2, and as such meet our first simple cut-off for BBB penetration. In 
particular compound 4.23 (LUF 5735) combined high affinity (Ki = 4 nM) with high 
selectivity for the A1 adenosine receptor and a PSA value of only 53 Å2.  
4.4 Experimental Section  
4.4.1 Molecular Modelling 
Molecular modelling work was performed on the SPARTAN molecular modelling package version 5.0 
(Wavefunction Inc.)12 running on a Silicon Graphics O2 workstation. Default values in the Merck Force Field 
were used in Molecular Mechanics minimisations. Conjugate gradient energy minimisations were continued 
until the rms energy derivative was less than 0.001kcal·mol-1Å-1. Conformers were then generated using the 
systematic search method and the lowest energy conformer was used for further calculations. The energy and 
molecular electrostatic potential was calculated using the semi-empirical molecular orbital program AM1. The 
electrostatic potentials were sampled over the entire accessible surface of the molecules (equal to a Van der 
Waals contact surface). The polar surface areas of the molecules were then calculated by applying Polsurf 1.0 to 
convert the raw data from the Spartan "input" and "proparc" files into the polar surface area of the molecule. [A 
copy of PolSurf and its (C) source code can be obtained from the author.] Further energy calculations on 
compound 4.26 were performed by taking the lowest energy conformer (as generated by the procedure described 
above) and subjecting this to ab initio calculations using 3-21G* as the basis set. 
4.4.2 Chemistry 
Materials and Methods 
All reagents used were obtained from commercial sources and all solvents were of an analytical grade. 1H and 
13C NMR spectra were recorded on a Bruker AC 200 (1H NMR, 200 MHz; 13C NMR, 50.29 MHz) spectrometer 
with tetramethylsilane as an internal standard. Chemical shifts are reported in δ (ppm) and the following 
abbreviations are used: s = singlet, d = doublet, dd = double doublet, t = triplet, m = multiplet, br = broad and ar 
= aromatic protons. Melting points were determined on a Büchi melting point apparatus and are uncorrected. 
Elemental analyses were performed by the Leiden Institute of Chemistry and are within 0.4% of the theoretical 
values unless otherwise stated. Reactions were routinely monitored by TLC using Merck silica gel F254 plates. 
Solid phase infrared spectra were measured with a Perkin-Elmer FT-IR Paragon 1000 spectrometer equipped 
with a Golden Gate Diamond ATR, using reflectance technique (neat, 4000-300 cm-1, res. 4 cm-1). Solution 
phase infrared was recorded on a Bruker 330V IR spectrophotometer equipped with a circle liquid analyzer from 
Spectra Tech. (4000-300 cm-1, res. 4 cm-1) 
General Procedure for the synthesis of the substituted chalcones (4.1-4.4). 
TiCl4 (5.17 mL, 47 mmol, 1.1 eq) was added carefully to CH2Cl2 (120 mL) at 0 ºC. To this was added 
a solution of aldehyde (43 mmol) and ketone (43 mmol) in CH2Cl2 (50 mL) and the reaction mixture 
stirred for 5 mins. A solution of Et3N (6.9 mL, 49 mmol, 1.14 mmol) in CH2Cl2 (20 mL) was then 
added and the reaction mixture then stirred at 0 ºC for a further 45 mins before pouring onto crushed ice. The 
organic layer was separated and washed with H2O and brine, dried (MgSO4) and the solvent evaporated. 
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4,4’-Dimethylchalcone (4.1). Yield 32%. 1H NMR δ (CDCl3): 7.96-7.91 (m, 2H, Ar-H), 7.83-7.75 (m, 1H, CH), 
7.57-7.45 (m, 3H, Ar-H + CH), 7.32-7.20 (m, 4H, Ar-H), 2.44, 2.40 (2 × s, 6H, 2 × CH3).  
4-Methylchalcone (4.2). Yield 16%. 1H NMR δ (CDCl3): 8.05-7.99 (m, 2H, Ar-H), 7.84-7.77 (d, 1H, J = 16 Hz, 
CH), 7.59-7.46 (m, 7H, Ar-H), 7.25-7.21 (m, 1H, CH), 2.40 (s, 3H, CH3).  
Cyclohexyl-1-phenyl-propenone (4.3). Yield 25%. 1H NMR δ (CDCl3): 7.94-7.90 (m, 2H, Ar-H), 7.54-7.41 
(m, 3H, Ar-H), 7.07-6.96 (m, 1H, CH), 6.87-6.78 (m, 1H, CH), 2.40-2.21 (m, 1H, CH), 1.86-1.18 (m, 10H, 
cHex).  
Isopropyl-1-phenyl-propenone (4.4). Yield 26%. 1H NMR δ (CDCl3): 7.95-7.90 (m, 2H, Ar-H), 7.53-7.41 (m, 
3H, Ar-H), 7.12-6.82 (m, 2H, 2 × CH), 3.52-3.41 (m, 1H, CH), 0.94-0.91 (m, 6H, 2 × CH3).  
General procedure for the synthesis of 2-amino-4,6-disubstitutedpyrimidines (4.5-4.13). 
A mixture of chalcone (benzylidenacetophenone) (38.6 g, 0.185 mol, 1.1 eq.) and guanidine 
hydrochloride (16 g, 0.168 mol, 1 eq.) were refluxed in ethanol (150 mL). Sodium hydroxide (21.6 
g, 0.539 mol, 3.2 eq.) was dissolved in a minimum amount of water (40 mL), and added dropwise 
to the refluxing mixture. The reaction mixture was then stirred at reflux for a further 6 h. Upon cooling, the 
reaction mixture was concentrated and then separated between ethyl acetate (200 mL) and water (200 mL). The 
aqueous layer was then extracted with ethyl acetate (2 × 100 mL). The combined organic layers were washed 
with water (200 mL) and brine (200 mL), dried over MgSO4, and concentrated in vacuo. The crude product was 
purified by column chromatography on SiO2, eluting with dichloromethane. Recrystallisation from ethyl acetate 
gave clear colourless crystals.  
2-Amino-4,6-diphenylpyrimidine (4.5). Yield 31%. 1H NMR δ (CDCl3): 8.09-8.04 (m, 4H, phenyl-H), 7.54-
7.48 (m, 7H, phenyl-H + pyrimidinyl-H), 5.25 (br s, 2H, NH2).   
2-Amino-4,6-di(4-chlorophenyl)-pyrimidine (4.6). Yield 44%. 1H NMR δ (CDCl3): 8.04-7.99 (m, 4H, phenyl-
H), 7.50-7.46 (m, 4H, phenyl-H), 7.40 (s, 1H, pyrimidinyl-H), 5.38 (br s, 2H, NH2).   
2-Amino-4,6-di(4-tolyl)-pyrimidine (4.7). Yield 27%. 1H NMR δ (CDCl3): 7.99-7.94 (m, 4H, Ar-H), 7.43 (s, 
1H, pyrimidinyl-H), 7.32-7.27 (m, 4H, Ar-H), 5.21 (br s, 2H, NH2).   
2-Amino-4,6-di(4-methoxyphenyl)-pyrimidine (4.8). Yield 35%. 1H NMR δ (CDCl3): 8.06-8.02 (m, 4H, Ar-
H), 7.37 (s, 1H, pyrimidinyl-H), 7.03-6.99 (m, 4H, Ar-H), 5.19 (br s, 2H, NH2), 3.88 (s, 6H, 2 × OCH3).  
2-Amino-4-(4-chlorophenyl)-6-phenylpyrimidine (4.9). Yield 51%. 1H NMR δ (CDCl3): 8.09-7.99 (m, 4H, 
Ar-H), 7.53-7.44 (m, 5H, Ar-H + pyrimidinyl-H), 5.36 (br s, 2H, NH2). 
2-Amino-4-(4-tolyl)-6-phenylpyrimidine (4.10).Yield 28%. 1H NMR δ (CDCl3): 8.09-8.04 (m, 2H, Ar-H), 
8.00-7.96 (m, 2H, Ar-H), 7.52-7.48 (m, 2H, Ar-H), 7.46 (s, 1H, pyrimidinyl-H), 7.33-7.26 (m, 2H, Ar-H), 5.23 
(br s, 2H, NH2), 2.44 (s, 3H, OCH3).  
2-Amino-4-(4-methoxyphenyl)-6-phenylpyrimidine (4.11). Yield 23%. 1H NMR δ (CDCl3): 8.08-8.04 (m, 4H, 
Ar-H), 7.51-7.48 (m, 3H, Ar-H), 7.43 (s, 1H, pyrimidinyl-H), 7.03-6.99 (m, 4H, Ar-H), 5.23 (br s, 2H, NH2), 
3.89 (s, 6H, OCH3).  
2-Amino-4-(cyclohexyl)-6-phenylpyrimidine (4.12). Yield 15%. 1H NMR δ (CDCl3): 7.97-7.92 (m, 2H, 
phenyl-H), 7.45-7.42 (m, 3H, phenyl-H), 6.88 (s, 1H, pyrimidinyl-H), 5.52 (br s, 2H, NH2), 2.57-2.45 (m, 1H, 
CH), 1.97-1.17 (m, 10H, cHex).   
2-Amino-4-(isopropyl)-6-phenylpyrimidine (4.13). Yield 36%. 1H NMR δ (CDCl3): 7.99-7.92 (m, 2H, phenyl-
H), 7.47-7.41 (m, 3H, phenyl-H), 6.86 (s, 1H, pyrimidinyl-H), 5.46 (br s, 2H, NH2), 2.18-2.08 (m, 1H, CH), 
0.98-0.95 (m, 6H, 2 × CH3).   
General Procedure for the Preparation of 2-Amidopyrimidines (4.14-4.42). 
To a solution of 2-amino-4,6-diphenylpyrimidine (0.202 mmol, 1 eq.) in 1,4-dioxane (5 mL) was 
added triethylamine (0.223 mmol, 1.1 eq.), followed by the appropriate acid chloride (0.304 
mmol, 1.5 eq.). This was then stirred at reflux until no starting material was visible by TLC. 
Upon completion, the reaction mixture was separated between ethyl acetate (20 mL) and water 
(20 mL). The aqueous layer was further extracted with ethyl acetate (2 × 20 mL) and the combined organic 
layers washed with water and brine. After drying over MgSO4 and evaporation under reduced pressure, the crude 
product was purified by column chromatography, eluting with a petroleum ether-ethyl acetate or a 
dichloromethane-methanol solvent system. Recrystallisation with ethanol or petroleum ether-ethyl acetate gave 
the corresponding amide in crystalline form. 
N-(4,6-Diphenyl-pyrimidin-2-yl)-benzamide (4.14). Yield 34%; white solid; mp 169-170 °C. 1H NMR δ 
(CDCl3): 8.75 (br s, 1H, N-H), 8.22-8.17 (m, 4H, phenyl-H), 8.02-7.98 (m, 2H, phenyl-H), 7.90 (s, 1H, 
pyrimidine-H), 7.56-7.52 (m, 9H, phenyl-H). 13C NMR δ (CDCl3): 166.1, 136.5, 132.1, 131.0, 128.9, 128.7, 
127.2, 108.1. MS (ES+): 351.50 Da. Anal. calc. for (C23H17N3O) (C 78.61; H 4.88; N 11.96) found (C 78.20; H 
4.88; N 12.38) %. 
N-(4,6-Diphenyl-pyrimidin-2-yl)-4-chloro-benzamide (4.15). Yield 82%; white solid; mp 185 °C. 1H NMR δ 
















phenyl-H). 13C-NMR δ (CDCl3): 166.1, 164.5, 157.9, 138.3, 136.4, 136.1, 133.1, 131.1, 128.9, 127.2, 113.4, 
108.1. MS (ES+): 385.84 Da. Anal. (C23H16ClN3O.0.2H2O) C, H, N. 
N-(4,6-diphenyl-pyrimidin-2-yl)-4-methoxy-benzamide (4.16). Yield 27%; white solid; mp 155 °C. 1H NMR 
δ (CDCl3): 8.82 (br s, 1H, NH), 8.22-8.13 (m, 4H, phenyl-H), 7.99-7.92 (d, 2H, phenyl-H), 7.85 (s, 1H, 
pyrimidinyl-H), 7.53-7.48 (m, 6H, phenyl-H), 7.00-6.93 (d, 2H, phenyl-H), 3.86 (s, 3H, CH3). 13C NMR δ 
(CDCl3): 165.9, 158.1, 136.5, 130.8, 129.3, 128.7, 127.1, 113.7, 107.8, 55.2. MS (ES+): 382.1 Da. Anal 
(C24H19N3O2.3H2O) C, H, N. 
N-(4,6-diphenylpyrimidin-2-yl)-4-methyl-benzamide (4.17). Yield 22%; white solid; mp 190 °C. 
1H NMR δ (CDCl3): 8.76 (br s, 1H, NH), 8.23-8.18 (m, 4H, phenyl-H), 7.94 (d, 2H, phenyl-H), 7.90 (s, 1H, 
pyrimidinyl-H), 7.56-7.53 (m, 6H, phenyl-H), 7.36-7.32 (d, 2H, phenyl-H), 2.46 (s, 3H, CH3). 13C NMR δ 
(CDCl3): 166.2, 165.2, 158.2, 142.9, 142.9, 136.7, 131.3, 131.1, 129.5, 128.9, 128.8, 127.6, 127.3, 108.1, 21.5. 
MS (ES+): 366.0 Da. Anal. (C24H19N3O.0.2H2O) C, H, N. 
3,4-Dichloro-N-(4,6-diphenyl-pyrimidin-2-yl)-benzamide (4.18). Yield 13%; white solid; mp 146-147 °C. 1H 
NMR δ (CDCl3): 8.67 (br s, 1H, NH), 8.18-8.11 (m, 4H, phenyl-H), 8.08-8.07 (m, 1H, phenyl-H), 7.93 (s, 1H, 
pyrimidinyl-H), 7.83-7.78 (m, 1H, phenyl-H), 7.64-7.51 (m, 7H, phenyl-H). 13C NMR δ (CDCl3): 166.2, 157.8, 
136.3, 134.4, 133.1, 131.1, 130.6, 129.6, 128.9, 127.2, 126.5, 108.4. MS (ES+): 419.5 Da. Anal. 
(C23H15Cl2N3O.1.3H2O) C, H, N. 
N-(4,6-Diphenyl-pyrimidin-2-yl)-3-chloro-benzamide (4.19). Yield 98%; white solid; mp 147-148 °C. 1H 
NMR δ (CDCl3): 8.96 (br s, 1H, NH), 8.16-8.11 (m, 4H, phenyl-H), 7.91-7.89 (m, 1H, phenyl-H), 7.85 (s, 1H, 
pyrimidinyl-H), 7.81-7.77 (m, 1H, phenyl-H), 7.54-7.45 (m, 6H, phenyl-H), 7.42-7.35 (m, 2H, phenyl-H). 13C 
NMR δ (CDCl3): 166.2, 164.2, 136.4, 134.8, 131.1, 129.9, 128.9, 127.7, 127.2, 125.5, 108.2, 98.0. MS (ES+): 
385.69 Da. Anal. (C23H16ClN3O.0.2H2O) C, H, N. 
N-(4,6-Diphenyl-pyrimidin-2-yl)-formamide (4.20).16 Formic acid (0.37g, 8.1 mmol, 10 eq.) was cooled to 0 
ºC, 2-amino-4,6-diphenylpyrimidine (0.2g, 0.81 mmol) and acetic anhydride (0.125 g, 1.2 mmol, 1.5 eq.) were 
added carefully and the mixture brought slowly to RT and stirred overnight. Ethyl acetate (20 mL) and H2O (5 
mL) were added and the layers separated. The organic layer was then further washed with H2O, saturated 
NaHCO3(aq.), brine and then dried (MgSO4) and the solvents evaporated in vacuo. Recrystallisation in hot EtOH 
rendered the pure product. Yield 81%; white solid; mp 186 °C. 1H NMR δ (CDCl3): 11.06 (br s, 1H, NH), 9.66 
(s, 1H, CHO), 8.36-8.30 (m, 5H, phenyl-H + pyrimidinyl-H), 7.59-7.56 (m, 6H, phenyl-H). 13C NMR δ (CDCl3): 
165.2, 158.1, 136.0, 131.4, 128.8, 127.4, 107.9. MS (ES+): 275.9 Da. Anal. (C17H13N3O) C, H, N. 
N-(4,6-Diphenyl-pyrimidin-2-yl)-acetamide (4.21). Yield 43%; white solid; mp 217-218 °C. 1H NMR δ 
(CDCl3): 8.15-8.10 (m, 5H, phenyl-H + N-H), 7.83 (s, 1H, pyrimidinyl-H), 7.56-7.53 (m, 6H, phenyl-H), 2.76 (s, 
3H, CH3). 13C NMR δ (CDCl3): 166.0, 148.5, 136.1, 131.1, 128.9, 127.1, 107.3, 25.5. MS (ES+): 289.91 Da. 
Anal (C18H17N3O.0.2H2O) C, H, N. 
N-(4,6-Diphenyl-pyrimidin-2-yl)-propionamide (4.22). Yield 21%; white solid; mp 165 °C. 1H NMR δ 
(CDCl3): 8.17-8.08 (m, 5H, phenyl-H + NH), 7.81 (s, 1H, pyrimidinyl-H), 7.56-7.50 (m, 6H, phenyl-H), 3.05 (q, 
2H, J = 7.30 Hz, CH2CH3), 1.32 (t, 3H, J = 7.31 Hz, CH2CH3). 13C NMR δ (CDCl3): 174.8, 157.7, 136.5, 131.0, 
128.8, 127.0, 107.2, 30.7, 11.5. MS (ES+): 303.86 Da. Anal (C19H17N3O.0.2H2O) C, H, N. 
N-(4,6-Diphenyl-pyrimidin-2-yl)-butyramide  (4.23). Yield 47%; white solid; mp 157 °C. 1H NMR δ (CDCl3): 
8.16-8.09 (m, 4H, phenyl-H), 8.08 (br s, 1H, NH), 7.83 (s, 1H, pyrimidinyl-H), 7.55-7.52 (m, 6H, phenyl-H), 
3.02 (t, 2H, J = 7.30 Hz, CH2CH2CH3), 1.86 (sextet, 2H, J = 7.30 Hz, CH2CH2 CH3), 1.08 (t, 3H, J = 7.30Hz, 
CH2CH2CH3). 13C NMR δ (CDCl3): 174.2, 166.0, 157.7, 131.0, 128.8, 127.1, 107.3, 39.3, 18.3, 11.8. MS (ES+): 
317.95 Da. Anal (C20H19N3O) C, H, N. 
Pentanoic acid (4,6-diphenyl-pyrimidin-2-yl)-amide (4.24). Yield 32%; white solid; mp 157 °C. 1H NMR δ 
(CDCl3): 8.16-8.11 (m, 4H, phenyl-H), 8.09 (br s, 1H, NH), 7.82 (s, 1H, pyrimidinyl-H), 7.56-7.52 (m, 6H, 
phenyl-H), 3.05 (t, 2H, J = 7.67 Hz, CH2CH2CH2CH3), 1.86-1.74 (m, 2H, CH2CH2CH2CH3), 1.58-1.40 (m, 2H, 
CH2CH2CH2CH3), 0.99 (t, 3H, J = 7.30 Hz, CH2CH2CH2CH3). 13C NMR δ (CDCl3): 165.9, 157.8, 136.6, 131.0, 
128.8, 127.1, 121.3, 113.6, 107.2, 37.2, 22.4, 11.8. MS (ES+): 331.86 Da. Anal. (C21H21N3O.0.2H2O) C, H, N. 
Hexanoic acid (4,6-diphenyl-pyrimidin-2-yl)-amide (4.25). Yield 86%; white solid; mp 164-165 °C. 1H NMR 
δ (CDCl3): 8.30 (br s, 1H, NH), 8.14-8.09 (m, 4H, phenyl-H), 7.79 (s, 1H, pyrimidinyl-H), 7.54-7.50 (m, 6H, 
phenyl-H), 3.00 (t, 2H, J = 7.67 Hz, CH2CH2CH2CH2CH3), 1.86-1.78 (m, 2H, CH2CH2CH2CH2CH3), 1.46-1.41 
(m, 4H, CH2CH2CH2CH2CH3), 0.93 (m, 3H, CH2CH2CH2CH2CH3). 13C NMR δ (CDCl3): 174.1, 165.9, 157.8, 
136.6, 131.0, 128.8, 127.1, 107.2, 37.2, 31.4, 24.4, 22.4, 13.9. MS (ES+): 345.95 Da. Anal. (C22H23N3O) C, H, N. 
N-(4,6-Diphenyl-pyrimidin-2-yl)-isobutyramide (4.26). Yield 39%; white solid; mp 160-161 °C. 1H NMR δ 
(CDCl3): 8.17-8.10 (m, 4H, phenyl-H), 8.09 (br s, 1H, NH), 7.84 (s, 1H, pyrimidinyl-H), 7.56-7.51 (m, 6H, 
phenyl-H), 3.41-3.38 (m, 1H, CH(CH3)2), 1.35 (d, 6H, J = 6.94 Hz, CH(CH3)2). 13C NMR δ (CDCl3): 166.0, 
157.7, 136.6, 136.0, 131.0, 128.8, 127.1, 107.5, 35.2, 19.2. MS (ES+): 317.94 Da. Anal (C20H19N3O) C, H, N. 
N-(4,6-diphenyl-pyrimidin-2-yl)-2,2-dimethyl-propionamide (4.27). Yield 64%; white solid; mp 128 °C. 1H 
NMR δ (CDCl3): 8.29 (br s, 1H, NH), 8.20-8.14 (m, 4H, phenyl-H), 7.82 (s, 1H, pyrimidinyl-H), 7.51-7.48 (m, 
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6H, phenyl-H), 1.39 (s, 9H, 3x CH3). 13C NMR δ (CDCl3): 175.7, 158.0, 136.6, 130.9, 128.8, 127.2, 107.8, 40.2, 
27.4. MS: 332.3 Da. Anal. (C21H21N3O.0.2H2O) C, H, N. 
N-(4,6-diphenyl-pyrimidin-2-yl)-3-methylbutyramide (4.28). Yield 48%; white solid; mp 134-135 °C. 1H 
NMR δ (CDCl3): 8.27 (br s, 1H, NH), 8.15-8.07 (m, 4H, phenyl-H), 7.79 (s, 1H, pyrimidinyl-H), 7.55-7.47 (m, 
6H, phenyl-H), 2.87 (d, 2H, J = 7.30, CH2), 2.40-2.26 (m, 1H, CH), 1.06 (d, 6H, J = 6.94, 2x CH3). 13C NMR δ 
(CDCl3): 173.1, 166.0, 157.8, 136.6, 131.1, 128.9, 127.2, 107.4, 46.3, 25.3, 22.6. MS: 345.9,367.6 Da. Anal. 
(C21H21N3O.0.3H2O) C, H, N. 
N-(4,6-Diphenyl-pyrimidin-2-yl)-2-ethyl-butyramide (4.29). Yield 22%; white solid; mp 120-121 °C. 1H 
NMR δ (CDCl3): 8.18-8.13 (m, 4H, phenyl-H), 8.11 (br s, 1H, NH), 7.84 (s, 1H, pyrimidinyl-H), 7.56-7.51 (m, 
6H, phenyl-H), 2.97 (m, 1H, CH(CH2CH3)2), 1.94-1.59 (m, 4H, CH(CH2CH3)2), 1.02 (t, 6H, J = 7.30 Hz, 
CH(CH2CH3)2). 13C NMR δ (CDCl3): 166.0, 157.7, 136.6, 130.9, 128.8, 127.1, 121.6, 107.6, 50.1, 24.9, 11.8. 
MS (ES+): 324.86, 690.57 Da. Anal. (C22H23N3O) C, H, N. 
Cyclopropane carboxylic acid (4,6-diphenyl-pyrimidin-2-yl)-amide (4.30). Yield 57%; white solid; mp 158 
°C. 1H NMR δ (CDCl3): 8.77 (br s, 1H, NH), 8.13-8.08 (m, 4H, phenyl-H), 7.78 (s, 1H, pyrimidinyl-H), 7.51-
7.47 (m, 6H, phenyl-H), 2.67 (m, 1H, -CHCH2CH2-), 1.29-1.21 (m, 2H, CHCH2CH2-), 0.99-0.90 (m, 2H, -
CHCH2CH2-). 13C NMR δ (CDCl3): 174.1, 165.9, 157.9, 136.5, 130.9, 128.8, 127.1, 107.4, 14.8, 9.4. MS (ES+): 
337.75 Da. Anal (C20H17N3O) C, H, N. 
Cyclobutane carboxylic acid (4,6-diphenyl-pyrimidin-2-yl)-amide (4.31). Yield 98%; white solid; mp 146-
147 °C. 1H NMR δ (CDCl3): 8.35 (br s, 1H, NH), 8.13-8.08 (m, 4H, phenyl-H), 7.76 (s, 1H, pyrimidinyl-H), 
7.52-7.48 (m, 6H, phenyl-H), 4.05-3.96 (m, 1H, -CHCH2CH2CH2-), 2.57-2.21 (m, 4H, -CHCH2CH2CH2-), 2.09-
1.92 (m, 2H, -CHCH2CH2CH2-). 13C NMR δ (CDCl3): 175.2, 165.9, 157.7, 136.5, 130.9, 128.8, 127.0, 113.5, 
107.2, 40.3, 24.8, 18.0. MS (ES+): 330, 331 Da. Anal. (C21H19N3O.0.1H2O) C, H, N. 
Cyclopentane carboxylic acid (4,6-diphenyl-pyrimidin-2-yl)-amide (4.32). Yield 98%; white solid; mp 145-
146 °C. 1H NMR δ (CDCl3): 8.16-8.11 (m, 4H, phenyl-H), 7.82 (s, 1H, pyrimidinyl-H), 7.55-7.51 (m, 6H, 
phenyl-H), 2.04-1.65 (m, 9H, cyclopentyl). 13C NMR δ (CDCl3): 176.2, 165.9, 157.8, 131.0, 128.8, 127.1, 107.4, 
45.7, 30.1, 26.0. MS: 344.2 Da. Anal. (C22H21N3O.0.1H2O) C, H, N. 
Cyclohexanecarboxylic acid-(4,6-diphenyl-pyrimidin-2-yl)-amide (4.33).  Yield 26%; white solid; mp 172 
°C. 1H NMR δ (CDCl3): 8.11-8.19 (m, 4H, phenyl-H), 7.83 (s, 1H, pyrimidinyl-H), 7.50-7.57 (m, 6H, phenyl-H), 
0.83-2.10 (m, 11H, CH2 + CH). 13C NMR δ (CDCl3): 166.1, 157.8, 136.6, 131.0, 128.8, 127.2, 022.7, 121.7, 
107.5, 44.9, 29.1, 25.6. MS: 357.8 Da. Anal. (C23H23N3O.0.2H2O) C, H, N. 
N-[4,6-Bis(4-chlorophenyl)-pyrimidin-2-yl]-benzamide (4.34). Yield 65%; white solid; mp 193 °C. 1H NMR δ 
(CDCl3): 8.19-8.15 (m, 4H, Ar-H), 8.08-8.04 (m, 2H, Ar-H), 7.83 (s, 1H, pyrimidinyl-H), 7.60-7.51(m, 7H, Ar-
H). 13C NMR δ (CDCl3): 165.2, 165.0, 158.7, 158.0, 137.4, 132.3, 129.1, 128.7, 128.5, 127.4, 107.3. MS: 419.5, 
421.5 Da. Anal. (C23H15Cl2N3O.0.25H2O) C, H, N. 
N-[4,6-Di-4-tolyl-pyrimidin-2-yl]-benzamide (4.35). Yield 97%; white solid; mp 210 °C. 1H NMR δ (CDCl3): 
8.69 (br s, 1H, N-H), 8.07 (d, 4H, J = 8.4 Hz, Ar-H), 7.99-7.95 (m, 2H, Ar-H), 7.83 (s, 1H, pyrimidinyl-H), 7.59-
7.46 (m, 3H, Ar-H), 7.32 (d, 2H, J = 8.4 Hz, Ar-H), 2.43 (s, 6H, 2 × CH3). 13C NMR δ (CDCl3): 166.0, 141.5, 
133.9, 132.1, 129.6, 128.7, 127.5, 127.2, 121.8, 107.4, 21.4. MS: 379.7 Da. Anal. (C25H21N3O.0.15H2O) C, H, N. 
N-[4,6-Bis(4-methoxyphenyl)-pyrimidin-2-yl]-benzamide (4.36). Yield 43%; white solid; mp 159-160 °C. 1H 
NMR δ (CDCl3): 8.81 (br s, 1H, N-H), 8.13-8.07 (m, 4H, Ar-H), 7.95-7.90 (m, 2H, phenyl-H), 7.69 (s, 1H, 
pyrimidinyl-H), 7.55-7.41 (m, 3H, phenyl-H), 7.00-6.96 (m, 4H, Ar-H), 3.84 (s, 6H, 2 × OCH3). 13C NMR δ 
(CDCl3): 165.4, 165.2, 161.9, 157.9, 134.8, 131.9, 129.1, 128.7, 128.6, 127.4, 121.5, 114.1, 106.2, 55.3. MS: 
411.7 Da. Anal. (C25H21N3O3.0.3H2O) C, H, N. 
N-[4-(4-Chlorophenyl)-6-phenyl-pyrimidin-2-yl]-benzamide (4.37). Yield 81%; white solid; mp 175 °C. 1H 
NMR δ (CDCl3): 8.72 (br s, 1H, N-H), 8.19-8.12 (m, 4H, Ar-H), 8.02-7.97 (m, 2H, Ar-H), 7.86 (s, 1H, 
pyrimidinyl-H), 7.62-7.43 (m, 8H, Ar-H). 13C NMR δ (CDCl3): 166.3, 165.3, 164.7, 158.1, 136.4, 134.9, 132.2, 
131.1, 129.0, 128.9, 128.7, 128.5, 127.4, 127.2, 107.7. MS: 385.7 Da. Anal. (C23H16ClN3O.0.25H2O) C, H, N. 
N-[4-(4-Tolyl)-6-phenyl-pyrimidin-2-yl]-benzamide (4.38). Yield 77%; white solid; mp 171-172 °C. 1H NMR 
δ (CDCl3): 8.82 (br s, 1H, N-H), 8.19-7.93 (m, 6H, Ar-H), 7.84 (s, 1H, pyrimidinyl-H), 7.57-7.44 (m, 6H, Ar-H), 
7.33-7.29 (m, 2H, Ar-H), 2.43 (s, 3H, CH3). 13C NMR δ (CDCl3): 166.0, 165.9, 165.3, 158.0, 141.5, 136.7, 
134.7, 133.7, 132.0, 130.9, 129.6, 128.8, 128.6, 127.4, 127.2, 127.1, 107.6, 21.4. MS: 365.9 Da. Anal. 
(C24H19N3O.0.25H2O) C, H, N. 
N-[4-(4-Methoxyphenyl)-6-phenyl-pyrimidin-2-yl]-benzamide (4.39). Yield 29%; white solid; mp 159-161 
°C. 1H NMR δ (CDCl3): 8.68 (br s, 1H, N-H), 8.19-8.14 (m, 4H, Ar-H), 8.01-7.96 (m, 2H, Ar-H), 7.82 (s, 1H, 
pyrimidinyl-H), 7.63-7.48 (m, 6H, Ar-H), 7.06-6.99 (m, 2H, Ar-H), 3.90 (s, 3H, OCH3). 13C NMR δ (CDCl3): 
165.5, 165.4, 162.1, 157.8, 132.0, 130.9, 128.9, 128.8, 128.6, 127.4, 127.1, 114.2, 107.1, 55.3. MS: 381.8 Da. 
Anal. (C24H19N3O2) C, H, N. 
N-[4-(4-Methoxyphenyl)-6-phenyl-pyrimidin-2-yl]-acetamide (4.40). Yield 58%; white solid; mp 164 °C. 1H 
NMR δ (CDCl3): 8.19 (br s, 1H, N-H), 8.10-8.06 (m, 4H, Ar-H), 7.71 (s, 1H, pyrimidinyl-H), 7.53-7.50 (m, 3H, 
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phenyl-H), 7.03-6.99 (m, 2H, Ar-H), 3.88 (s, 3H, CH3), 2.72 (s, 3H, CH3). 13C NMR δ (CDCl3): 171.8, 165.5, 
165.3, 162.1, 157.6, 142.3, 136.6, 130.9, 128.8, 128.6, 127.0, 114.1, 106.2, 55.3, 25.5. MS: 319.9 Da. Anal. 
(C19H17N3O2) C, H, N. 
N-(4-Cyclohexyl-6-phenyl-pyrimidin-2-yl)-benzamide (4.41). Yield 50%; white solid; mp 98 °C. 1H NMR δ 
(CDCl3): 8.71 (br s, 1H, N-H), 8.13-8.08 (m, 2H, Ar-H), 7.97-7.93 (m, 2H, Ar-H), 7.56-7.44 (m, 6H, Ar-H), 7.35 
(s, 1H, pyrimidinyl-H), 2.76-2.63 (m, 1H, CH), 2.03-0.86 (m, 10H, cHex). 13C NMR δ (CDCl3): 177.1, 165.3, 
157.7, 136.7, 132.1, 130.8, 128.8, 128.7, 127.5, 127.3, 109.6, 46.1, 32.0, 26.2. MS: 358.2 Da. Anal. 
(C23H23N3O.0.2H2O) C, H, N. 
N-(4-Isopropyl-6-phenyl-pyrimidin-2-yl)-benzamide (4.42). Yield 18%; white solid; mp 95-96 °C. 1H NMR δ 
(CDCl3): 8.81 (br s, 1H, N-H), 8.15-7.99 (m, 2H, Ar-H), 7.98-7.94 (m, 2H, Ar-H), 7.53-7.47 (m, 6H, Ar-H), 7.30 
(s, 1H, pyrimidinyl-H), 2.24-2.04 (m, 1H, CH), 0.98 (d, 6H, J = 7.8 Hz, 2 × CH3). 13C NMR δ (CDCl3): 172.3, 
165.1, 132.2, 131.0, 128.9, 128.7, 127.5, 127.3, 112.0, 47.0, 28.6. MS: 332.3 Da. Anal. (C20H19N3O.0.1H2O) C, 
H, N. 
N-(4-Phenyl-pyrimidin-2-yl)-benzamide (4.43). To 4-phenyl-pyrimidin-2-ylamine (20 mg, 0.117 mmol) in 
pyridine (0.5 mL) was added benzoyl chloride (16.3 µL, 0.140 mmol, 1.2 eq.) and the reaction mixture stirred at 
RT for 2 h. The reaction mixture was then separated between H2O and CH2Cl2, and the organic layer then further 
washed with brine and dried (MgSO4). Chromatography of the crude product on SiO2 eluting with CH2Cl2 gave 
the title product as a white solid. Yield 47%  1H NMR δ (CDCl3): 8.74-8.71 (m, 2H, pyrimidinyl-H), 8.12-8.07 
(m, 2H, phenyl-H), 7.99-7.95 (m, 2H, phenyl-H), 7.55-7.46 (m, 7H, Ar-H + N-H). MS: 276.1 Da.  
4.4.3 Biology  
Materials and Methods  
[3H]DPCPX and [125I]AB-MECA were purchased from Amersham Biosciences (NL). [3H]ZM 241385 was 
obtained from Tocris Cookson, Ltd. (UK). HEK 293 cells stably expressing the human adenosine A2A and A3 
receptor were gifts from Dr. Wang (Biogen, USA) and Dr. K.-N. Klotz (University of Würzburg, Germany), 
respectively.  
All compounds made were tested in radioligand binding assays to determine their affinities at the human 
adenosine A1, A2A and the A3 receptors as described in Chapter 3. 
Data Analysis 
Ki values were calculated using a non-linear regression curve-fitting program (GraphPad Prism, GraphPad 
Software Inc., San Diego, CA, USA). KD values of the radioligands were 1.6 nM, 1.0 nM, and 5.0 nM for 
[3H]DPCPX, [3H]ZM 241385, and [125I]AB-MECA, respectively. 
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Chapter 5  
 
 
2,6-Disubstituted and 2,6,8-Trisubstituted Purines 

















Purines have long been exploited as adenosine receptor antagonists. The 
substitution pattern about the purine ring has been well investigated and certain 
criteria have become almost a prerequisite for good affinity at the adenosine A1 
receptor. The adaptation of the pharmacophore and the initial series of 
pyrimidines developed earlier in this thesis resulted in a series of purines with an 
entirely new substitution pattern. One compound in particular, 8-cyclopentyl-2,6-
diphenylpurine (5.31, LUF 5962) has been shown to be very promising with an 
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5.1 Introduction 
In Chapter 3 it was shown that a rudimentary pharmacophore (see Figure 5.3) can lead to new 
types of adenosine A1 receptor antagonists.1 The resulting 2,4,6-trisubstituted pyrimidines 
were shown to be both potent and very selective for the A1 receptor (Chapters 3 and 4). In an 
attempt to judge the relative location of the hydrogen-bond acceptor close to the 'top' of a 
central aromatic group and a more precise orientation of the L2 lipophilic group in relation to 
the central ring, fixation of this group was considered. Figure 5.1 shows the logical 
development of the 4-amido-2,6-diphenylpyrimidines into the purines explored in this 
chapter. Fixing the hydrogen-bond accepting group at the 'top' of the central group prompted 
the change of the heteroatom, for both synthetic ease and to preserve the C=Heteroatom 







Figure 5.1 a) 2,6-diphenyl-4-amidopyrimidine; b) the fixation of the hydrogen-bond acceptor at the 
‘top’ of the molecule; c) the change of the heteroatom to accomplish this fixation.  
Purines have been explored at length as adenosine receptor antagonists as detailed in Chapter 
2. However, these have mainly been direct analogues of adenine, in the sense that the N6 
group has always been preserved. This N6 amino group has also usually been substituted with 
a cyclopentyl group to attain good affinity for the A1 receptor.2-7 Further exploration of this 
central core also deems the necessity of N9 substitution for potency, with both large benzyl 
derivatives (compound 2.49)5 and small methyl (2.51)7 or ethyl substituents (2.50)6 showing 
good affinity for the A1 receptor. De Ligt et al. postulated certain features to enhance the 
selectivity of the basic adenine-ring (Figure 5.2).7 The 
resulting series of compounds displayed good affinity 
for the adenosine A1 receptor, with N6 - cyclopentyl-8-
(N-methylisopropylamino)-9-methyladenine showing 
the best Ki value at 7.7 nM. These types of 
compounds, with the presence of the N6 group and 
with N9 substitution show good affinity at the A1 
receptor, corroborating with the model detailed in 
Chapter 3 in a manner shown in Figure 5.3. The 
hydrogen-bond donating group (denoted B) is 
represented by the available hydrogen on the N6 and 
the hydrogen-bond acceptor groups A or C may be one 















9-substitution: gain of affinity? 

















gain of affinity 
Figure 5.2 The features proposed by 
De Ligt et al.7 to enhance affinity 
and selectivity at the A1 receptor and 
the numbering about the purine ring. 
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orientation and the size of possible substitutents on the other positions of the purine ring. The 
lipophilic pocket denoted L2 may be filled with the substituent labelled R1 and either L1 or 
L3 are satisfied by the R2 substituent. Optimal receptor interaction may be provided by 











Figure 5.3 The model detailed in Chapter 3 (in the upper left corner) and the two possible orientations 
of the ‘traditionally’ substituted adenines to fit this model. 
In this chapter, a new perspective upon the purines is realised according to the model 
proposed in Chapter 3, where excellent affinity for the A1 adenosine receptor is achieved 
despite the lack of the seemingly essential N6 and the N9 
groups/substituent proposed in earlier papers. Direct aromatic 
substitution at the C2 and C6 positions (labelled R1 and R2 in Figure 5.4) 
provide analogy to the 2,6-aromatic substituents on the 4-amino-
pyrimidines (Chapter 3). C8 substitution (R3) explores the ‘L2’ pocket, 
and R4 should be, according to the model, left unsubstituted to achieve 
high affinity at the A1 adenosine receptor. In accordance to the PSA 
requirement, as detailed in Chapter 4, the value for these purines lies in 
the region of 50 Å2. 
5.2 Results and Discussion 
5.2.1 Chemistry 
The purines were made via two routes. The 2,6-disubstituted purines were synthesised from 
commercially available 2,6-dichloropurine as described in Scheme 5.1. Substitution of the 
chlorines was possible through metal-mediated cross-coupling reactions. Both Stille and 
Suzuki-Miyaura couplings of purines have been reported in literature.8-15 To facilitate the 
Suzuki cross-coupling, protection of the nitrogen at N9 was necessary. This was successfully 
achieved with tetrahydropyran (THP). Initial attempts with a benzylic group rendered the 
product far too stable, and removal of the protecting group was impossible under usual 
hydrogenation or transfer hydrogenation conditions. Substitution of both chlorines with the 
same phenyl derivative occurred under standard Suzuki conditions as detailed by Hocek et al. 




















R1 and R2 interact 
with L2 and L3 pockets,
respectively 
R1 and R2 interact 





















Figure 5.4 Proposed 
substitution about 
the purine structure. 
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employed instead of conventional heating methods, reducing reaction time from 8 hours to 
approximately 20 minutes. An excess of the boronic acid (3 equivalents) encouraged the 
reactions to completion. Where the 2- and 6-substituents differed, one equivalent of the 
boronic acid provided initial singular substitution at the 6-position (compounds 5.15-5.17), 
confirmed by X-ray crystallography. Further reaction with an excess of the second boronic 









Scheme 5.1 a) dihydropyran, pTSA, THF; b) 1 eq. PhB(OH)2, K2CO3, Pd(PPh3)4, PhMe; c) 3 eq. 
R1B(OH)2, K2CO3, Pd(PPh3)4, PhMe; d) 1.2 eq R1B(OH)2, K2CO3, Pd(PPh3)4, PhMe; e) dowex, EtOH. 
For substitution at the 8-position, bromination of a protected 2,6-dichloropurine to provide a 
more versatile intermediate was attempted following the procedure described by De Ligt et 
al.7 in their evaluation of N0840 analogues. Unfortunately, this was unsuccessful, and the 8-
substituent was introduced into the purine frame at an earlier stage, as described in Scheme 
5.2. To make the vital intermediate 5.18, a four step procedure described in a number of 
papers by Biagi et al. was broadly exploited.16-18 Reaction of commercially available 
benzamidine with diethyl malonate created a pyrimidine ring, after which various substitution 
steps resulted in intermediate 5.18. Ring closure was attempted by several different methods 
that are detailed in literature, e.g., using trimethylorthoformate, triethylorthoformate or PPA 
as the reaction medium.19,20 These methods were either poor-yielding or were difficult to 
work up or purify. Finally, a two-step reaction incorporating the addition of the appropriate 
acid chloride followed by cyclisation under basic conditions provided a more ideal synthetic 
pathway.21 The 6-chloro-2-phenyl-8-substituted purine was then subjected to metal-catalysed 
cross-coupling reactions as described above, furnishing compounds 5.28-5.36. It was 
discovered that protection at N9 was no longer necessary, probably due to the increased steric 
bulk around this position preventing the complexation of the catalyst and/or the boronic acid. 
Methylation of compound 5.32 following standard procedures with methyl iodide in basic 
conditions rendered compound 5.37.  
5.2.2 Structure Activity Relationships 
The results of the radioligand binding assays performed on these purines are shown in Table 
5.1. Compounds 5.11-5.17 are unsubstituted in the C8 position and are varied at C2 and C6. 
2,6-Diphenyl-9H-purine (5.11) has an affinity of 4 nM for the hA1 receptor, already matching 
the 'best' ligands from the two pyrimidine series (Chapters 3 and 4). The selectivity is in 
   R1    R2 
5.4,   5.11   Ph     Ph 
5.5,   5.12  4-ClPh    4-ClPh 
5.6,   5.13  4-MePh    4-MePh 
5.7,   5.14  4-MeOPh  4-MeOPh
5.8,   5.15  4-ClPh     Ph 
5.9,   5.16  4-MePh     Ph 
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general however, somewhat lower, with good affinities registered at both the A2A and the A3 
receptors (52 and 38 nM, respectively). An identical substitution at the 4-position of both of 
the phenyl groups (5.12-5.14) is to the great detriment of the affinity for the A1 and A2A 
receptors, in contrast to the improved affinity (9 nM) at the A3 receptor by the bis-4-methyl 
substitution (5.13). The single substitution of just the C2 phenyl group shows no enhancement 
for the A1 receptor, with both the 4-Cl (5.15) and the 4-MeO (5.17) moieties reducing the 
affinity of the ligand for this receptor, whilst compound 5.16 possessing the 4-Me group 
retains the affinity of the unsubstituted diphenylpurine at 4 nM. The great beneficiary of this 
particular substitution pattern is the A3 receptor, where both the 4-Me (5.16) and the 4-MeO 
(5.17) compounds display significantly enhanced affinity (Ki values of 9 and 3 nM, 
respectively) when compared to compound 5.11. 4-Methoxy-substitution of phenyl groups 
have usually been shown to enhance the affinity for the A3 receptor in a number of different 
series of adenosine antagonists,22,23 thus it may seem surprising that the bis-4-Me substituted 
variety (5.13) displayed significantly higher affinity for the A3 receptor than the analogous 
bis-4-MeO ligand (5.14). However, the results of the mono-substituted compounds (5.16, 9 
nM and 5.17, 3 nM) confirm that the 4-MeO- group is still preferred by the A3 receptor. Bis-
4-MeO-substitution is probably just too large for optimal binding in the A3 receptor pocket, 
accounting for its poorer affinity compared to the slightly smaller bis-4-Me variation. It seems 
that for the A1 receptor, unsubstituted phenyl groups may be the optimal R1 and R2 groups for 

















Scheme 5.2 a) (i) R3COCl, pyridine, DCM; (ii) 2M NaOH; b) dihydropyran, pTSA, THF; c) 1.5 eq. 
R2B(OH)2, K2CO3, Pd(PPh3)4, PhMe; d) dowex, EtOH; e) 1.5 eq. R2B(OH)2, K2CO3, Pd(PPh3)4, 
















































            R3       R2 
5.19     Ph       Ph       
5.20     Pr       Ph       
5.21     iPr       Ph       
5.22    cPent    Ph       
5.23    cHex     Ph       
           cHex      4-ClPh       
           cHex     3,4-diClPh 
           cHex     4-MePh      
           cHex     4-MeOPh   
  
5.28 
5.24, 5.26, 5.29 
5.30 
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Table 5.1. Affinities of the 2,6,8-Trisubstituted-Purines 5.11-5.37 in Radioligand Binding Assays of 
Human Adenosine Receptors. 
Ki (nM) or % disp.a  R1 R2 R3 R4 
hA1b hA2Ac hA3d 
5.11 Ph Ph H H 4.1 ± 0.5 52.5 ± 14 38 ± 12 
5.12 4-ClPh 4-ClPh H H 20.8% 11% 71 ± 12 
5.13 4-MePh 4-MePh H H 235 ± 25 4% 9.6 ± 2 
5.14 4-MeOPh 4-MeOPh H H 40% 37% 163 ± 39 
5.15 4-ClPh Ph H H 27 ± 6 315 ± 96 93 ± 11 
5.16 4-MePh Ph H H 4.1 ± 0.6 289 ± 19 9.7 ± 4 
5.17 4-MeOPh Ph H H 32 ± 6 47% 3.3 ± 2 
5.28 Ph Ph Ph H 21 ± 12 66 ± 4 50 ± 18 
5.29 Ph Ph Pr H 4.4 ± 0.7 167 ± 25 17 ± 8 
5.30 (LUF 5956) Ph Ph iPr H 0.82 ± 0.08 148 ± 27 9.3 ± 0.9 
5.31 (LUF 5962) Ph Ph cPent H 0.29 ± 0.07 55 ± 3 34 ± 14 
5.32 (LUF 5957) Ph Ph cHex H 0.73 ± 0.07 118 ± 17 195 ± 43 
5.33 Ph 4-ClPh cHex H 25 ± 5 24% 239 ± 88 
5.34 Ph 3,4-diClPh cHex H 37 ± 10 20% 37.2% 
5.35 Ph 4-MePh cHex H 36 ± 4 9% 41% 
5.36 Ph 4-MeOPh cHex H 3.7 ± 0.5 27% 135 ± 41 
5.37 Ph Ph cHex Me 24% 0% 25% 
aKi ± SEM (n = 3), % displacement (n = 2). bDisplacement of specific [3H]DPCPX binding in CHO cell 
membranes expressing human adenosine A1 receptors or % displacement of specific binding at 1 µM 
concentrations. cDisplacement of specific [3H]ZM 241385 binding in HEK 293 cell membranes expressing 
human adenosine A2A receptors or % displacement of specific binding at 1 µM concentrations. dDisplacement of 
specific [125I]AB-MECA binding in HEK 293 cell membranes expressing human adenosine A3 receptors or % 
displacement of specific binding at 1 µM concentrations.  
Exploration of the C8 position of the purine led in general to significant improvements in the 
affinity for the A1 receptor. A phenyl group in the 8-position (5.28) is evidently too large for 
the A1 receptor binding pocket with a drop in affinity to 21 nM. Both the A2A and A3 
receptors seem to tolerate this much larger substituent well, on the whole retaining the affinity 
achieved by the comparable unsubstituted compound 5.11. This indicates, perhaps, more 
space in this part of the respective A2A and A3 receptor pockets than in the A1 receptor site. 
The single straight-chained alkyl group (nPr, 5.29) showed a Ki value of 4 nM, improving on 
the selectivity over the A2A receptor when compared to the unsubstituted form (5.11) by a 
factor of 3. However, the affinity at the A3 receptor also showed an improvement to 16.5 nM. 
The most active compounds at the adenosine A1 receptor registered sub-nanomolar affinity. 
These were the C8- isopropyl (5.30), cyclopentyl (5.31) and cyclohexyl (5.32) derivatives at 
0.82, 0.29, 0.73 nM, respectively. In particular, the cyclopentyl moiety (5.31) displayed an 
impressive gain in affinity at the A1 receptor, whilst retaining the same degree of affinity at 
the A2A and A3 receptors in comparison to ligand 5.11. In comparison to the cyclopentyl 










receptor, yet showed a significant drop in affinity at the A2A and A3 receptors. To see whether 
both C8 substitution and substitution at one of the phenyl groups would be well tolerated, 
compounds 5.33-5.36 were synthesised and tested. Again, a significant loss in affinity is 
noted across the three receptors, although the 4-MeO moiety seems to interfere the least, 
retaining an affinity of 4 nM for the A1 receptor. Compound 5.37 highlights the importance of 
the free N9 proton to act as a hydrogen-bond donor, since the methyl substitution results in a 
complete loss of affinity at the adenosine receptors. 
Comparing the most potent compound at the A1 receptor of this series, 5.31 (0.29 nM), to the 
most potent purine published to-date, compound 2.51 (Chapter 2, 8 nM), it may be speculated 
that the affinity to the A1 receptor is much improved (almost 30-fold) because both the L1 and 
the L3 pockets are now subject to interaction with the ligand. In Figure 5.5, the two possible 
ways of superimposing these compounds is depicted, following the proposed model, as 
mentioned in Figure 5.3. Superimposition a suggests that there are no interactions with the L1 
pocket, as provided by the C2-phenyl group of 5.31, whilst b suggests that there likewise is 
little interaction with the L3 pocket, provided by the C6-phenyl of 5.31. In the lowest energy 
state of the compound, the 8-substituent of 2.51 is also most probably orientated out of the 
plane of the core heterocycle, although this may not be a significant factor upon the final 
ligand-receptor complex.  










Figure 5.5 The two possible ways of superimposing compounds 5.31 and 2.51. 
By immobilising the H-bond acceptor at the ‘top’ of the molecule to form the fused 
heterocyclic ring, the position, and thus the orientation towards the receptor, of the L2 group 
is shifted slightly higher than predicted in the model detailed in Chapter 3. This slight 
relocation of the L2 group has brought about substantial improvements in the affinity for the 
A1 receptor. This is best illustrated by comparing the analogous compounds 3.19 
(cyclopentanecarboxylic acid (2,6-diphenyl-pyrimidin-4-yl)-amide) and 5.31 (8-cyclopentyl-
2,6-diphenyl-9H-purine). In both series these two compounds displayed the highest affinity 
for the A1 receptor, yet 5.31 was, at 0.29 nM, significantly more active than 3.19 (2.14 nM). 
The selectivity for the A1 receptor over the A2A and A3 receptors was also somewhat better for 
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consideration these results and refine the pharmacophoric model given in Chapter 3. Figure 
5.6 displays schematically the new refinements. It has previously been discovered and 
discussed in both of the pyrimidines series (Chapters 3 and 4) and in this current chapter that 
the optimal L2 group seems to be somewhat smaller than the L1 and L3 groups and the 
lipophilic pocket that this group fills lacks the ability to interact with π-electrons. The ideal L2 
group is therefore an alkyl group that consists of an alkyl chain of 2-3 carbons in length (i.e., 
ethyl or propyl) and a secondary-branched moiety (i.e., isopropyl, cyclopentyl, etc). Although 
this chapter details the development of a fused bicyclic ring, the central aromatic region was 
sufficiently covered by a single ring, as detailed in Chapters 3 and 4. Thus, it is appropriate to 
assume that it is not the size of the aromatic ring that is particularly important, but the relative 








Figure 5.6 Refinement of the model proposed in Chapter 3. 
5.3 Conclusions 
This chapter describes a series of 2,6,8-trisubstituted purines synthesised as a consequence of 
the refinement of the model proposed in Chapter 3. The fixation of the H-bond acceptor at the 
‘top’ of the molecule repositions the relative location of the L2 group. Exchanging the 
heteroatom for a nitrogen creates the imidazole ring. The benefits of these modifications are 
highlighted by compound 5.31, LUF 5962, 8-cyclopentyl-2,6-diphenyl-9H-purine, which has 
an affinity of 0.29 nM at the human adenosine A1 receptor.  
5.4 Experimental 
5.4.1 Chemistry 
Materials and Methods  
All reagents used were obtained from commercial sources and all solvents were of an analytical grade. 1H and 
13C NMR spectra were recorded on a Bruker AC 200 (1H NMR, 200 MHz; 13C NMR, 50.29 MHz) spectrometer 
with tetramethylsilane as an internal standard. Chemical shifts are reported in δ (ppm) and the following 
abbreviations are used: s = singlet, d = doublet, dd = double doublet, t = triplet, m = multiplet, br = broad and ar 
= aromatic protons. Melting points were determined on a Büchi melting point apparatus and are uncorrected. 
Elemental analyses were performed by the Leiden Institute of Chemistry and are within 0.4% of the theoretical 
values unless otherwise stated. Reactions were routinely monitored by TLC using Merck silica gel F254 plates. 
Microwave reactions were performed on an Emrys Optimizer (Biotage AB, formerly Personal Chemistry). 
Wattage was automatically adjusted so as to maintain the desired temperature.  
To protect the purines with the THP group a procedure reported in literature by Cassidy et al. was followed.24 
Compounds 5.224 and 5.1818 have been reported previously.  
General Preparation for the Suzuki-Miyaura Cross-Coupling Under Microwave Conditions 
THP-protected-2,6-dichloropurine 5.2 (1 eq.) was dissolved in dry toluene (5 mL). To this was 
added the appropriate boronic acid (3 eq. if double substitution required or 1 eq. if single 
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vial was then sealed and heated at 150 °C for 20 minutes. Upon completion of the reaction (monitored by TLC), 
the solvents were evaporated and the crude product pre-absorbed on silica. Purification with column 
chromatography gave the desired product.  
2-Chloro-6-phenyl-9-(tetrahydro-pyran-2-yl)-9H-purine (5.3). 
White solid, 71%. 1H-NMR δ(CDCl3): 8.80-8.75 (m, 2H, phenyl-H), 8.32 (s, 1H, purine-H), 7.57-7.51 (m, 3H, 
phenyl-H), 5.84 (m, 1H, THP), 4.22-4.17 (m, 1H, THP), 3.86-3.75 (m, 1H, THP), 2.20-1.57 (m, 6H, THP). 
2,6-Diphenyl-9-(tetrahydropyran-2-yl)-9H-purine (5.4). 
White solid, 80%. 1H-NMR δ(CDCl3): 9.05-8.94 (m, 2H, phenyl-H), 8.73-8.69 (m, 2H, phenyl-H), 8.32 (s, 1H, 
purine-H), 7.66-7.4 (m, 4H, phenyl-H), 5.93 (dd, 1H, J = 6.6, 2.9 Hz, THP), 4.23-4.16 (m, 1H, THP), 3.88-3.75 
(m, 1H, THP), 2.24-1.67 (m, 6H, THP). 
2,6-Bis(4-chlorophenyl)-9-(tetrahydropyran-2-yl)-9H-purine (5.5). 
White solid, 91%. 1H-NMR δ(CDCl3): 8.85 (d, 2H, J = 8.0 Hz, Ar-H), 8.54 (d, 2H, J = 8.0 Hz, Ar-H), 8.29 (s, 
1H, purine-H), 7.53-7.43 (m, 4H, Ar-H), 5.89 (dd, 1H, J = 6.6, 2.9 Hz, THP), 4.24-4.17 (m, 1H, THP), 3.89-3.76 
(m, 1H, THP), 2.18-1.71 (m, 6H, THP). 
2,6-Bis(4-tolyl)-9-(tetrahydropyran-2-yl)-9H-purine (5.6). 
White solid, 77%. 1H-NMR δ(CDCl3): 8.83 (d, 2H, J = 8.0 Hz, Ar-H), 8.55 (d, 2H, J = 8.0 Hz, Ar-H), 8.29 (s, 
1H, purine-H), 7.41-7.30 (m, 4H, Ar-H), 5.95 (dd, 1H, J = 5.8, 3.6 Hz, THP), 4.25-4.19 (m, 1H, THP), 3.92-3.81 
(m, 1H, THP), 2.46, 2.45 (2× s, 6H, 2×CH3), 2.22-1.72 (m, 6H, THP). 
2,6-Bis(4-methoxyphenyl)-9-(tetrahydropyran-2-yl)-9H-purine (5.7). 
White solid, 82%. 1H-NMR δ(CDCl3): 8.93 (d, 2H, J = 9.5 Hz, Ar-H), 8.61 (d, 2H, J = 8.8 Hz, Ar-H), 8.25 (s, 
1H, purine-H), 7.11-7.01 (m, 4H, Ar-H), 5.91 (dd, 1H, J = 6.6, 2.2 Hz, THP), 4.24-4.18 (m, 1H, THP), 3.92-3.83 
(m, 1H, THP), 3.91 (s, 6H, 2×OCH3), 2.18-1.67 (m, 6H, THP). 
2-(4-Chlorophenyl)-6-phenyl-9-(tetrahydropyran-2-yl)-9H-purine (5.8). 
White solid, 87%. 1H-NMR δ(CDCl3): 8.91-8.86 (m, 2H, phenyl-H), 8.60-8.55 (m, 2H, Ar-H), 8.29 (s, 1H, 
purine-H), 7.62-7.44 (m, 5H, phenyl-H+Ar-H), 5.87 (dd, 1H, J = 6.6, 2.9 Hz, THP), 4.21-4.15 (m, 1H, THP), 
3.87-3.76 (m, 1H, THP), 2.17-1.68 (m, 6H, THP). 
2-Tolyl-6-phenyl-9-(tetrahydropyran-2-yl)-9H-purine (5.9). 
White solid, 90%. 1H-NMR δ(CDCl3): 8.94-8.88 (m, 2H, phenyl-H), 8.55 (d, 2H, J = 8.8 Hz, Ar-H), 8.28 (s, 1H, 
purine-H), 7.63-7.49 (m, 3H, phenyl-H), 7.31 (d, 2H, J = 8.0 Hz, Ar-H) 5.92 (dd, 1H, J = 7.3, 2.9 Hz, THP), 
4.21-4.15 (m, 1H, THP), 3.88-3.75 (m, 1H, THP), 2.43 (s, 3H, CH3), 2.17-1.68 (m, 6H, THP). 
2-(4-Methoxyphenyl)-6-phenyl-9-(tetrahydropyran-2-yl)-9H-purine (5.10). 
Oil, 97%. 1H-NMR δ(CDCl3): 8.93-8.89 (m, 2H, phenyl-H), 8.63-8.58 (m, 2H, Ar-H), 8.26 (s, 1H, purine-H), 
7.62-7.51 (m, 3H, phenyl-H), 7.03-6.99 (m, 2H, Ar-H) 5.88 (dd, 1H, J = 6.6, 2.9 Hz, THP), 4.19-4.12 (m, 1H, 
THP), 3.85 (s, 3H, CH3), 3.79-3.75 (m, 1H, THP), 2.15-1.64 (m, 6H, THP). 
General Procedure for the Removal of the THP Protecting Group25 
2,6-Bis(4-chlorophenyl)-9-(tetrahydropyran-2-yl)-9H-purine (0.67 mmol) and Dowex® (50WX2-
100) ion exchange resin (300 mg) were refluxed in EtOH (20 mL) and H2O (0.7 mL) until no 
starting material was evident by TLC. The mixture was then filtered whilst hot and the resin 
further washed with aliquots of hot EtOH. The combined filtrates were evaporated and then co-
distilled with toluene to remove the last traces of H2O to yield the free purine.  
2,6-Diphenyl-9H-purine (5.11).  
Recrystallised from EtOAc/PE. White solid, 53%. mp: >252 ºC dec. 1H-NMR δ(DMSO): 11.44 (br s, 1H, NH), 
9.04-9.01 (m, 2H, phenyl-H), 8.67-8.58 (m, 2H, phenyl-H), 7.64-7.56 (m, 6H, phenyl-H). 13C-NMR δ(DMSO): 
157.2, 154.6, 152.1, 145.3, 138.1, 136.0, 131.0, 130.1, 129.5, 128.7, 127.8. MS (ESI): 273.0. Anal. 
(C17H12N4·0.4EtOAc) C, H, N.  
2,6-Bis(4-chlorophenyl)-9H-purine (5.12).  
Recrystallised from CH2Cl2. White solid, 43%. mp: >290 ºC dec. 1H-NMR δ(DMSO): 8.98-8.94 (m, 2H, 4-
chlorophenyl-H), 8.66 (s, 1H, purine-H), 8.54-8.50 (m, 2H, 4-chlorophenyl-H), 7.70-7.57 (m, 4H, 4-
chlorophenyl-H). 13C-NMR δ(DMSO): 156.0, 145.6, 136.7, 135.8, 134.9, 134.5, 131.0, 129.4, 128.7, 128.6. MS 
(ESI): 340.7. Anal. (C17H10N4Cl2·0.1H2O.0.05CH2Cl2) C, H, N.  
2,6-Bis(4-tolyl)-9H-purine (5.13).  
Recrystallised from CH2Cl2. White solid, 52%. mp: >288 ºC dec. 1H-NMR δ(DMSO): 8.90-8.86 (m, 2H, 4-tolyl-
H), 8.61 (s, 1H, purine-H), 8.48-8.44 (m, 2H, 4-tolyl-H), 7.47-7.35 (m, 4H, 4-tolyl-H), 2.44, 2.41 (2s, 6H, 
2×CH3). 13C-NMR δ(DMSO): 157.2, 151.9, 144.9, 141.8, 140.8, 139.6, 135.5, 133.2, 131.7, 129.4, 129.2, 129.0, 
127.7, 21.2, 21.0. MS (ESI): 300.9. Anal. (C19H16N4·0.06CH2Cl2) C, H, N.  
2,6-Bis(4-methoxyphenyl)-9H-purine (5.14).  
Recrystallised several times from various solvents, including CH2Cl2, EtOH, MeOH and EtOAc/petroleum ether 
mixtures. White solid. mp: 282 ºC. 1H-NMR δ(MeOD): 8.66-8.61 (m, 4H, 4-methoxyphenyl-H), 8.41 (s, 1H, 
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2-(4-chlorophenyl)-6-phenyl-9H-purine (5.15).  
Recrystallised from MeOH. White solid, 46%. mp: 262 ºC. 1H-NMR δ(DMSO): 8.97-8.93 (m, 2H, phenyl), 8.69 
(s, 1H, purine-H), 8.56 (d, 2H, J = 8.8 Hz, Ar-H), 7.63-7.59 (m, 5H, phenyl-H). 13C-NMR δ(DMSO): 156.2, 
155.0, 151.9, 145.7, 137.0, 135.8, 134.9, 131.0, 128.5, 128.7. MS (ESI): 306.8. Anal. (C17H11ClN4) C, H, N.  
2-Tolyl-6-phenyl-9H-purine (5.16).  
Recrystallised from MeOH. White solid, 43%. mp: 251 ºC. 1H-NMR δ(DMSO): 8.99-8.96 (m, 2H, phenyl), 8.65 
(s, 1H, purine-H), 8.50-8.46 (d, 2H, J = 8.04 Hz, 4-tolyl-H), 7.66-7.57 (m, 3H, phenyl-H), 7.39-7.35 (d, 2H, J = 
8.04 Hz, 4-tolyl-H), 2.41 (s, 3H, CH3). 13C-NMR δ(DMSO): 157.3, 151.9, 145.2, 139.7, 136.0, 135.5, 130.9, 
129.3, 128.7, 127.8, 21.1. MS (ESI): 286.8. Anal. (C18H14N4·0.16MeOH) C, H, N.  
2-(4-methoxyphenyl)-6-phenyl-9H-purine (5.17).  
Recrystallised from MeOH. White solid, 55%. mp: 269 ºC. 1H-NMR δ(DMSO): 8.98-8.96 (m, 2H, phenyl), 8.63 
(s, 1H, purine-H), 8.54 (d, 2H, J = 8.8 Hz, Ar-H), 7.67-7.62 (m, 3H, phenyl-H), 7.13 (d, 2H, J = 8.8 Hz, Ar-H), 
3.88 (s, 3H, OCH3). 13C-NMR δ(DMSO): 161.0, 157.3, 155.0, 151.8, 145.0, 136.0, 130.9, 130.7, 129.4, 128.7, 
114.0, 55.3. MS (ESI): 302.8. Anal. (C18H14N4) C, H, N.  
General Ring-Closing Procedure to Form the Purine Moiety21 
The appropriate acid chloride (4.53 mmol) in CH2Cl2 (10 mL) was added to 6-chloro-4,5-diamino-2-
phenylpyrimidine (1 g, 4.53 mmol) in dry pyridine (5 mL) and stirred at room temperature overnight. H2O (15 
mL) was then added and the mixture separated.  The solvents were evaporated and the intermediate purified by 
column chromatography on SiO2, eluting with a CH2Cl2 and MeOH mixture (99:1). This intermediate was then 
dissolved in 2M NaOH (15 mL), adding MeOH until a clear solution was obtained and refluxed overnight. The 
cooled reaction mixture was then adjusted to pH 7 using 1M HCl forming a white precipitate. This solid was 
then filtered and dried and purified where necessary to give the respective 8-substituted-purine.  
6-Chloro-2,8-diphenyl-9H-purine (5.19). 
White solid, 66%. 1H-NMR δ(MeOD/DMSO): 8.44-8.42 (m, 2H, phenyl-H), 8.27-8.16 (m, 2H, phenyl-H), 7.63-
7.39 (m, 6H, phenyl-H). 
2-Phenyl-6-chloro-8-propyl-9H-purine (5.20). 
White solid, 51%. 1H-NMR δ(MeOD): 8.40-8.36 (m, 2H, phenyl-H), 7.44-7.34 (m, 3H, phenyl-H), 2.89 (t, 2H, J 
= 7.3 Hz, CH2), 1.97-1.79 (m, 2H, CH2), 1.02 (t, 3H, J = 7.3 Hz, CH3). 
2-Phenyl-6-chloro-8-isopropyl-9H-purine (5.21). 
White solid, 78%. 1H-NMR δ(MeOD): 8.40-8.35 (m, 2H, phenyl-H), 7.45-7.39 (m, 3H, phenyl-H), 3.33-3.19 (m, 
1H, CH), 1.42  (d, 6H, J = 7.3 Hz, 2×CH3). 
2-Phenyl-6-chloro-8-cyclopentyl-9H-purine (5.22). 
White solid, 44%. 1H-NMR δ(MeOD): 8.38-8.33 (m, 2H, phenyl-H), 7.42-7.39 (m, 3H, phenyl-H), 3.42-3.30 (m, 
1H, CH), 2.27-1.70 (m, 8H, 4×CH2). 
2-Phenyl-6-chloro-8-cyclohexyl-9H-purine (5.23).  
White solid, 99%. 1H-NMR δ(MeOD): 8.39-8.34 (m, 2H, phenyl-H), 7.45-7.41 (m, 3H, phenyl-H), 3.00-2.88 (m, 
1H, CH), 2.09-1.42 (m, 10H, 5×CH3). 
2-Phenyl-6-chloro-8-propyl-9-(tetrahydropyran-2-yl)-9H-purine (5.24). 
White solid, 53%. 1H-NMR δ(CDCl3): 8.51-8.46 (m, 2H, phenyl-H), 7.52-7.46 (m, 3H, phenyl-H), 5.78 (dd, 1H, 
J = 8.8, 2.2 Hz, THP), 4.26-4.19 (m, 1H, THP), 3.85-3.70 (m, 2H, THP), 3.53-3.37 (m, 1H, THP), 3.10-3.00 (m, 
2H, CH), 2.90-2.73 (m, 1H, THP), 2.06-1.70 (m, 5H, THP + CH2), 1.09 (t, 3H, J = 7.3 Hz, CH3). 
2-phenyl-6-chloro-8-cyclopentyl-9-(tetrahydropyran-2-yl)-9H-purine (5.25). 
White solid, 75%. 1H-NMR δ(CDCl3): 8.50-8.46 (m, 2H, phenyl-H), 7.53-7.45 (m, 3H, phenyl-H), 5.76 (dd, 1H, 
J = 8.8, 2.2 Hz, THP), 4.25-4.18 (m, 1H, THP), 3.79-3.68 (m, 1H, THP), 3.51 (pent, 1H, J = 8.0 Hz, CH), 3.03-
2.83 (m, 1H, THP), 2.18-1.52 (m, 13H, THP+4×CH2). 
2,6-diphenyl-8-propyl-9-(tetrahydropyran-2-yl)-9H-purine (5.26). 
White solid, 46%. 1H-NMR δ(CDCl3): 9.06-8.93 (m, 2H, phenyl-H), 8.68-8.63 (m, 2H, phenyl-H), 7.60-7.44 (m, 
6H, phenyl-H), 5.85 (dd, 1H, J = 8.8, 2.2 Hz, THP), 4.23-4.16 (m, 1H, THP), 3.79-3.68 (m, 1H, THP), 3.14-2.96 
(m, 2H, CH2), 2.79-2.71 (m, 1H, THP), 2.10-1.61 (m, 7H, THP + CH2), 1.11 (t, 3H, J = 7.3 Hz, CH3). 
2,6-diphenyl-8-cyclopentyl-9-(tetrahydropyran-2-yl)-9H-purine (5.27).  
White solid, 32%. 1H-NMR δ(CDCl3): 9.05-9.00 (m, 2H, phenyl-H), 8.69-8.64 (m, 2H, phenyl-H), 7.59-7.43 (m, 
6H, phenyl-H), 5.78 (dd, 1H, J = 8.8, 2.2 Hz, THP), 4.20-4.14 (m, 1H, THP), 3.75-3.62 (m, 1H, THP), 3.54 
(pent, 1H, J = 8.0 Hz, CH), 2.98-2.86 (m, 1H, THP), 2.18-1.56 (m, 13H, THP+4×CH2). 
2,6,8-Triphenyl-9H-purine (5.28).  
Recrystallised from MeOH. White solid, 87%. mp: 233 ºC. 1H-NMR δ(CDCl3): 9.14-9.11 (m, 2H, phenyl-H), 
8.61-8.56 (m, 2H, phenyl-H), 7.98-7.94 (m, 2H, phenyl-H), 7.65-7.26 (m, 9H, phenyl-H). 13C-NMR δ(CDCl3): 
137.9, 135.8,130.4, 130.0, 129.2, 128.3, 127.9, 127.7, 127.5, 126.7. MS (ESI): 348.7. Anal. (C23H16N4·0.12 




8-Propyl-2,6-diphenyl-9H-purine (5.29).  
Recrystallised from MeOH. White solid, 52%. mp: 149 ºC. 1H-NMR δ(CDCl3/MeOD): 8.60-8.52 (m, 4H, 
phenyl-H), 7.63-7.47 (m, 6H, phenyl-H), 3.01 (t, 2H, J = 7.30 Hz, CH2), 2.00-1.89 (m, 2H, CH2), 1.08 (t, 3H, J = 
7.3 Hz, CH3). 13C-NMR δ(CDCl3): 155.6, 135.4, 130.2, 129.5, 128.8, 128.1, 127.9, 127.6, 30.4, 20.9, 12.8. MS 
(ESI): 314.8. Anal. (C20H18N4) C, H, N.  
8-Isopropyl-2,6-diphenyl-9H-purine (5.30).  
Recrystallised from MeOH. White solid, 36%. mp: 214 ºC. 1H-NMR δ(CDCl3): 8.94-8.89 (m, 2H, phenyl-H), 
8.53-8.49 (m, 2H, phenyl-H), 7.62-7.38 (m, 6H, phenyl-H), 3.34-3.27 (m, 1H, CH), 1.48 (d, 6H, J = 7.3 Hz, 
2×CH3). 13C-NMR δ(CDCl3/MeOD): 162.7, 157.6, 152.4, 138.3, 136.0, 133.3, 132.9, 132.1, 131.8, 131.6, 130.2, 
129.5, 128.5, 128.1, 127.8, 127.3, 29.2, 20.6. MS (ESI): 314.8. Anal. (C20H18N4·0.11EtOH) C, H, N.  
8-Cyclopentyl-2,6-diphenyl-9H-purine (5.31).  
Recrystallised from DCM. White solid, 45%. mp: 224 ºC. 1H-NMR δ(CDCl3): 8.53-8.65 (m, 4H, phenyl-H), 
7.48-7.63 (m, 6H, phenyl-H), 3.33-3.50 (m, 1H, CH), 1.79-2.28 (m, 8H, 4×CH2). 13C-NMR δ(CDCl3/MeOD): 
162.5, 157.7, 156.0, 151.0, 137.7, 135.4, 129.8, 129.1, 128.7, 127.8, 127.6, 127.3, 126.3, 125.2, 39.2, 31.5, 24.9. 
MS (ESI): 341.0. Anal. (C22H20N4·0.04CH2Cl2) C, H, N.  
8-Cyclohexyl-2,6-diphenyl-9H-purine (5.32).  
Recrystallised from EtOH. White solid, 49%. mp: 209 ºC. 1H-NMR δ(CDCl3): 9.07-9.04 (m, 2H, phenyl-H), 
8.70-8.63 (m, 2H, phenyl-H), 7.61-7.57 (m, 6H, phenyl-H), 2.66-2.54 (m, 1H, CH), 1.92-1.29 (m, 10H, 5×CH3). 
13C-NMR δ(CDCl3): 161.6, 157.7, 155.4, 152.9, 138.6, 136.2, 133.2, 130.7, 130.0, 129.9, 128.7, 128.5, 128.4, 
127.6, 38.1, 25.5. MS (ESI): 354.8. Anal. (C23H22N4·0.1H2O) C, H, N.  
8-Cyclohexyl-6-(4-chlorophenyl)-2-phenyl-9H-purine (5.33).  
Recrystallised from MeOH. White solid, 86%. mp: 156 ºC. 1H-NMR δ(CDCl3): 8.78-8.70 (m, 2H, 4-
chorophenyl-H), 8.54-8.50 (m, 2H, phenyl-H), 7.64-7.41 (m, 5H, (4-chloro)phenyl-H), 3.07-2.92 (m, 1H, CH), 
2.11-1.30 (m, 10H, 5×CH2). 13C-NMR δ(CDCl3): 164.2, 158.4, 154.5, 138.0, 136.0, 134.4, 130.6, 129.3, 128.6, 
128.1, 127.9, 127.5, 30.8, 30.8, 25.4. MS (ESI): 388.9, 390.2. Anal. (C23H21ClN4·0.7H2O.0.5MeOH) C, H, N.  
8-Cyclohexyl-6-(3,4-dichlorophenyl)-2-phenyl-9H-purine (5.34).  
Recrystallised from EtOH. White solid, 64%. mp: 201 ºC. 1H-NMR δ(CDCl3): 12.50 (br s, 1H, NH2), 9.09-9.08 
(m, 1H, 3,4-dichorophenyl-H), 8.91-8.86 (m, 1H, 3,4-dichorophenyl-H), 8.57-8.52 (m, 2H, phenyl-H), 7.64-7.57 
(m, 3H, phenyl-H), 7.24-7.14, 6.78-6.77, 6.59-6.53 (3×m, 1H, 3,4-dichorophenyl-H), 2.60-2.49 (m, 1H, CH), 
1.89-0.98 (m, 10H, 5×CH2). 13C-NMR δ(CDCl3): 162.2, 157.9, 155.5, 150.3, 138.3, 136.1, 134.9, 132.8, 131.4, 
130.5, 130.1, 129.2, 128.9, 128.5, 117.5, 115.4, 38.5, 31.1, 25.5. MS (ESI): 422.7, 425.2. Anal. 
(C23H20Cl2N4·0.7EtOH) C, H, N.  
8-Cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine (5.35).  
Recrystallised from MeOH. White solid, 98%. mp: 149 ºC. 1H-NMR δ(CDCl3): 8.93-8.88 (d, 2H, J = 8.04 Hz, 4-
tolyl-H), 8.61-8.56 (m, 2H, phenyl-H), 7.59-7.51 (m, 3H, phenyl-H), 7.39-7.35 (d, 2H, J = 8.04 Hz, 4-tolyl-H), 
2.57-2.50 (m, 1H, CH), 2.46 (s, 1H, CH3), 1.89-0.98 (m, 10H, 5×CH2). 13C-NMR δ(CDCl3): 161.3, 157.7, 155.2, 
153.0, 141.0, 138.7, 133.3, 130.6, 130.0, 129.8, 129.3, 128.7, 128.4, 38.5, 31.1, 25.5, 21.6. MS (ESI): 368.5. 
Anal. (C24H24N4·0.9H2O.0.35MeOH) C, H, N.  
8-Cyclohexyl-6-(4-methoxyphenyl)-2-phenyl-9H-purine (5.36).  
Recrystallised from MeOH. White solid, 29%. mp: 141 ºC. 1H-NMR δ(CDCl3): 9.05-9.01 (d, 2H, J = 8.78 Hz, 4-
methoxyphenyl-H), 8.61-8.57 (m, 2H, phenyl-H), 7.58-7.54 (m, 3H, phenyl-H), 7.11-7.07 (d, 2H, J = 8.78 Hz, 4-
methoxyphenyl-H), 3.90 (s, 1H, OCH3), 2.57-2.50 (m, 1H, CH), 1.89-0.98 (m, 10H, 5×CH2). 13C-NMR 
δ(CDCl3): 161.8, 161.1, 157.7, 155.1, 138.8,131.6, 130.0, 129.0, 128.7, 128.4, 113.9, 55.35, 38.49, 31.18, 25.5. 
MS (ESI): 384.9. Anal. (C24H24N4O·0.95H2O.0.3MeOH) C, H, N.  
8-Cyclohexyl-9-methyl-2,6-diphenyl-9H-purine (5.37).  
Recrystallised from CHCl3. White solid, 30%. mp: 200-202 °C. 1H-NMR δ(CDCl3): 9.03-9.00 (m, 2H, phenyl-
H), 8.65-8.62 (m, 2H, phenyl-H), 7.63-7.53 (m, 6H, phenyl-H), 3.92 (s, 3H, CH3), 3.25-3.31 (m, 1H, CH), 2.10-
1.44 (m, 10H, 5×CH2). 13C-NMR δ(CDCl3): 161.0, 157.3, 55.0, 151.9, 140.9, 138.7, 136.5, 130.3, 129.7, 129.6, 
128.3, 128.2, 128.0, 36.7, 30.8, 28.3, 25.9, 25.6. MS (ESI): 369.1. Anal. (C24H24N4·0.09CHCl3) C, H, N.  
5.4.2 Biology  
Materials and Methods  
[3H]DPCPX and [125I]AB-MECA were purchased from Amersham Biosciences (NL). [3H]ZM 241385 was 
obtained from Tocris Cookson, Ltd. (UK). CHO cells expressing the human adenosine A1 receptor were 
provided by Dr. Andrea Townsend-Nicholson, University College London, UK. HEK 293 cells stably expressing 
the human adenosine A2A and A3 receptor were gifts from Dr. Wang (Biogen, USA) and Dr. K.-N. Klotz 
(University of Würzburg, Germany), respectively.  
All compounds were tested in radioligand binding assays to determine their affinities at the human adenosine A1, 
A2A and the A3 receptors as described previously in Chapter 3, with the exception of non-specific binding on the 
A2A receptor was determined in the presence of 10 µM CGS21680 instead of 100 µM CPA.  The human A1 
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receptors were expressed in CHO cells, and [3H]DPCPX used as the radioligand. The A2A and A3 receptors were 
expressed in HEK 293 cells, and [3H]ZM 241385 and [125I]AB-MECA were used as the respective radioligands.  
Data Analysis 
Ki values were calculated using a non-linear regression curve-fitting program (GraphPad Prism, GraphPad 
Software Inc., San Diego, CA, USA). KD values of the radioligands were 1.6 nM, 1.0 nM and 5.0 nM for 
[3H]DPCPX, [3H]ZM  241385 and [125I]AB-MECA, respectively.  
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Chapter 6  
 
 













Exploration of the pyrimidine and purine series in the preceding three chapters led 
to a refinement of the pharmacophore defined (in Chapter 3) for antagonists of the 
adenosine A1 receptor. This chapter details the adoption of these new criteria to 
produce a series of 1-deazapurines with consistently high affinity for the 
adenosine A1 receptor. 1-Deazapurines (otherwise known as 3H-imidazo[4,5-
b]pyridines) are structurally very similar to the purines, however, in a synthetic 
sense they pose an array of difficulties, mainly as a result of the reduced reactivity 
about the 6-membered ring. The desired double aromatic substituents at the 2- and 
6-positions were amongst the most troublesome features to incorporate. An 
eventual adaptation of a known route resulted in a series with five of the 
derivatives displaying Ki values in the sub-nanomolar region. The most potent of 
these, compound 6.10 (LUF 5978), displays an affinity of 0.55 nM at the human 






In Chapter 5, the re-analysis of the purine ring and its substitution pattern in accordance to the 
pharmacophore developed in Chapter 3 produced a very good series of ligands, with 
particular examples displaying sub-nanomolar affinity at the A1 receptor. The subsequent 
analysis of the results led to a refinement of the original model, highlighting the relative 
position of the L2 lipophilic group to the stipulated H-bond acceptors and donors.  
The purine derivatives that were devised in Chapter 5 came about as a direct result of their 
structural similarity to 4-amido-2,6-diphenylpyrimidines (Chapter 3) (Figure 5.1). However, 
the 4-amido-2,6-diphenylpyrimidines were eclipsed by the analogous 2-amido-4,6-
diphenylpyrimidines (Chapter 4) in terms of displaying similar levels of affinity and better 
selectivity for the adenosine A1 receptor. Extrapolating the 2-amido-4,6-diphenylpyrimidines 
in the same manner as the 4-amido-2,6-diphenylpyrimidines, 5,7-diphenyl-3,3a-dihydro-
[1,2,4]triazolo[1,5-a]pyrimidines are fashioned (Figure 6.1). The specifications of the refined 
model still only demand the fulfilment of three hydrogen-bonding regions, thus it is 
reasonable to assume that the extra nitrogen atom in the triazolopyrimidine ring will not play 
an important role in the affinity of the compound for the A1 receptor, in terms of hydrogen-
bonding. This nitrogen also disturbs the planarity of the central core; therefore, its 
replacement with a carbon is more compliant with the model. The removal of this nitrogen 
also reduces the PSA value from approximately 46 Å2 to 41 Å2. The resulting 3H-
imidazo[4,5-b]pyridine (Figure 6.2) bears comparison to the 2-amido-4,6-diphenylpyridines 
originally planned in Chapter 4, of which one example was synthesised displaying similar Ki 








Figure 6.1 On the left the refined model detailed in Chapter 5; a) 2-amido-4,6-diphenylpyrimidine; b) 
the fixation of the hydrogen-bond acceptor at the ‘top’ of the molecule; c) the change of the 
heteroatom to accomplish this fixation resulting in a 5,7-diphenyl-3,3a-dihydro-[1,2,4]triazolo[1,5-
a]pyrimidine.  
Trivially, 3H-imidazo[4,5-b]pyridine is also known as 1-deazapurine (and 4-
azabenzimidazole). Figure 6.2 shows the numbering about the ring for the systematic 
nomenclature (a) and the numbering system adopted from the purines (b). In this chapter, the 
trivial name and numbering system are used for the purpose of easy comparison to the purines 
(Chapter 5). The new stipulations of the model disclosed in Chapter 5 require the L2 





























carbons. In this chapter, the further refinements to the pharmacophore outlined in Chapter 5 






Figure 6.2 a) The systematic (IUPAC) name: 3H-imidazo[4,5-b]pyridine with the corresponding 
numbering system; b) 1-deazapurine and the purine numbering system.  
6.2 Results and Discussion 
6.2.1 Chemistry 
Synthesis of the 1-deazapurines was less than straightforward, with little or no precedence for 
creating compounds with two aromatic substituents in the 2- and 6- positions of the ring. In 
this section, a brief description of the known routes to compounds similar to the target ligands 
is described, along with the potential variations to produce the target structures.   
A series of 1-deazapurines were published in 2003 as corticotropin releasing factor receptor 
ligands.1 The compounds featured direct aromatic substitution at the 6-position, with further 
derivatisation at N9. The synthetic procedure numbered 9 steps from commercially available 
starting materials and is described in Scheme 6.1. Functional group interconversions allowed 
various substitutions to create a functionalised pyridine ring that could be ring-closed to form 











Scheme 6.1 The synthetic route described by Arvanitis et al.1 to 6-,8-disubstituted-1-deazapurines. 
Compounds featuring direct aromatic substitution at the C2 position of the 1-deazapurine ring 
have been explored by Oguchi et al. (Scheme 6.2).2 A primary amine reacted preferentially at 
the 2-position of the commercially available 2,6-dichloro-3-nitropyridine. This intermediate 
then underwent substitution under Suzuki conditions to allow an aromatic group to reside at 


































































Scheme 6.2 The synthesis of a series of 1-deazapurine substituted directly with an aromatic group at 
the C2 position, as described by Oguchi et al.2 
One example where an aromatic substituent at C2 and another substituent at C6 exist 
concurrently is the series of NK-3 receptor antagonists by Giardina et al.3 A phenyl group and 
a carboxylate substituent were incorporated into the pyridine ring by the reaction of a 
diketone and nitroacetamidine in a Guareshi condensation following a procedure by Batt and 
Houghton.4 Subsequent ring closure yielded the respective 1-deazapurines (Scheme 6.3). One 
compound that would have been an extremely interesting intermediate for the target 
compounds in this chapter was attempted by Batt and Houghton. This was 2-amino-3-nitro-
4,6-diphenylpyridine. However, dibenzoylmethane could not be induced to react with 
nitroacetamide at all, even 4-methoxy-4’-nitrodibenzoylmethane, a relatively activated form 





Scheme 6.3 The synthetic route towards 2,6,8-trisubstituted-1-deazapurines as described by            
Batt and Houghton.4 
Further explorations of direct carbon-carbon bonds at the 2- and 6-positions of 1-deazapurines 
generally seem to be restricted to simple alkyl groups. The majority of these compounds are 
angiotensin II receptor ligands and require further substitution at N9.5-7 The synthesis of these 
compounds is relatively straightforward, in that 2-amino-4,6-dimethylpyridine is 
commercially available. Nitration of this ring, followed by reduction creates a 2,3-diamino 
species that can be ring-closed to form the 5-membered imidazole part of the deazapurine 
system. 
All of these routes detailed above require the ring closure of a 2,3-diaminopyridine and as in 
the synthesis of the purines (Chapter 5) there are a variety of procedures to accomplish this. 
An unsubstituted C8 position can be made by refluxing the pyridine in 
tri(m)ethylorthoformate.8 Substitution is generally introduced by the use of a carboxylic acid 
at elevated temperatures, either neat2 or in the presence of a medium such as PPA 
(polyphosphoric acid).6 As an alternative, a two-step technique using an acid chloride in the 




































Scheme 6.4 The synthesis of 1-deazaadenines as described by Cristalli et al.10 
There is precedent to form 2,6-disubstituted 1-deazapurines where the substituents are often 
amines,11 sulfides,12 halogens13,14 or mixtures of these. Cristalli et al. have reported on the 
synthesis of 1-deaza analogues of 2-chloroadenosine from the commercially available 
unsubstituted intact 1-deazapurine species (Scheme 6.4).10 This procedure starts with the 
manipulation of the reactivity about the pyridine ring allowing chloro-substitution of C2 and 
C6 leading to the possibility of further functional group interconversions.  
Thus, it seems that the majority of the synthetic routes to the singly, doubly, or triply 2-, 6-, or 
8-substituted deazapurines can be split into two different branches. The first option focuses on 
incorporating groups on the pyridine part of the 1-deazapurine system as the initial phase of 
the synthesis, i.e. creating substituted 2,3-diaminopyridines. Ring-closure of this intermediate 
with a carboxylic acid derivative provides an 8-substituent. The second route requires the 
introduction of the 8-substituent in an intact functional deazapurine ring. The first method 
leads to an intermediate of the form a in Scheme 6.5, the latter method leading to intermediate 
b. Both methods should, ideally provide intermediates that allow late-stage variation of the 










Scheme 6.5 The two general routes detailed in literature to form 2,(6),(8)-(di)(tri)substituted-1-
deazapurines. 
Numerous attempts were made to create the 2,3-diaminopyridine intermediate (Scheme 6.5a); 
these are summarised in Scheme 6.6. The routes chosen mirror the various synthetic routes 
described earlier in this section. The main problems encountered were based upon the reactive 
nature and polarity of the functional groups and the reactivity of the positions about the 
pyridine ring. The first issue could probably be solved using protecting groups on the free 
heteroatoms (i.e., the amine and hydroxyl moieties), however using protecting groups 
incorporates a minimal of two further steps into an already long, multi-stepped synthesis. The 
latter problem is much more difficult to overcome. The electronegative nature of the nitrogen 

















































resulting electron-poor ring is then several orders of magnitude less reactive than benzene and 
electrophilic substitution occurs only under relatively extreme conditions.15 Activation of the 
ring with electron-donating substituents or the use of catalysts is a way of promoting these 
reactions. From Figure 6.3a it can also be seen that the positions susceptible to electrophilic 
substitution are the 3- and 5- positions. On the contrary, N-oxide derivatives allow 2-, 4- and 
6-substitution (Figure 6.3b), although the rather unreactive nature of the pyridine ring still 






Figure 6.3 (a) The resonance forms of pyridine showing that electrophilic substitution occurs at the 3- 
and 5- positions, and (b) the relative partial charges about an N-oxide derivative. 
The synthesis of 2,3-diamino-4,6-dihalopyridines has been reported in literature. De Roos and 
Salemink showed that the reduction of 2-amino-3-nitro-4-chloropyridine with stannous 
chloride sporadically yields small quantities of 2,3-diamino-4,6-dichloropyridine.16 Schelling 
and Salemink converted 2-amino-4,6-dichloropyridine through nitration and reduction steps 
into the desired diamino derivative.13 The 2-amino-4,6-dichloropyridine was however in turn 
synthesised following a preparation by Graf.17 This was a 5 step reaction sequence, starting 
from picolinic acid in a 10-day reflux period to create 4,6-dichloropicolinic acid. Although it 
has been shown to be possible to make this vital intermediate, the number of steps, the harsh 
conditions and problematical work-up procedures favoured the exploration of alternative 











Scheme 6.6 A summary of some of the various routes to create a 2,3-diamino-4,6-disubstituted 
pyridine intermediate. 
The alternative route exploiting the commercially available and intact 1-deazapurine was also 
undertaken (Schemes 6.5 and 6.7a). The 2,6-dichloro-1-deazapurine intermediate was 



























































were then made to functionalise the 8-position of the 1-deazapurine ring. The relatively acidic 
N9 proton was found to disrupt the intended reactions and thus protection of this group was 
necessary (studies have also shown that N3 and N7 substitution occurs as minor isomers in 
these reactions).18 This was initially performed with a benzyl moiety. Unfortunately, the 
stability of this benzyl group presented difficulties in isolating the target compounds; standard 
catalytic hydrogenation using H2 was sluggish, as was microwave-assisted catalytic transfer 
hydrogenation, despite reaching pressures of more than 20 bar at 150 ºC. Tetrahydropyran 
(THP) was later found to be much more suitable. Straightforward bromination techniques as 
described by De Ligt et al. for purine moieties,19 using bromine and a phosphate buffer gave 
preferred substitution at the C1 position to the C8 position, a detail confirmed by NMR (seen 
both in 1H and 13C). Bromination at C8 was more successful using nBuLi and NBS. This 
product was accomplished by the lithiation at this position by nBuLi at -78 ºC, according to a 
procedure by Leonard and Bryant as applied to purines.20 Lithiation of purine nucleosides 
regiospecifically at C8 has also been achieved in literature using LDA at low temperatures.21 
Further reaction of this species with an alkyl boronic acid to form an 8-alkyl substituent 











Scheme 6.7 The manipulation of an intact 1-deazapurine to create 2-, 6- and 8- substitution. 
To increase the chances of a successful coupling reaction at this position, a better leaving 
group in the form of iodine was introduced. Iodination of the THP-protected deazapurine 
using NIS was, according to analysis of its NMR spectrum, successfully achieved at C8. The 
iodo compound underwent Suzuki-coupling with phenylboronic acid to provide 2,6-dichloro-
8-phenyl-THP-protected-1-deazapurine in a 75% yield. Unfortunately, again attempts to carry 
out alkyl substitution under these conditions were not successful probably due to the 
relatively inactivated state of the boronic acid substrate. According to literature,20,22 the 
quenching of the lithiated species with other electrophiles is also possible and this was 
successfully achieved with acetone, although not with an alkyl iodide. 
The SAR revealed from the series detailed in Chapters 3-5 meant that the most favourable 
target compounds at C8 were directly linked alkyl groups. Therefore, the failure of the Suzuki 






































choice to quench the 8-lithiated-deazapurine led to the simultaneous examination of the route 
incorporating the 8-derivative as one of the first steps of the synthesis (Scheme 6.7b).  
Three compounds were synthesised following the method detailed in Scheme 6.7, the 
unsubstituted forms (6.4 and 6.5), where the deazapurine was already commercially available 
and 8-cyclopentyl-2,6-diphenyl-deazapurine (6.13). The intermediate 2,6-dichloro-1-
deazapurine was benzyl protected and subsequent aryl coupling gave 6.5 and deprotection 
yielded compound 6.4. The third derivative was made by reacting 2,3-diaminopyridine with 
cyclopentyl carboxylic acid in the presence of PPA. The product, 8-cyclopentyl-1-
deazapurine, was then subjected to the first three steps described in Scheme 6.4. The inclusion 
of a C8 substituent dramatically changed the reactivity of the species and each of the 
subsequent steps was significantly worse than the unsubstituted equivalent, in terms of yields 
and ease of handling. Another negative aspect of this route is the number of reactions 
involved to produce a series from which further SAR can be drawn. Incorporating the 8-
derivative at the initial step in this manner leads to a 7-step synthetic sequence for each target 
product. With an aim to make more than 10 different compounds to be able to explore the 











Scheme 6.8 The process development route to angiotensin II antagonist MK-996.23,24 
Attention was thus turned on to another alternative procedure that seemed to offer a more 
encouraging pathway. In the process development of angiotensin II antagonists at Merck, a 
new approach to the key intermediate MK-996, benzylated imidazolutidine (Scheme 6.8), was 
investigated.23,24 Malonamamidine (Scheme 6.8a) was condensed with a β-diketone (b) to 
provide the nicotinamide (c). The Hoffman rearrangement of this nicotinamide resulted in the 
isocyanate, which then reacted intramolecularly with the 2-amino group to give the urea (d). 
This compound was ingeniously found to react with a mixture of a carboxylic acid and 
anhydride in the presence of MgCl2 to give 8-alkyl-2,6-dimethyl-1-deazapurines. Our fears 
for utilising this reaction pathway, similarly to many of the previous attempts to make 2,6-
diaryl-1-deazapurine analogues, was that the desired diaryl-substituents would have a major 
(negative) influence on the reactivity of firstly the ketone, followed by each of the subsequent 
























nitroacetamide to produce 2-amino-3-nitro-4,6-diphenylpyridine failed due to the unreactive 
nature of the diketone.4 In this case the ring-closure of dibenzoylmethane with 
malonamamidine was extremely low-yielding (6%). We thus sought the construction of the 
nicotinamide in a different manner. A 2-step approach employing a chalcone and 
malononitrile in the presence of ammonium acetate formed a cyanopyridine, which upon 
hydrolysis gave the target nicotinamide (Scheme 6.9).25 This route also allows regioselective 
substitution about the pyridine ring if so desired, a feature not possible in the original route 
with the diketone. The Hoffman rearrangement proceeded without any significant problems 












Scheme 6.9 The synthesis of 8-alkyl-2,6-diphenyl-1-deazapurine. a) KOH, MeOH, RT; b) KOH, 
PhI(OAc)2, MeOH, RT; c) NH4OAc, EtOH, ∆; d) KOH, EtOH, ∆; e) MgCl2, R3CO2H, µw. 
Substitution of the 8-OH was performed as described by Senanayake et al. 23 using a mixture 
of an acid and the corresponding anhydride in the presence of MgCl2. The one main 
difference introduced was the use of the microwave for this procedure. Aromatic substituents 
at the 2- and 6-positions of the 1-deazapurine ring significantly lower its reactivity, and the 
employment of conventional heating methods resulted in very low yields and considerable 
quantities of by-products, which made the final product difficult to isolate. Using the 
microwave, rapid heating of the sealed vessel created very high temperatures quickly and 
elevated pressures. This method improved the synthesis dramatically, leading to better yields 
and easier isolation of the final target products.  
The carboxylic acid anhydrides used were all commercially available, except for the 
cyclohexyl variant. This was synthesised according to a method as described by Kazemi et al. 
employing tosyl choride and potassium carbonate with a minimal use of solvents.26 To 
remove the excess of the acid/anhydride reagents the crude material was distilled 
azeotropically with water. Removal of the last traces of water was subsequently performed by 















































6.2.2 Structure Activity Relationships 
The compounds 6.1-6.14 were tested in radioligand binding assays and the results of these 
assays are presented in Table 6.1. It is clear that the substitution at C2 (R1) and C6 (R2) of the 
1-deazapurines is vital for affinity at the adenosine receptors. Compound 6.1, lacking in 
substituents at these positions displays no affinity for the A1, A2A, or A3 adenosine receptors. 
The π-electrons of the phenyl groups at these two positions provide seemingly essential 
interactions with the receptor pocket, although alkyl groups may afford some contact points 
for interaction, i.e., 6.2  (Ki(hA1) = 101 nM). Further substitution at the phenyl rings was not 
conducted due to the negative outcome obtained in the pyrimidine series (Chapter 4) and the 
purine series (Chapter 5).  
Table 6.1. Affinities of the 2,6,8-Trisubstituted-1-Deazapurines 6.1-6.14 in Radioligand Binding 
Assays of Human Adenosine Receptors. 
 
Ki (nM) or % disp.a  R1 R2 R3 R 
hA1b hA2Ac hA3d 
6.1 H H cPent H 6% 3% 0% 
6.2 Me Me Et H 101 ± 26 8% 49% 
6.3 Ph Ph OH H 8.6 ± 3 192 ± 97 262 ± 25 
6.4 Ph Ph H H 1.2 ± 0.3  39 ± 9.0 180 ± 70 
6.5 Ph Ph H Bn 38% 2% 15% 
6.6 Ph Ph Me H 14 ± 5 375 ± 28 61 ± 14 
6.7 Ph Ph Et H 2.4 ± 0.4 177 ± 13 8.5 ± 6 
6.8 Ph Ph Pr H 2.5 ± 0.2 114 ± 34 69 ± 22 
6.9   (LUF 5980) Ph Ph iPr H 0.61 ± 0.04 230 ± 40 7.3 ± 2 
6.10 (LUF 5978) Ph Ph 2-MePr H 0.55 ± 0.3 189 ± 23 25 ± 16 
6.11 (LUF 5983) Ph Ph 1-EtPr H 0.87 ± 0.1 247 ± 61 171 ± 49 
6.12 Ph Ph tBu H 5.5 ± 2 1055 ± 129 115 ± 15 
6.13 (LUF 5816) Ph Ph cPent H 0.62 ± 0.3 49% 6.9 ± 1 
6.14 (LUF 5981) Ph Ph cHex H 0.90 ± 0.2 194 ± 57 637 ± 71 
aKi ± SEM (n = 3), % displacement (n = 2). bDisplacement of specific [3H]DPCPX binding in CHO cell 
membranes expressing human adenosine A1 receptors or % displacement of specific binding at 1 µM 
concentrations. cDisplacement of specific [3H]ZM 241385 binding in HEK 293 cell membranes expressing 
human adenosine A2A receptors or % displacement of specific binding at 1 µM concentrations. dDisplacement of 
specific [125I]AB-MECA binding in HEK 293 cell membranes expressing human adenosine A3 receptors or % 
displacement of specific binding at 1 µM concentrations.  
Of the 2,6-diphenyl compounds, the derivative with the unsubstituted C8 position (6.4) was 
an encouraging start with an affinity of 1 nM at the A1 receptor. The N9-substituted 
compound (6.5) again showed that the free proton is necessary as a hydrogen-bond donor 
from the ligand to the receptor (cf. 5.37). The C8-substituent was shown to have a drastic 









the final route, 6.3, shows that although an alkyl group is more tolerated at this position, the 
hydrogen-bonding potential of the hydroxyl group does not disturb too greatly the binding 
affinity of the deazapurines. Ethyl (6.7, Ki(hA1) = 2 nM) and propyl (6.8, Ki(hA1) = 2 nM) 
substitution confirmed the requisites of the model, in that as groups with a chain length of 
either 2 or 3 carbons, they were more effective than the methyl variant (6.6, Ki(hA1) = 14 
nM). Fortifying the claims of the refined model, the predicted secondary-branched 
substituents possessed by far the most affinity for the adenosine A1 receptor (6.9-6.11, 6.13 
and 6.14) with sub-nanomolar Ki values. The single tertiary-branched variety, the t-butyl 
derivative (6.12, Ki = 5.5 nM) displayed a 9-fold loss of potency at the A1 receptor compared 
to the isopropyl derivative (6.9). 
The selectivity of the 1-deazapurines for the A1 over the A2A receptor was better than the 
analogous purine compounds. Derivatives 6.4, 6.9, 6.13 and 6.14 had selectivity ratios of 33, 
377, >1600 and 215 respectively, compared to 13, 180, 190 and 161 from the analogous 
purines 5.11 and 5.30-5.32. The binding affinity of the deazapurines at the adenosine A3 
receptor was also shown to be worse than those measured at the A1 receptor. Namely, 
compounds 6.11 and 6.14 with selectivity ratios of 199 and 718, respectively, were significant 
examples. Analysing the A3 affinity values of the whole series, it seems that there is an 
obvious optimal two carbon-chain length. Of the simple unbranched alkyl groups (6.6-6.8), 
the ethyl moiety was easily the most potent at this receptor. Similarly, in the branched alkyl 
series (6.9-6.11) the iPr with an affinity of 7 nM was the best compound compared to the 2-
methylpropyl (6.10, Ki = 25 nM) and 1-ethylpropyl (6.11, Ki = 173 nM). Of the two 
cycloalkyl variants made, the cyclopentyl (6.13) was also more influential at the A3 receptor, 
with an affinity of 7 nM, than the cyclohexyl group (6.14) with its three-carbon chain length 
(Ki = 646 nM). 
6.3 Conclusions 
This series of 1-deazapurines confirms that the subtle refinements to the model in the previous 
chapter are substantial enough to produce a series with very good affinity for the adenosine A1 
receptor. In particular, compound 6.10 (LUF 5978) with a Ki value of 0.55 nM at the A1 
receptor is noteworthy in terms of affinity. However, compound 6.14 with a Ki value of 0.90 
nM and selectivity ratios over the A2A and A3 receptors of 216 and 718, respectively, is 
overall the most interesting 1-deazapurine derivative presented in this chapter.  
6.4 Experimental Section  
6.4.1 Chemistry 
Materials and Methods 
All reagents used were obtained from commercial sources and all solvents were of an analytical grade. 1H and 
13C NMR spectra were recorded on a Bruker AC 200 (1H NMR, 200 MHz; 13C NMR, 50.29 MHz) spectrometer 
with tetramethylsilane as an internal standard. Chemical shifts are reported in δ (ppm) and the following 
abbreviations are used: s = singlet, d = doublet, dd = double doublet, t = triplet, m = multiplet, br = broad and ar 
= aromatic protons. Melting points were determined on a Büchi melting point apparatus and are uncorrected. 
Elemental analyses were performed by the Leiden Institute of Chemistry and are within 0.4% of the theoretical 
values unless otherwise stated. Reactions were routinely monitored by TLC using Merck silica gel F254 plates. 
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Microwave reactions were performed in an Emrys Optimizer (Biotage AB, formerly Personal Chemistry). 
Wattage was automatically adjusted so as to maintain the desired temperature. 
1-Deazapurine-N-oxide27 
To a solution of 4-azabenzimidazole (1-deazapurine) (1.3 g, 10.9 mmol) in acetic acid (6.5 mL) was 
added H2O2 (35% in H2O) (1.2 mL) and the mixture stirred at 70 ºC for 3 h. A further aliquot of H2O2 
was then added (0.9 mL) and the reaction heated at 60 ºC for 16 h. The reaction mixture was allowed to 
cool to RT, upon which a precipitate formed. This was filtered to give a crystalline product (96%). 1H NMR 
δ(MeOD): 8.45 (s, 1H, C8-H), 8.34 (d, 1H, J = 7.3 Hz, C6-H), 7.87 (d, 1H, J = 7.3 Hz, C2-H), 7.34-7.29 (m, 1H, 
C1-H).  
6-Nitro-1-deazapurine-N-oxide27 
1-Deazapurine-N-oxide (1.4 g, 10.4 mmol) was dissolved in TFA (9.7 mL, 125 mmol, 12 eq.) at 0 ºC 
and to this was added fuming HNO3 (6.6 mL, 157 mmol, 15 eq.). The reaction mixture was then heated 
at 90 ºC for 3 h and then left to cool to RT. Only slight precipitation occurred, thus the mixture was 
neutralised carefully with cNH4OH, revealing further product. This was then filtered and the yellow 
solids were dried in vacuo at 40 ºC (67%). 1H NMR δ(DMSO): 8.27 (s, 1H, C8-H), 8.10 (d, 1H, J = 7.3 Hz, C2-
H), 7.89 (d, 1H, J = 6.58 Hz, C1-H). 
2,6-Dichloro-1-deazapurine10 
6-Nitro-1-deazapurine-N-oxide (1.2 g, 6.66 mmol) was added portionwise to an ice-cooled solution 
of POCl3 (20 mL) in DMF (10 mL). The reaction mixture was then refluxed for 2 h, allowed to cool 
then added slowly to crushed ice. After neutralising carefully with 2M NaOH soln. the product was 
extracted with EtOAc (3 × 150 mL). The combined organic phases were then washed with H2O (3 × 100 mL), 
dried over MgSO4 and concentrated to give an off-white solid (80%). 1H NMR δ(MeOD): 8.45 (s, 1H, C8-H), 
7.46 (s, 1H, C1-H). 
2,6-Dichloro-9-benzyl-1-deazapurine 
2,6-Dichloro-1-deazapurine (0.34 g, 1.80 mmol) was dissolved in DMF (15 mL). K2CO3 (0.77 
g, 5.60 mmol, 3.1 eq.) was added and stirred for 30 mins. Benzyl chloride (0.29 mL, 2.53 mmol, 
1.4 eq.) was then added and the reaction mixture stirred for 16 h at RT. The solids were filtered 
off and the filtrate separated between EtOAc (100 mL) and H2O (100 mL). The aqueous layer 
was then further extracted with EtOAc (2 × 50 mL) and the combined organic layers then washed with H2O (3 × 
150 mL), dried over MgSO4 and the solvents evaporated in vacuo to give a yellow oil. This crude product was 
chromatographed on SiO2 eluting with a mixture of petroleum ether (bp 40-60 ºC) and EtOAc (gradient elution 
5:1 to 2:1) to give the title compound (42 %).  1H NMR δ(CDCl3): 8.02 (s, 1H, C8-H), 7.35-7.30 (m, 6H, Ar), 
5.42 (s, 2H, CH2). 
2,6-diphenyl-9-benzyl-1-deazapurine (6.5)  
2,6-Dichloro-9-benzyl-1-deazapurine (150 mg, 0.54 mmol), phenyl boronic acid (197 mg, 
1.62 mmol, 3 eq.), Pd(PPh3)4 (32 mg, 0.03 mmol, 0.05 eq.), K2CO3 (112 mg, 0.81 mmol, 1.5 
eq.) and toluene (5 mL) were heated in a sealed vessel in the microwave for 30 mins at 150 
ºC. The reaction mixture was then filtered and the filtrate pre-absorbed onto SiO2 and 
chromatographed, eluting with petroleum ether (bp 40-60 ºC) and EtOAc (gradient elution 5:1 
to 2:1). A white solid was obtained (91 %), which was further recrystallised from acetonitrile. mp 143 ºC; 1H 
NMR δ(CDCl3): 8.17-8.13 (m, 4H, Ph), 8.04 (s, 1H, C8-H), 7.89 (s, 1H, C1-H), 7.56-7.29 (m, 11H, Ph), 5.50 (s, 
2H, CH2). 13C-NMR δ(CDCl3): 152.8, 148.0, 143.8, 140.3, 139.7, 136.2, 136.0, 132.0, 129.1, 128.8, 128.6, 
128.1, 127.9, 127.1, 114.1, 47.0. MS (ES+): 362.0 Da. Anal. (C25H19N3.0.2CH3CN) C, H, N. 
2,6-diphenyl-1-deazapurine (6.4)  
2,6-Diphenyl-9-benzyl-1-deazapurine (100 mg, 0.233 mmol), Pd(OH)2/C (20% Pd, Pearlman’s 
catalyst) (20 mg), ammonium formate (147 mg, 2.3 mmol, 10 eq.) and EtOH (3 mL) were heated 
in a sealed vessel in the microwave at 140 ºC for 5 mins (pressure reached 11 bar). Upon cooling 
the septum was pierced to release the remaining pressure trapped in the vessel. The TLC showed 
only a slight trace of a new product. Further amount of ammonium formate added (300 mg) and 
the vessel resealed and heated at 150 ºC for 15 mins (pressure reached 22 bar). The reaction 
mixture was pre-absorbed onto SiO2 and chromatographed eluting with CH2Cl2 and MeOH (gradient elution 
98:2 to 90:10). A white solid was obtained  (41%). mp 259-261 ºC; 1H NMR δ(DMSO): 8.52 (s, 1H, C8-H), 
8.28-8.02 (m, 5H, Ph + C1-H), 7.65-7.41 (m, 6H, Ph). 13C-NMR δ(DMSO): 163.0, 156.6, 156.3, 151.6, 139.4, 
135.8, 29.0, 128.7, 126.9. MS (ES+): 272.1 Da. Anal. (C18H13N3.0.2DMF) C, H, N. 
8-Cyclopentyl-1-deazapurine (6.1)  
Polyphosphoric acid (~5 mL) was added to 2,3-diaminopyridine (0.43 g, 3.94 mmol), followed by 
cyclopentyl carboxylic acid (0.52 mL, 4.73 mmol, 1.2 eq.). This was then stirred at 100 ºC for 5 h, 
cooled in an ice-water bath to 0 ºC and neutralised carefully with cNH4OH. The product was 




























Chromatography on SiO2, eluting with CH2Cl2 and MeOH (gradient elution 98:2 to 90:10) gave an off-white 
solid. Recrystallisation from MeOH provided the title product (10 %). mp 161 ºC; 1H NMR δ(CDCl3): 8.18 (d, 
1H, 4.4 Hz, C6-H), 7.90 (d, 1H, J = 7.32 Hz, C2-H), 7.11-7.06 (m, 1H, C1-H), 3.36 (pent, 1H, J = 8.0 Hz, CH), 
2.17-1.63 (m, 8H, 4 × CH2) 13C-NMR δ(DMSO): 161.0, 149.2, 141.3, 135.0, 125.9, 117.3, 39.9, 31.8, 25.5. MS 
(ES+): 188.2 Da. Anal. (C11H13N3.0.1H2O) C, H, N. 
8-Cyclopentyl-1-deazapurine-N-oxide 
To a solution of 8-cyclopentyl-1-deazapurine (1.0 g, 5.51 mmol) in acetic acid (5 mL) was added 
H2O2 (35% in H2O) (0.9 mL) and the mixture stirred at 70 ºC for 3 h. A further aliquot of H2O2 
was then added (0.7 mL) and the reaction heated at 60 ºC for 16 h. The reaction mixture was 
allowed to cool to RT. The acetic acid was concentrated to approximately 1 mL, a few drops of H2O were then 
added and the oil left to stand at room temperature, upon which precipitation occurred. The solid was collected 
and dried in vacuo to give a quantitative amount of the crude product. 1H NMR δ(DMSO): 8.12-8.09 (d, 1H, J = 
6.6 Hz, C6-H), 7.45-7.44 (m, 1H, C2-H), 7.17-7.11 (m, 1H, C1-H), 1.94-1.71 (m, 9H, 4 × CH2).  
9-Benzyl-8-cyclopentyl-2,6-dichloro-1-deazapurine 
8-Cyclopentyl-1-deazapurine-N-oxide (1.1 g, 5.51 mmol) was dissolved in TFA at 0 ºC. To this 
was added fuming HNO3 (3.5 mL) and the mixture was heated at 90 ºC for 3 h. This was 
allowed to cool to room temperature. Upon neutralisation with cNH4OH no precipitation 
occurred (unlike for the unsubstituted analogue described earlier). The solution was then 
concentrated to half its volume whereby some solids appeared. This was probably inorganic 
matter (no UV chromophore) and thus the mixture was filtered, the filtrate collected and further concentrated. 
The resulting solids were taken on to the next step without further purification.  These solids were dissolved in 
DMF (10 mL) at 0 ºC, careful addition of POCl3 (25 mL) was followed by 30 mins reflux. The reaction mixture 
was then poured carefully onto ice (~300 mL) and brought to pH 6-7 with 2M NaOH. Organic material was 
extracted with EtOAc (3 × 150 mL), dried (MgSO4) and solvents were evaporated in vacuo. The TLC at this 
point showed no clear product spot, thus the crude material was again taken on to the next step without further 
purification. Dissolution in DMF (10 mL) was followed by the addition of K2CO3 (3.4 g, 0.025 mol) and benzyl 
chloride (1.27 mL, 11 mmol). After stirring at RT for 48 h, the solids were filtered off. The filtrate was taken up 
in EtOAc (200 mL) and H2O (200 mL) and separated. Further extraction of the aqueous layer with EtOAc (2 × 
100 mL) followed. The combined organic phases were washed with H2O (150 mL) and brine (150 mL), dried 
(MgSO4) and concentrated to a brown oil. Chromatography on SiO2 eluting with petroleum ether and EtOAc 
(gradient elution 5:1 to 3:1) resulted in a yellow oil which solidified upon standing, 140 mg. 1H NMR δ(CDCl3): 
7.37-7.2 (m, 6H, Ar), 5.80 (s, 2H, CH2), 3.00-2.80 and 2.30-1.90 (m, 9H, cyclopentyl). 
9-Benzyl-8-cyclopentyl-2,6-diphenyl-1-deazapurine 
9-Benzyl-8-cyclopentyl-2,6-dichloro-1-deazapurine (140 mg, 0.39 mmol), PhB(OH)2 (171 
mg, 1.40 mmol, 3.5 eq.), Pd(PPh3)4 (27 mg, 0.02 mmol, 0.05 eq.), K2CO3 (97 mg, 0.7 mmol, 
1.8 eq.) and toluene (5 mL) were heated in a sealed tube in the microwave at 150 ºC for 20 
mins. The reaction mixture was then filtered, concentrated and chromatographed on SiO2 
eluting with petroleum ether and EtOAc mixtures (gradient elution 10:1 to 5:1). Yield 70%. 
1H NMR δ(CDCl3): 8.25-8.21 (m, 2H, Ph), 8.07-8.02 (m, 2H, Ph), 7.86 (s, 1H, C1-H), 7.59-
7.40 (m, 11H, Ph), 5.89 (s, 2H, CH2), 2.86-2.78, 2.47-2.04, 1.97-1.89 (m, 9H, cyclopentyl).   
8-Cyclopentyl-2,6-diphenyl-1-deazapurine 6.13 
9-Benzyl-8-cyclopentyl-2,6-diphenyl-1-deazapurine (40 mg, 0.093 mmol), ammonium 
formate (120 mg, 0.47 mmol, 10 eq.), Pd(OH)2/C (20% Pd, Pearlman’s catalyst) (20 mg), and 
EtOH (3 mL) were heated in a sealed vessel in the microwave at 140 ºC for 5 min. The 
pressure reached 18 bar and upon cooling remained at 11 bar, this was released by piercing 
the septum carefully. Chromatography on SiO2 eluting with petroleum ether and EtOAc 
mixtures (gradient elution 10:1 to 5:1) resulted in a white solid. Yield 32%. mp 236 ºC; 1H NMR δ(MeOD + 
CDCl3): 8.03-7.96 (m, 3H, Ph + NH), 7.89 (s, 1H, C1-H), 7.71-7.64 (m, 2H, Ph), 7.57- 7.40 (m, 6H, Ph), 3.41-
3.35 (m, 1H, CH), 2.21-2.19 (m, 2H, CH2), 1.99-1.95 (m, 2H, CH2), 1.94-1.89 (m, 2H, CH2), 1.77-1.76 (m, 2H, 
CH2). 13C-NMR δ(MeOD + CDCl3): 157.1, 144.7, 142.6, 141.1, 133.6, 133.4, 133.2, 132.2, 131.9, 131.7, 131.3, 
119.6, 44.9, 37.1, 30.3. MS (ES+): 340.3 Da. Anal. (C23H21N3.1.2H2O) C, H, N. 
2,6-Dichloro-9-THP-1-deazapurine28 
2,6-Dichloropurine (320 mg, 1.7 mmol) was stirred in EtOAc, and to this suspension was added 
pTSA (4.5 mg, 0.024 mmol) and the mixture stirred at 50 ºC. Dihydropyran (0.17 mL, 1.9 mmol, 
1.1 eq.) was then added dropwise over 30 min. The mixture was stirred at 55 ºC for 1 h then 
allowed to cool to RT. cNH4OH (2 mL) was then added and the product extracted with EtOAc ( 2 × 
20 mL). The collected organics were then dried (Na2SO4) and concentrated to a clear oil that crystallised upon 
standing. Yield 90%. 1H NMR δ(CDCl3): 8.28 (s, 1H, C8-H), 7.32 (s, 1H, C1-H), 5.82-5.76 (m, 1H, THP), 4.20-






















2,6-Dichloro-9-THP-1-deazapurine (135 mg, 0.5 mmol) was dissolved in dry THF (6 mL) and the 
solution cooled to -78 ºC. nBuLi (0.35 mL, 0.55 mmol, 1.1 eq.) was then added dropwise and the 
mixture stirred at  -78 ºC for 1 h. N-Iodosuccinimide (124 mg, 0.55 mmol, 1.1 eq.) in THF (3 mL) 
was added and the reaction mixture stirred for a further hour at -78 ºC before allowing to warm to 
room temperature. Saturated aqueous NH4Cl (10 mL) was then added and the mixture extracted 
with CH2Cl2 (3 × 10 mL). The collected organic layers were then washed with NaHCO3, dried (Na2SO4) and 
concentrated. Chromatography on SiO2 eluting with CH2Cl2 gave a white solid. Yield 40 %. 1H NMR δ(CDCl3): 
7.23 (s, 1H, C1-H), 5.73-5.67 (m, 1H, THP), 4.21-4.15, 3.77-3.67 (m, 2H, CH2), 1.89-1.58 (m, 6H, 3 × CH2). 
2-Amino-4-6-dimethyl-nicotinamide24 
Malonamamidine hydrochloride (1.38 g, 10 mmol, 1 eq.) was added as a solid to a solution of 
potassium hydroxide (0.67 g, 12 mmol, 1.2 eq.) in methanol (35 mL). 2,4-Pentanedione (1.03 mL, 
10 mmol) was then added to the solution and stirred at RT for 24 h. Solvents were then evaporated 
and the crude material chromatographed on SiO2, eluting with CH2Cl2 and MeOH mixtures (gradient elution 
95:5 to 80:20). Yield 34%. White solid. 1H NMR δ(MeOD): 6.43 (s, 1H, py-H), 2.28 (s, 6H, 2 × CH3). 
2,6-Dimethyl-8-hydroxy-1-deazapurine24 
2-Amino-4-6-dimethyl-nicotinamide (0.56 g, 3.4 mmol) was dissolved in MeOH (12 mL). To this 
was added KOH (0.68 g, 12 mmol, 3.5 eq.) in MeOH (10 mL) and the mixture stirred for 30 mins 
before cooling to -5 ºC. Iodobenzenediacetate was then added (1.09 g, 3.4 mmol, 1 eq.) and the 
mixture allowed to warm to RT overnight. The crude solid was collected by filtration and purified by 
chromatography on SiO2, eluting with CH2Cl2 and MeOH mixtures (gradient elution 95:5 to 80:20). Yield 48%. 
1H NMR δ(DMSO): 6.64 (s, 1H, py-H), 2.34 (s, 3H, CH3), 2.23 (s, 3H, CH3). 
2,6-Dimethyl-8-ethyl-1-deazapurine (6.2)24 
2,6-Dimethyl-8-hydroxy-1-deazapurine (0.27 g, 1.6 mmol) was added to a mixture of propionic 
acid (2.3 mL, 31 mmol, 19 eq.) and propionic anhydride (2.3 mL, 18 mmol, 11 eq.). MgCl2 (0.16 
mg, 1.6 mmol, 1 eq.) was added and the mixture heated at 120 ºC for 16 h. The reaction mixture 
was allowed to cool to approx. 60 ºC and MeOH (3 mL) was added. After stirring for 10 minutes the mixture 
was evaporated to near-dryness, followed by azeotropic distillation with H2O to remove the excess 
acid/anhydride. Further co-distillation with toluene removed the last traces of water. The remaining solid was 
purified by chromatography on SiO2, eluting with CH2Cl2 and MeOH mixtures (gradient elution 99:1 to 95:5). 
Yield 56%. mp 142-146 ºC (lit 143 ºC5 and 147-148 ºC24) ; 1H NMR δ(MeOD): 6.94 (s, 1H, C8-H), 2.92 (q, 2H, 
J = 7.3 Hz, CH2), 1.40 (t, 3H, CH3). 13C-NMR δ(MeOD): 158.9, 153.1, 148.8, 145.2, 136.0, 119.7, 23.4, 23.3, 
16.3, 12.7. MS (ES+): 176.2 Da. Anal. (C18H13N3.0.7 MeOH) C, H, N. 
2-Amino-4,6-diphenyl-nicotinonitrile25  
Chalcone (benzylideneacetophenone) (20.8 g, 100 mmol), malononitrile (6.6 g, 100 mmol, 1 eq.), 
ammonium acetate (61.6 g, 800 mmol, 8 eq.) were dissolved in EtOH (15 mL) and refluxed for 5 
h, whereupon no starting material was evident by TLC. The reaction mixture was allowed to cool 
to RT and the solvents evaporated to leave a yellow solid. This was taken up in approx. 10 mL of 
hot EtOH and filtered. The remaining off-white solids were then washed with petroleum ether. 
This was recrystallised from hot ethanol to give white crystals. Yield 40% mp 170-174 ºC; 1H NMR δ(DMSO): 
8.17-8.14 (m, 2H, Ph), 7.73-7.50 (m, 8H, Ph), 7.30 (s, 1H, py-H), 7.05 (br s, 2H, NH2). 13C-NMR δ(DMSO): 
160.8, 158.6, 154.9, 137.5, 137.0, 130.1, 129.5, 128.6, 128.3, 127.2, 117.0, 109.2. MS (ES+): 272.0 Da. Anal. 
(C18H13N3.0.16Hex) C, H, N. 
2-Amino-4,6-diphenyl-nicotinamide29 
2-Amino-diphenyl-nicotinonitrile (10.8 g, 39.7 mmol) was refluxed in 20% KOH(aq.) (30 g) and 
EtOH (150 mL) for 22 h. H2O (100 mL) was then added and the reaction mixture allowed to 
stand, upon which crystallisation occurred. This yellow solid was collected and dried in vacuo  at 
40 ºC. Quantitative yield. 1H NMR δ(DMSO): 8.03-8.00 (m, 2H, Ph), 7.62-7.58 (m, 2H, Ph), 
7.47-7.31 (m, 6H, Ph), 6.98 (s, 1H, py-H).  
2,6-Diphenyl-8-hydroxy-1-deazapurine (6.3)30 
2-Amino-4,6-diphenyl-nicotinamide (12.75 g, 44 mmol) was dissolved in a 
solution of KOH (6.43 g, 110 mmol, 2.5 eq.) in MeOH (300 mL) and stirred 
for 30 mins at RT. The reaction mixture was then cooled to -5 ºC, 
iodobenzenediacetate (14.2 g, 44 mmol, 1 eq.)  added, allowed to warm to 
room temperature and left to stand for 40 h. The reaction mixture was then 
further dissolved/diluted with methanol (175 mL) and H2O (100 mL) and the solution neutralised with 1M HCl, 
then stirred with cyclohexane to remove traces of the iodobenzenediacetate. The hexane layer was then separated 
and the remaining MeOH/H2O layer concentrated to leave a yellow solid. Recrystallised from EtOH to give a 































7.60-7.36 (m, 7H, C1-H + Ph). 13C-NMR δ(DMSO): 155.2, 147.9, 145.8, 139.1, 135.2, 129.0, 128.6, 128.3, 
128.0, 126.2, 120.3. MS (ES+): 287.6 Da. Anal. (C18H13N3O.0.4EtOH) C, H, N. 
General procedure for the preparation of 8-alkyl-2,6-diphenyl-1-deazapurines (6.6-6.12, 6.14) 
2,6-Diphenyl-8-hydroxy-1-deazapurine (200 mg, 0.7 mmol), isobutyric acid (1.5 mL, 16.2 
mmol, 23 eq.), isobutyric anhydride (1.5 mL, 9.0 mmol, 13 eq.) and MgCl2 (66 mg, 0.7 mmol, 1 
eq.) were heated in a sealed vessel at 180 ºC for 10 h. The reaction mixture was then 
concentrated and co-distilled with water to remove the excess acid/anhydride. Co-distilling with 
toluene removed the last traces of water. The crude material was then purified by column 
chromatography on SiO2, eluting with CH2Cl2 and MeOH (99:1), then recrystallised. 
2,6-Diphenyl-8-methyl-1-deazapurine (6.6) 
Yield 87 %. mp 188-192 ºC; 1H NMR δ(CDCl3): 8.16-8.03 (m, 4H, Ph), 7.77 (s, 1H C1-H), 7.59-7.47 (m, 6H, 
Ph), 2.01 (s, 3H, CH3). 13C-NMR δ(CDCl3): 153.9, 151.8, 150.5, 140.3, 139.6, 136.3, 133.1, 129.0, 128.8, 128.6, 
127.7, 114.6, 14.9. MS (ES+): 286.0 Da. Anal. (C19H15N3.0.02CHCl3) C, H, N. 
2,6-Diphenyl-8-ethyl-1-deazapurine (6.7) 
Yield 36 %. mp 188-192 ºC; 1H NMR δ(CDCl3 + MeOD): 7.93-7.87 (m, 4H, Ph), 7.62 (s, 1H C1-H), 7.42-7.36 
(m, 6H, Ph), 2.72 (q, 2H, J = 7.3 Hz, CH2), 1.22 (t, 3H, J = 7.3 Hz, CH3). 13C-NMR δ(CDCl3 + MeOD): 159.1, 
152.1, 139.8, 136.0, 130.8, 128.7, 128.6, 128.5, 128.3, 127.1, 114.7, 22.5, 12.0. MS (ES+): 300.0 Da. Anal. 
(C20H17N3.0.4 H2O) C, H, N. 
2,6-Diphenyl-8-propyl-1-deazapurine (6.8) 
Yield 29 %. mp 156-158 ºC; 1H NMR δ(MeOD): 8.05-8.04 (m, 2H, Ph), 8.00-7.89 (m, 2H, Ph), 7.70 (s, 1H C1-
H), 7.54-7.35 (m, 6H, Ph), 2.88 (t, 2H, J = 7.3 Hz, CH2), 1.88 (m, 2H, CH2), 1.01 (t, 3H, J = 7.3 Hz, CH3). 13C-
NMR δ(CDCl3): 153.4, 151.6, 150.0, 141.3, 137.4, 129.7, 129.4, 128.0, 115.3, 31.8, 22.6, 13.8. MS (ES+): 314.0 
Da. Anal. (C21H19N3.0.3EtOH) C, H, N. 
2,6-Diphenyl-8-isopropyl-1-deazapurine (6.9) 
Yield 71 %. mp 232-234 ºC; 1H NMR δ(MeOD + CDCl3): 8.01-7.99 (m, 2H, Ph), 7.97-7.87 (m, 2H, Ph), 7.66 (s, 
1H C1-H), 7.49-7.37 (m, 6H, Ph), 3.29-3.22 (m, 1H, CH), 1.43 (d, 6H, J = 7.3 Hz, 2 × CH3). 13C-NMR 
δ(DMSO): 162.1, 150.4, 150.2, 139.6, 137.1, 136.1, 131.6, 129.1, 128.7, 128.5, 128.3, 126.7, 112.2, 29.0, 21.1. 
MS (ES+): 314.0 Da. Anal. (C21H19N3.0.1 CHCl3) C, H, N. 
2,6-Diphenyl-8-isobutyl-1-deazapurine (6.10) 
Yield 65 %. mp 179-181 ºC; 1H NMR δ(CDCl3): 8.22-8.19 (m, 2H, Ph), 8.10-8.06 (m, 2H, Ph), 7.80 (s, 1H C1-
H), 7.55-7.44 (m, 6H, Ph), 2.24 (d, 2H, J = 7.3 Hz, CH2), 1.86-1.80 (m, 1H, CH), 0.64 (d, 6H, J = 5.8 Hz, 2 × 
CH3). 13C-NMR δ(CDCl3): 157.2, 151.7, 150.4, 140.4, 139.5, 136.3, 133.1, 129.2, 128.7, 17.7, 114.6, 38.1, 22.1. 
MS (ES+): 328.0 Da. Anal. (C22H21N3.0.6 H2O) C, H, N. 
2,6-Diphenyl-8-(1-ethylpropyl)-1-deazapurine (6.11) 
Yield 39 %. mp 196-197 ºC; 1H NMR δ(CDCl3): 8.27-8.24 (m, 2H, Ph), 8.11-8.07 (m, 2H, Ph), 7.82 (s, 1H C1-
H), 7.57-7.43 (m, 6H, Ph), 2.37-2.30 (m, 1H, CH), 1.53-1.43 (m, 4H, 2 × CH2), 0.70-0.63 (m, 6H, 2 × CH3). 13C-
NMR δ(CDCl3): 160.3, 151.8, 150.0, 140.4, 139.2, 136.4, 132.7, 129.3, 128.9, 128.8, 128.5, 127.5, 114.3, 43.5, 
26.6, 11.7. MS (ES+): 342.0 Da. Anal. (C23H23N3.0.05 CHCl3) C, H, N. 
2,6-Diphenyl-8-tButyl-1-deazapurine (6.12) 
Yield 76 %. mp 233-234 ºC; 1H NMR δ(CDCl3): 8.33-8.29 (m, 2H, Ph), 8.01-7.98 (m, 2H, Ph), 7.82 (s, 1H C1-
H), 7.55-7.41 (m, 6H, Ph), 1.44 (s, 9H, 3 × CH3). 13C-NMR δ(CDCl3): 163.8, 152.1, 150.1, 140.2, 139.0, 138.2, 
136.2, 132.3, 129.3, 128.9, 128.8, 128.7, 128.4, 128.3, 127.4, 114.1, 33.6, 28.9. MS (ES+): 328.0 Da. Anal. 
(C22H21N3.0.04 CHCl3) C, H, N. 
Cyclohexane carboxylic anhydride26 
Cyclohexane carboxylic acid (1.24 mL, 10 mmol) was ground together with K2CO3 (6 g) for 
approx. 5 min. Tosyl chloride (0.95 g, 5 mmol, 0.5 eq.) was then added portionwise with a few 
drops of EtOAc. Grinding was continued for approx 40 min, whereupon the tosyl chloride was 
barely visible by TLC. The solids were then washed with CH2Cl2 (3 × 20 mL), filtered and the filtrate 
concentrated. Yield 26 %. 1H NMR δ(CDCl3): 2.46-2.33 (m, 2H, CH), 1.99-1.23 (m, 20H, cHex). 
2,6-Diphenyl-8-cyclohexyl-1-deazapurine (6.14) 
Yield 49 %. mp 210-213 ºC; 1H NMR δ(CDCl3): 8.32-8.22 (m, 2H, Ph), 8.11-8.08 (m, 2H, Ph), 7.83 (s, 1H C1-
H), 7.55-7.45 (m, 6H, Ph), 2.51-2.44 (m, 1H, CH), 1.10-1.06 (m, 10 H, cHex). 13C-NMR δ(CDCl3): 161.4, 
151.8, 150.2, 140.2, 139.4, 136.4, 129.3, 129.0, 128.8, 128.6, 127.5, 114.3, 38.6, 31.3, 25.7. MS (ES+): 354.0 Da. 
Anal. (C24H23N3.0.5 EtOH) C, H, N. 
6.4.2 Biology  
Materials and Methods  
[3H]DPCPX and [125I]AB-MECA were purchased from Amersham Biosciences (NL). [3H]ZM 241385 was 
obtained from Tocris Cookson, Ltd. (UK). CHO cells expressing the human adenosine A1 receptor were 








the human adenosine A2A and A3 receptor were gifts from Dr. Wang (Biogen, USA) and Dr. K.-N. Klotz 
(University of Würzburg, Germany), respectively.  
All compounds were tested in radioligand binding assays to determine their affinities at the human adenosine A1, 
A2A and the A3 receptors as described previously in Chapter 3, with the exception of non-specific binding on the 
A2A receptor was determined in the presence of 10 µM CGS21680 instead of 100 µM CPA.  The human A1 
receptors were expressed in CHO cells, and [3H]DPCPX used as the radioligand. The A2A and A3 receptors were 
expressed in HEK 293 cells, and [3H]ZM 241385 and [125I]AB-MECA were used as the respective radioligands.  
Data Analysis 
Ki values were calculated using a non-linear regression curve-fitting program (GraphPad Prism, GraphPad 
Software Inc., San Diego, CA, USA). KD values of the radioligands were 1.6 nM, 1.0 nM and 5.0 nM for 
[3H]DPCPX, [3H]ZM 241385 and [125I]AB-MECA, respectively.  
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Chapter 7  
 
 
A Series of Ligands Displaying a Remarkable 





Adenosine receptor agonists are usually variations on the natural ligand, 
adenosine. The ribose moiety in the ligand has previously been shown to be of 
great importance for the agonistic effects of the compound. In this chapter, a 
series of non-adenosine ligands selective for the adenosine A1 receptor with an 
extraordinary pharmacological profile is presented. 2-Amino-4-benzo[1,3]dioxol-
5-yl-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile 7.70, LUF 5853) 
shows full agonistic behaviour comparable with the reference compound CPA, 
whilst also displaying comparable receptor binding affinity (Ki = 11 nM). In 
contrast, compound 7.58 (2-amino-4-(3-trifluoromethyl-phenyl)-6-(2-hydroxy-
ethylsulfanyl)-pyridine-3,5-dicarbonitrile, LUF 5948) has a binding affinity of 14 
nM and acts as an inverse agonist. Also present within this same series are 
compounds that show neutral antagonism of the adenosine A1 receptor, for 
example compound 7.65 (2-amino-4-(4-difluoromethoxy-phenyl)-6-(2-hydroxy-
ethylsulfanyl)-pyridine-3,5-dicarbonitrile, LUF 5826). 
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7.1 Introduction 
The adenosine A1 receptor is the most extensively researched of the family of adenosine 
receptors, which also include the A2A, A2B, and the A3 receptors. Many different classes of 
ligands have been designed, synthesised and tested at the A1 receptor, and to date there are 
several recurring factors which almost define the affinity or efficacy of the compound. The 
antagonists can be generally split into two groups, those based on the xanthine core structure 
and those heterocycles which are non-xanthine compounds. This latter category encompasses 
all manner of different mono-, bi-, tri- and even quadri-cyclic mostly nitrogen containing 
aromatic compounds,1-3 as detailed in Chapter 2. On the contrary, until very recently (partial) 
agonists were all derivatives of the natural ligand itself, adenosine. Research had shown that, 
in general, manipulation of the ribose moiety results in a reduction of the intrinsic activity 
towards the adenosine A1 receptor,4-7 and thus accordingly all new non-adenosine ligands 
were assumed to be antagonists. The main exception to this is modification at the 5' position, 
where replacement of the 5'-hydroxyl with 5'-N-carboxamides is particularly well tolerated, 
e.g., NECA and derivatives thereof, although these ligands tend not to be very selective.1 
Recently, based upon some data published in patent literature, it was shown that certain  
2-amino-4-(substituted)phenyl-6-(1H-imidazol-2-yl-methylsulfanyl)-pyridine-3,5-dicarbonitr-
iles had varying degrees of efficacy, ranging from full to partial agonists at the different 
adenosine receptors.8 Most significantly, these compounds displayed a considerable affinity 
and efficacy at the A2B receptor that had not been reported previously. However, these ligands 
were not particularly selective at any of the adenosine receptors (being only slightly more 
favourable towards the A1 receptor). In this chapter a novel series based upon this same 
template is explored and the affinity and selectivity for the adenosine A1 receptor is examined. 
The remarkable pharmacological profile of these compounds, in terms of the ability to block 
or activate the human A1 receptor influencing the cAMP production in CHO cells stably 
expressing this receptor, is shown. 
 
7.2 Results and Discussion 
7.2.1 Chemistry 
The compounds 7.55-7.72 were synthesised according to Scheme 7.1.9,10 The aldehyde was 
reacted with malononitrile in a straightforward Knoevenagel condensation in the presence of a 
few drops of piperidine to give the intermediates (7.1-7.18) in moderate to good yields (30-
93%). Pyridine formation occurred according to a preparation by Kambe et al.11 to give the 
phenyl protected sulfide in the 6-position of the ring. The functionalised malononitrile was 
refluxed with another equivalent of malononitrile and an equivalent of thiophenol in ethanol 
and triethylamine, resulting in compounds 7.19-7.36 (generally between 20-50% yields). To 
obtain the free thiol in the 6-position of the pyridine ring, 3.3 equivalents of sodium sulfide in 
DMF at 80 °C for 2-3 hours resulted in quantitative yields of compounds 7.37-7.54. 
Throughout the synthesis, purification of the crude product was not performed, nor were the 
reactions optimised. The yields stated correspond to the crude material, and it was this crude 
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substance that was used in subsequent reactions. The final step was the reaction of the free 
thiol with 2-bromoethanol in the presence of NaHCO3 in DMF at room temperature to give 
compounds 7.55-7.72 in modest to good yields. The final products were purified by 
















Scheme 7.1. Synthetic route to 2-amino-4-[(substituted)phenyl]-6-(2-hydroxy-ethylsulfanyl)-pyridine-
3,5-dicarbonitriles 7.55-7.72 (a) piperidine, EtOH, 1 h reflux; (b) malononitrile, thiophenol, 
triethylamine, EtOH, 4 h reflux; (c) (i) Na2S, DMF, (ii) 1M HCl; (d) 2-bromoethanol, NaHCO3, DMF. 
 
7.2.2 Biology 
All compounds were tested in radioligand binding assays to determine their affinities at the 
respective human adenosine receptors (Table 7.1). Compounds for which the affinities were 
determined (i.e., compounds which showed greater than 50 % displacement of the radioligand 
at 1 µM) were tested in functional assays for their ability to influence the levels of cAMP in 
CHO cells expressing the human adenosine A1 receptor. The compounds were tested at 
concentrations of mostly 100 x Ki, and at least 20 x Ki , where the receptor sites should be 
almost fully occupied and the reference ligands CPA, DPCPX and N0840 were included in 
the assays. In [35S]GTPγS binding assays on similar cell membranes from CHO cells these 
three particular ligands are respectively reported as a full agonist, an inverse agonist and a 
neutral antagonist.12,13 In cAMP assays on whole cells expressing the human A1 receptor, 
CPA has been shown to be a full agonist and DPCPX as an inverse agonist.13 To exclude the 
possibility of effects caused by endogenous adenosine that may be present in the system, 
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7.2.3 Structure Activity Relationships 
The results of the radioligand binding assays are presented in Table 7.1. The compounds are 
highly selective for the human A1 adenosine receptor, with not one variation displaying more 
than 50% displacement of the radioligand at a concentration of 1 µM on the human A2A or A3 
receptors. Fluorine substitution caused many different effects on both the binding and efficacy 
of the compounds compared to the non-fluorinated analogues. Compounds 7.56 and 7.57, the 
3- and 4-fluorophenyl derivatives, possessed a Ki value of 40 and 81 nM respectively, 
compared to the phenyl derivative (7.55), which had an affinity of 15 nM. In general, the 
highly electronegative fluorine atom was detrimental for binding affinity compared to its non-
fluorinated analogue, but for two exceptions. One exception was compound 7.58 with a Ki 
value of 14 nM, showing more than 5 times more affinity to the A1 receptor than the 3-tolyl 
derivative 7.60 (Ki = 81 nM). Compound 7.59 abides by the generalisation and possesses an 
affinity of 150 nM (cf., compound 7.61, Ki = 49 nM).  
The presence of the hydroxyl group (7.62, 7.63) also increases the electronegativity of this 
region of the ligand and thus might also have been detrimental for binding affinity. However, 
the presence of the hydrogen atom probably induces hydrogen-bonding with the receptor, 
accounting for similarly high affinities (12 and 23 nM, respectively) to that of the non-
substituted phenyl derivative (7.55, Ki = 15 nM). As mentioned earlier, the presence of the 
fluorine atom was generally detrimental for binding, and this was illustrated by the fluorine-
substituted methoxyphenyl ligands (7.64, 7.66 and 7.67) which showed less affinity for the 
receptor than the analogous methoxyphenyl ligands (7.68, 7.69). The other exception to the 
detrimental effect of fluorine was the 4-difluoromethoxyphenyl ligand 7.65, which displayed 
comparable affinity to the 4-methoxyphenyl derivative 7.69 in the 30-40 nM range. With an 
affinity of 4 nM the compound with the most encouraging potency at the A1 receptor was the 
3-methoxyphenyl ligand (7.68).  
In general, substitution in the 3-position was more positive for binding than substitution in the 
4-position of the phenyl ring. The only exceptions to this were the tolyl compounds (7.60, 
7.61). The spatial benefit of substitution in the 3- versus the 4-position is illustrated well by 
compounds 7.68-7.70. The 3-methoxyphenyl derivative 7.68 displays almost 10-fold better 
affinity than the 4-methoxyphenyl ligand 7.69 at 4.3 nM and 41 nM, respectively.  
Compound 7.70, which can perhaps be seen as a compromise of these two moieties, holds an 
affinity consistent with this theory at 11 nM. The 3,4-dimethoxyphenyl  derivative 7.71, a 
combination of compounds 7.68 and 7.69, has a much-reduced affinity at the A1 receptor, 
with a displacement of the radioligand of only 25% at a concentration of 1 µM.  It is obvious 
that the two methoxy groups create too much steric bulk for good binding in the pocket to 
occur. The 4-dimethylaminophenyl derivative 7.72, like the methoxy-analogues, possesses a 
methyl group connected to a hydrogen-bond acceptor. However, the existence of a second 
methyl substituent on this hydrogen-bond acceptor (causing steric hindrance, both in terms of 
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optimal fit in the receptor and in perhaps preventing the occurrence of H-bonding) probably 
explains its relatively poor affinity at the A1 adenosine receptor at 245 nM.  
The behaviour of the compounds in efficacy assays is displayed in Figure 7.1. The ligands 
were tested at concentrations of mostly 100 × Ki, and at least 20 × Ki, where the receptor sites 
should be almost fully occupied. The actual percentage inhibition or stimulation relative to the 
full agonist CPA (100 % inhibition) and DPCPX (full inverse agonist, set at 100 % 
stimulation) is given in Table 7.1. As the A1 receptor is coupled to an inhibitory G protein 
forskolin was used to induce the production of cAMP. N0840 (reported in [35S]GTPγS assays 
to be a neutral antagonist)12,13 was shown in this whole cell cAMP assay to have properties 
consistent with an inverse agonist, although on lower levels than DPCPX.  
Table 7.1. Affinities of the 2-amino-4-[(substituted)phenyl]-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-
dicarbonitriles (7.55-7.72) in radioligand binding assays at the human adenosine receptors and the 








Ki (nM) or % disp.a  R R1 
hA1b hA2Ac hA3d 
% change 
in cAMPe 
CPA - - 10 ± 1.3 1652 ± 344  281 ± 5614 -100 
DPCPX - - 6.1 ± 1.6 12915 1700 ± 17012 100 
N0840 - - 1081 ± 69 n.d. 15%12 72 ± 7 
7.55 H H 15 ± 4 23% 26% -72 ± 6 
7.56 F H 40 ± 10 19% 8% -102 ± 10 
7.57 H F 81 ± 5 4% 0% -51 ± 10 
7.58 (LUF 5948) CF3 H 14 ± 2 22% 49% 85 ± 12 
7.59 H CF3 150 ± 38 13% 0% 48 ± 6 
7.60 CH3 H 81 ± 17 29% 5% -78 ± 6 
7.61 H CH3 49 ± 9 20% 0% -16 ± 6 
7.62 OH H 12 ± 3 25% 16% -105 ± 22 
7.63 H OH 23 ± 3 37% 0% -93 ± 12 
7.64 OCF2H H 25 ± 4 8% 12% 6 ± 5 
7.65 (LUF 5826) H OCF2H 34 ± 7 0% 23% 4 ± 6 
7.66 OCF3 H 30 ± 7 3% 11% 80 ± 13 
7.67 H OCF3 156 ± 40 0% 10% 42 ± 12 
7.68 OCH3 H 4.3 ± 0.6 21% 18% -58 ± 10 
7.69 H OCH3 41 ± 8 8% 21% -16 ± 19 
7.70 (LUF 5853) -OCH2O- 11 ± 2 33% 13% -111 ± 16 
7.71 OCH3 OCH3 25% 25% 0% - 
7.72 H N(CH3)2 245 ± 100 0% 7% -65 ± 23 
aKi ± SEM (n = 3), % displacement (n = 2). bDisplacement of specific [3H]DPCPX binding in CHO cell 
membranes expressing human adenosine A1 receptors or % displacement of specific binding at 1 µM 
concentrations. cDisplacement of specific [3H]ZM 241385 binding in HEK 293 cell membranes expressing 
human adenosine A2A receptors or % displacement of specific binding at 1 µM concentrations.  dDisplacement of 
specific [125I]AB-MECA binding in HEK 293 cells expressing human adenosine A3 receptors or % displacement 
of specific binding at 1 µM concentrations. e% change of cAMP ± SEM (n = 3) compared to CPA (full agonist, -
100%) and DPCPX (full inverse agonist 100%). cAMP generation was stimulated with 10 µM forskolin and 
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Almost full agonistic activity was found for four compounds (7.56, 7.62, 7.63, 7.70), the 3-
fluorophenyl, the hydroxyphenyl substitutents and the benzo[1,3]dioxol-5-yl derivative. Five 
further compounds (7.55, 7.57, 7.60, 7.68, 7.72) display high levels of agonism, with efficacy 
ranging from 50-80%, with respect to full inhibition by CPA. Lower levels of partial agonism 
were demonstrated by compound 7.61 (the 4-tolyl derivative) and 7.69 (the 4-methoxyphenyl 
substitutent). The compounds with trifluoro-derivatives (7.58, 7.59, 7.66, 7.67) induce inverse 
agonism, resulting in an increase of cAMP levels. The two difluoromethoxyphenyl 
derivatives (7.64 and 7.65) show very little effect on the levels of cAMP even after 
stimulation by forskolin, indicating almost neutral antagonism. These compounds compare 
favourably with a previous exploration for neutral antagonists by De Ligt et al.12 In that paper, 
an 8-substituted N6-cyclopentyl-9-methyladenine, LUF 5674, possessed a binding affinity at 
the A1 adenosine receptor of 75 nM whilst displaying neutral antagonism. In this study we 

















Figure 7.1 The effect of reference and synthesised ligands on forskolin-induced cAMP levels at hA1 
receptors compared to CPA (full agonist, 100% inhibition) and DPCPX (full inverse agonist, 100% 
stimulation). 
For each pair of 3- and 4-substituted analogues the 3-substituent shows more acute behaviour 
than the 4-substituent. For example, the 3-fluorophenyl derivative 7.56 is a full agonist 
compared to partial agonism displayed by the 4-fluorophenyl derivative (7.57), and the 3-CF3 
derivative (7.58) displays a higher inverse agonistic behaviour than compound 7.59, the 4-CF3 
analogue. Although binding affinity and efficacy are not necessarily correlated, these findings 
support the outcome of the binding studies. The results suggest that substitution in the 3-
position fits the receptor pocket better than substitution in the 4-position to induce either 


































































The mode of activation of these ligands at the adenosine A1 receptor is far from clear. The 
long held theory of the necessity of the ribose group to activate the receptor proposed the 
existence of a ribose-specific binding domain in the receptor in which the activation ‘trigger’ 
resides. This current series of compounds, all without a ribose moiety, possess possible 
hydrogen-bonding groups (OH or NH2) that may bind in the ribose-specific domain and 
activate the receptor. However, the potential to reside in this specific domain alone may not 
explain the observations recorded. All the compounds in the series comprise of the same 
elements and only vary at the phenyl moiety, some distance away from the potential H-
bonding hydroxyl and amino- functions, and yet it is these substitutions that cause the great 
differences in receptor activation. A review by Visiers et al.16 highlights the complexities 
involved with receptor activation/inactivation and summarises our understanding of it. There 
are many proposed sites of importance in the activation of a G protein-coupled receptor 
(GPCR). The binding site itself for many endogenous ligands at rhodopsin-like receptors has 
been identified as being a spatially compact binding microdomain, most probably in 
transmembrane (TM) helices 3, 5 and 6, and there is evidence to suggest ligand orientation 
can be crucial for efficacy. Almaula et al.17 described how not only the binding affinity, but 
also the activation of the serotonin 5-HT2A receptor was affected by small differences in the 
mode of interaction of the ligand with the receptor pocket. Following this, Ebersole et al.18 
investigated partial agonism of the human serotonin 5-HT2A receptor. Based on mutagenesis 
studies and computational simulation, they found that ligand orientation affected the H-
bonding at serine residues in TM3 and TM 5 and caused a reduction in efficacy. In 
conclusion, it was hypothesised that the same structurally specific mechanism holds for other 
GPCRs. Translating the proposals to the current findings, we speculate that the strongly 
electron-withdrawing trifluoromethyl and trifluoromethoxy groups cause such a change in 
electron density about the molecule that the manner of binding (with respect to the non-
substituted ligand 7.55) at the receptor is distorted dramatically. This prevents not only 
activation of the receptor but induces the stabilisation of an already active receptor to adopt an 
inactive form. We can also hypothesise that the electron-withdrawing trifluoro-moieties (7.58, 
7.59, 7.66, 7.68) are capable of accepting hydrogen bonds from the protein in a manner 
stabilising the receptor, despite the potential from other parts of the molecule to activate the 
receptor. In comparison, the difluoromethoxy derivatives (7.64, 7.65) possess less 
electronegativity than the trifluoro species, distorting the manner of binding less, and so 
resulting in neutral antagonists. In the same speculative vein, the singularly substituted 
fluorine moiety (7.55, 7.56) is probably not sufficiently electronegative and not large enough 
to induce a different binding mode, thus agonism is conserved.  
In an attempt to form a clearer basis to this speculation we looked at the electronic and spatial 
properties of these compounds in the molecular modelling package Spartan.19 The agonists 
were modelled in comparison to the known agonist, CPA. For the clarity of the following 
discussion, CPA and its corresponding numbering system is shown in Figure 7.2. Assuming 
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that the conservation of the 3'OH is necessary for activation of the 
agonist (as reported by Taylor et al.20), we propose two alternative 
models of superimposition depicted in Figures 7.3 (CPA and 
compound 7.68). The first proposition suggests that the -
SCH2CH2OH region can be overlayed upon the 3'OH area (Figure 
7.3a). Examining the electronic configuration of the compounds, the 
electronegative regions of the H-bond accepting nitrile groups seem 
to correspond to the electronegative N1 and N7 of the purine ring. 
The advantage of 3-substitution of the phenyl ring above 4-
substitution can be seen clearly in this representation of compound 7.68 vs. CPA. The 3-
methoxy group seems to be superimposable with the cyclopentyl moiety of CPA. In contrast 
4-substitution would show much less overlap with the N6 substituent of the adenosine 
derivative CPA. 
An alternative superimposition is depicted in Figure 7.3b. This time the 2-amino group from 
the current series has been overlayed with the 3'OH of the ribose ring. The 3- and 5-nitrile 
groups of compound 7.68 now lie in the region of the 2'OH of the ribose group and the N7 of 
the purine ring, respectively. Again 3-substitution at the phenyl group confers overlap with 
the N6-cyclopentyl domain of CPA, offering more spatial compatibility than 4-substitution.  
The rationale in this modelling procedure was to search for maximal overlap between the two 
structures. However, it should be kept in mind that the binding sites for the two compounds 
(CPA and 7.68) may be (partially or even entirely) different, but converge in the subsequent 
activation of the receptor. 
In Chapter 5, the original model proposed for ‘good’ adenosine A1 receptor antagonists was 
refined and this refined model was subsequently exploited to achieve ligands with extremely 
low Ki values for the adenosine A1 receptor (Chapter 6).  Since members of this series of 
pyridine-3,5-dicarbonitriles also show antagonistic behaviour, it is appropriate to compare the 
properties of these molecules to those proposed by the model. As illustrated in Figure 7.4, the 
very vital hydrogen-bond interacting regions A, B and C are consistently represented in this 
new series of ligands. The L3 group is also well represented by the 4-phenyl substituent. The 
lowest Ki value reported for the antagonists/inverse agonists of this series was 14 nM, almost 
50-times greater than compound 5.31 (0.29 nM). Thus the ‘missing’ elements of these 
pyridine-3,5-dicarbonitriles compounds (that may provide more compatibility to the proposed 
model) may account for its lower affinity for the A1 receptor. Therefore, it is very likely that 
the antagonists in this series bind in the same position as the other antagonists detailed in 
previous chapters.  
7.3 Conclusion 
This chapter describes a series of ligands displaying very different activity at the A1 adenosine 
receptor. Several compounds are full agonists with affinity and efficacy comparable to the 
















































Figure 7.3. (a) 2-Amino-4-(3-methoxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-
dicarbonitrile (7.68) superimposed upon CPA. The first two representations depict the proposed 
overlap of electron density between the two nitrile groups and the purine ring. The right-hand picture 
is the superimposition shown from a different angle and displays the steric overlap of the N6 
substituent of CPA and the 3-methoxy substituent of the phenyl group. Also seen more clearly in this 
illustration is the compatibility of the 3'OH group from the ribose ring and the hydroxyl moiety from 
compound 7.68. (b) An alternative superimposition of compound 7.68 and CPA. Here the anchor point 
has been taken as the 2-amino group of 7.68 with the 3'OH of the ribose ring. The first two pictures 
suggest overlap of the ribose 2'OH group with the 3-nitrile moiety, and the purine N7 with the 5-nitrile 
group. The depiction on the right is the superimposition shown from a different angle and displays 












































Figure 7.4 The model depicted on the left and manner in which the pyridine-3,5-dicarbonitriles may 
fit this model. 
compounds in this series that display fully inverse agonistic behaviour, almost on levels 
comparable to the reference ligand DPCPX. Most strikingly, neutral antagonists have also 
been discovered which retain high affinity and selectivity for the adenosine A1 receptor. It is 
perhaps particularly noteworthy that these effects vary with the presence or absence of 
fluorine atoms distant from the phenyl ring. This suggests the substantial influence of 




Materials and Methods 
All reagents used were obtained from commercial sources and all solvents were of an analytical grade. 1H and 
13C NMR spectra were recorded on a Bruker AC 200 (1H NMR, 200 MHz; 13C NMR, 50.29 MHz) spectrometer 
with tetramethylsilane as an internal standard. Chemical shifts are reported in δ(ppm) and the following 
abbreviations are used: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. Melting points were 
determined on a Büchi melting point apparatus, the lowest point of the melting point range is given and the 
values are uncorrected. Elemental analyses were performed by the Leiden Institute of Chemistry and are within 
0.4 % of the theoretical values unless otherwise stated. Reactions were routinely monitored by TLC using Merck 
silica gel F254 plates. 
 
General Procedure for functionalised malononitriles (7.1-7.18) 
To malononitrile (1.32 mL, 20.8 mmol) dissolved in EtOH (14 mL) was added an aldehyde (20 
mmol) followed by 3 drops of piperidine. This reaction mixture was then refluxed for an hour, and 
then allowed to cool to room temperature, upon which a precipitate formed. The crude product was 
collected by filtration and used without any further purification. 
2-Benzylidene-malononitrile (7.1) 
Off-white solid, 65% yield. 1H NMR δ(CDCl3): 7.93-7.86 (m, 2H, phenyl-H), 7.79 (s, 1H, CH), 7.68-7.50 (m, 
3H, phenyl-H). 
2-(3-Fluoro-benzylidene)-malononitrile (7.2) 
Off-white solid, 56% yield. 1H NMR δ(DMSO): 8.59 (s, 1H, CH), 7.84-7.60 (m, 4H, phenyl-H). 
2-(4- Fluoro-benzylidene)-malononitrile (7.3) 
Off-white solid, 93% yield. 1H NMR δ(DMSO): 8.55 (s, 1H, CH), 8.09-8.01 (m, 2H, phenyl-H), 7.55-7.47 (m, 
2H, phenyl-H). 
2-(3-Trifluoro-benzylidene)-malononitrile (7.4) 
Off-white solid, 42% yield. 1H NMR δ(DMSO): 8.67 (s, 1H, CH), 8.27-8.21 (m, 1H, phenyl-H), 8.09-8.05 (m, 
1H, phenyl-H), 7.92-7.84 (m, 1H, phenyl-H). 
2-(4-Trifluoro-benzylidene)-malononitrile (7.5) 
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Off-white solid, 29% yield. 1H NMR δ(DMSO): 8.51 (s, 1H, CH), 7.80-7.77 (m, 2H, phenyl-H), 7.54-7.51 (m, 
2H, phenyl-H), 2.37 (s, 3H, CH3). 
2-(4-Methyl-benzylidene)-malononitrile (7.7) 
Off-white solid, 46% yield. 1H NMR δ(DMSO): 8.49 (s, 1H, CH), 7.87 (d, 2H, J = 8.0 Hz, phenyl-H), 7.45 (d, 
2H, J = 8.0 Hz), 2.41 (s, 3H, CH3). 
2-(3-Hydroxy-benzylidene)-malononitrile (7.8) 
Off-white solid, 40% yield. 1H-NMR δ(CDCl3/MeOD): 7.92 (s, 1H, CH), 7.40-7.36 (m, 3H, phenyl-H), 7.13-
7.10 (m, 1H, phenyl-H).  
2-(4-Hydroxy-benzylidene)-malononitrile (7.9) 
Off-white solid, 66% yield. 1H-NMR δ(CDCl3/MeOD): 7.86 (d, 2H, J = 8.8 Hz, phenyl-H), 7.71 (s, 1H, CH), 
6.94 (d, 2H, J = 8.8 Hz, phenyl-H). 
2-(3-Difluoromethoxy-benzylidene)-malononitrile (7.10) 
Off-white solid, 45% yield. 1H-NMR δ(CDCl3): 7.79-7.75 (m, 2H, phenyl-H), 7.66 (s, 1H, CH), 7.56 (m, 1H, 
phenyl-H), 7.43-7.39 (m, 1H, phenyl-H), 6.58 (t, 1H, J = 72.3 Hz, OCF2H). 
2-(4- Difluoromethoxy-benzylidene)-malononitrile (7.11) 
Off-white solid, 68% yield. 1H-NMR δ(CDCl3): 7.96 (d, 2H, J = 8.76 Hz, phenyl-H), 7.75 (s, 1H, CH), 7.27 (d, 
2H, J = 8.8 Hz, phenyl-H), 6.65 (t, 1H, J = 72.3 Hz, OCF2H). 
2-(3-Trifluoromethoxy-benzylidene)-malononitrile (7.12) 
Off-white solid, 48% yield. 1H-NMR δ(CDCl3): 7.89-7.86 (m, 1H, phenyl-H), 7.80 (s, 1H, CH), 7.74 (m, 1H, 
phenyl-H), 7.62 (m, 1H, phenyl-H), 7.51-7.47 (m, 1H, phenyl-H). 
2-(4-Trifluoromethoxy-benzylidene)-malononitrile (7.13) 
Off-white solid, 30% yield. 1H-NMR δ(CDCl3): 7.99 (d, 2H, J = 8.8 Hz, phenyl-H), 7.78 (s, 1H, CH), 7.38 (d, 
2H, J = 8.8 Hz, phenyl-H). 
2-(3-Methoxy-benzylidene)-malononitrile (7.14) 
Off-white solid, 82% yield. 1H-NMR δ(CDCl3): 7.75 (s, 1H, CH), 7.45-7.39 (m, 3H, phenyl-H), 7.20-7.14 (m, 
1H, phenyl-H), 3.87 (s, 3H, CH3). 
2-(4-Methoxy-benzylidene)-malononitrile (7.15) 
Off-white solid, 68% yield. 1H-NMR δ(CDCl3/MeOD): 7.96-7.91 (m, 3H, phenyl-H + CH), 7.04 (d, 2H, J = 8.8 
Hz, phenyl-H), 3.90 (s, 3H, CH3).  
2-Benzo[1,3]dioxol-5-ylmethylene-malononitrile (7.16) 
Off-white solid, 46% yield. 1H-NMR δ(DMSO): 8.39 (s, 1H, CH), 7.57-7.54 (m, 2H,  phenyl-H), 7.24-7.19 (m, 
1H, phenyl-H), 6.25 (s, 2H, -OCH2O-).  
2-(3,4-Dimethoxy-benzylidene)-malononitrile (7.17) 
Off-white solid, 53% yield. 1H-NMR δ(DMSO): 8.39 (s, 1H, CH), 7.66-7.60 (m, 2H,  phenyl-H), 7.27-7.22 (m, 
1H, phenyl-H), 3.91 (s, 3H, CH3), 3.83 (s, 3H, CH3).  
2-(4-Dimethylamino-benzylidene)-malononitrile (7.18) 
Off-white solid, 45% yield. 1H-NMR δ(DMSO): 8.08 (s, 1H, CH), 7.87 (d, 2H, J = 9.5 Hz phenyl-H), 6.89 (m, 
2H, J = 9.5 Hz, phenyl-H), 3.13 (s, 6H, 2 × CH3). 
 
General Procedure for 2-Amino-4-(substituted)-phenyl-6-phenylsulfanyl-pyridine-3,5-dicarbonitriles 
(7.19-7.36) To a solution of the functionalised malononitrile (7.1-7.18) (10 mmol) in EtOH (10 
mL), was added malononitrile (0.64 mL, 10 mmol), thiophenol (1.02 mL, 10 mmol) and 
triethylamine (50 µL), and the mixture heated at reflux for approximately 4 h. The reaction 
mixture was then allowed to cool to room temperature. The crude product precipitated upon 
cooling and was collected by filtration. 
2-Amino-4-phenyl-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.19) 
Yellow solid, 41% yield. 1H-NMR δ(DMSO): 7.83 (br s, 2H, NH2), 7.66-7.52 (m, 10H, phenyl-H). 
2-Amino-4-(3-fluoro-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.20) 
Yellow solid, 24% yield. 1H-NMR δ(DMSO): 7.90 (br s, 2H, NH2), 7.71-7.40 (m, 9H, phenyl-H). 
2-Amino-4-(4-fluoro-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.21) 
Yellow solid, 42% yield. 1H-NMR δ(DMSO): 7.64 (br s, 2H, NH2), 7.62-7.59 (m, 4H, phenyl-H), 7.52-7.40 (m, 
5H, phenyl-H). 
2-Amino-4-(3-trifluoromethyl-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.22) 
Yellow solid, 34% yield. 1H-NMR δ(DMSO): 7.85 (br s, 2H, NH2), 7.83-7.70 (m, 4H, phenyl-H), 7.66-7.61 (m, 
2H, phenyl-H), 7.56-7.51 (m, 3H, phenyl-H). 
2-Amino-4-(4-trifluoromethyl-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.23) 
Yellow solid, 50% yield. 1H-NMR δ(DMSO): 8.01-7.92 (m + br s, 3H, NH2 + CF3-phenyl-H), 7.83-7.78 (m, 2H, 
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2-Amino-4-(3-methyl-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.24) 
Yellow solid, 29% yield. 1H-NMR δ(DMSO): 7.83 (br s, 2H, NH2), 7.66-7.61 (m, 2H, phenyl-H), 7.56-7.49 (m, 
3H, phenyl-H), 7.45-7.33 (m, 4H, tolyl-H), 2.41 (s, 3H, CH3). 
2-Amino-4-(4-methyl-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.25) 
Yellow solid, 46% yield. 1H-NMR δ(DMSO): 7.60 (br s, 2H, NH2), 7.55-7.52 (m, 2H, phenyl-H), 7.50-7.38 (m, 
7H, phenyl-H + tolyl-H), 2.43 (s, 3H, CH3). 
2-Amino-4-(3-hydroxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.26) 
Yellow solid, 20% yield. 1H-NMR δ(CDCl3/MeOD): 7.60-7.32 (m, 6H, phenyl-H), 6.99-6.94 (m, 3H, phenyl-H). 
2-Amino-4-(4-hydroxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.27) 
Yellow solid, 25% yield. 1H-NMR δ(CDCl3/MeOD): 7.58-7.39 (m, 7H, phenyl-H), 6.95 (d, 2H, J = 8.8 Hz, 
phenyl-H). 
2-Amino-4-(3-difluoromethoxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.28) 
Yellow solid, 42% yield. 1H-NMR δ(DMSO): 7.88 (br s, 2H, NH2), 7.67-7.34 (m, 9H, phenyl-H), 6.95 (m, 1H, 
OCF2H). 
2-Amino-4-(4-difluoromethoxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.29) 
Yellow solid, 32% yield. 1H-NMR δ(DMSO): 7.85 (br s, 2H, NH2), 7.69-7.38 (m, 9H, phenyl-H), 7.07 (m, 1H, 
OCF2H). 
2-Amino-4-(3-trifluoromethoxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.30) 
Yellow solid, 16% yield. 1H-NMR δ(DMSO): 7.89 (br s, 2H, NH2), 7.75-7.51 (m, 9H, phenyl-H). 
2-Amino-4-(4-trifluoromethoxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.31) 
Yellow solid, 4% yield. 1H-NMR δ(DMSO): 7.89 (br s, 2H, NH2), 7.76 (d, 2H, J = 6.6 Hz, OCF3-phenyl-H), 
7.66 (m, 7H, OCF3-phenyl-H + phenyl-H). 
2-Amino-4-(3-methoxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.32) 
Yellow solid, 32% yield. 1H-NMR δ(CDCl3/DMSO): 7.57-7.42 (m, 6H, phenyl-H), 7.10-6.95 (m, 3H, phenyl-
H), 3.87 (s, 3H, CH3). 
2-Amino-4-(4-methoxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.33) 
Yellow solid, 32% yield. 1H-NMR δ(DMSO): 7.77 (br s, 2H, NH2), 7.65-7.50 (m, 7H, phenyl-H), 7.15 (d, 2H, J 
= 8.8 Hz, phenyl-H), 3.87 (s, 3H, CH3). 
2-Amino-4-benzo[1,3]dioxol-5-yl-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.34) 
Yellow solid, 34% yield. 1H-NMR δ(DMSO): 7.80 (br s, 2H, NH2), 7.64-7.60 (m, 2H, S-phenyl-H), 7.53-7.50 
(m, 3H, S-phenyl-H), 7.20-7.04 (m, 3H, phenyl-H), 6.18 (s, 2H, -OCH2O-). 
2-Amino-4-(3,4-dimethoxy-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.35) 
Yellow solid, 28% yield. 1H-NMR δ(DMSO): 7.77 (br s, 2H, NH2), 7.65-7.50 (m, 7H, phenyl-H), 7.15 (d, 2H, J 
= 8.8 Hz, phenyl-H), 3.67 (s, 3H, CH3), 3.63 (s, 3H, CH3). 
2-Amino-4-(4-dimethylamino-phenyl)-6-phenylsulfanyl-pyridine-3,5-dicarbonitrile (7.36) 
Yellow solid, 32% yield. 1H-NMR δ(DMSO): 7.68 (br s, 2H, NH2), 7.64-7.60 (m, 2H, phenyl-H), 7.54-7.48 (m, 
2H, phenyl-H), 7.44 (d, 2H, J = 8.8 Hz, 4-NMe2-phenyl-H), 6.86 (d, 2H, J = 8.8 Hz, 4-NMe2-phenyl-H), 3.03 (s, 
6H, 2 × CH3). 
 
General Procedure for 2-Amino-4-(substituted)-phenyl-6-mercapto-pyridine-3,5-dicarbonitriles (7.37-
7.54) 
The pyridine (7.19-7.36) (3 mmol) was dissolved in DMF (10 mL) and to this was added sodium 
sulfide (0.78 g, 10 mmol) and the mixture stirred at 80 °C for 2 h. Upon cooling to room 
temperature, 1 M HCl (20 mL) was added, resulting in the formation of a yellow precipitate. The 
crude product was collected by filtration. 
2-Amino-4-phenyl-6-mercapto-pyridine-3,5-dicarbonitrile (7.37) 
Yellow solid, quantitative yield. 1H-NMR δ(CDCl3/MeOD): 7.51-7.20 (m, 5H, phenyl-H). 
2-Amino-4-(3-fluoro-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.38) 
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.65-7.59 (m, 1H, phenyl-H), 7.48-7.35 (m, 3H, phenyl-
H). 
2-Amino-4-(4-fluoro-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.39) 
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.58-7.52 (m, 2H, phenyl-H), 7.44-7.39 (m, 2H, phenyl-
H). 
2-Amino-4-(3-trifluoromethyl-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.40) 
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.91-7.78 (m, 4H, phenyl-H). 
2-Amino-4-(4-trifluoromethyl-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.41) 











Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.57-7.30 (m, 4H, phenyl-H), 2.40 (s, 3H, CH3). 
2-Amino-4-(4-methyl-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.43) 
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.53-7.35 (m, 4H, phenyl-H), 2.41 (s, 3H, CH3). 
2-Amino-4-(3-hydroxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.44) 
Yellow solid, quantitative yield. 1H-NMR δ(CDCl3/MeOD): 7.46-7.34 (m, 1H, phenyl-H), 6.95-6.93 (m, 3H, 
phenyl-H). 
2-Amino-4-(4-hydroxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.45) 
Yellow solid, quantitative yield. 1H-NMR δ(CDCl3/MeOD): 7.41 (d, 2H, J = 8.8 Hz, phenyl-H), 6.94 (d, 2H, J = 
8.8 Hz, phenyl-H). 
2-Amino-4-(3-difluoromethoxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.46) 
Yellow solid, quantitative yield. 1H-NMR δ(MeOH): 7.46-7.33 (m, 4H, phenyl-H), 6.89 (t, 1H, J = 73.4 Hz, 
OCF2H). 
2-Amino-4-(4-difluoromethoxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.47) 
Yellow solid, quantitative yield. 1H-NMR δ(MeOD): 7.59 (m, 2H, phenyl-H), 7.30 (m, 2H, phenyl-H), 6.97 (t, 
1H, J = 73.1 Hz, OCF2H). 
2-Amino-4-(3-trifluoromethoxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.48) 
Yellow solid, quantitative yield. 1H-NMR δ(MeOD): 7.67-7.62 (m, 1H, phenyl-H), 7.54-7.47 (m, 3H, phenyl-H). 
2-Amino-4-(4-trifluoromethoxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.49) 
Yellow solid, quantitative yield. 1H-NMR δ(MeOD): 7.67-7.63 (m, 2H, phenyl-H), 7.48-7.44 (m, 2H, phenyl-H). 
2-Amino-4-(3-methoxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.50) 
Yellow solid, quantitative yield. 1H-NMR δ(CDCl3/MeOD): 7.47-7.39 (m, 1H, phenyl-H), 7.09-7.01 (m, 3H, 
phenyl-H), 3.89 (s, 3H, CH3). 
2-Amino-4-(4-methoxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.51) 
Yellow solid, quantitative yield. 1H-NMR δ(CDCl3/MeOD): 7.49 (m, 2H, phenyl-H), 7.03 (m, 2H, phenyl-H) 
3.88 (s, 3H, CH3). 
2-Amino-4-benzo[1,3]dioxol-5-yl-6-mercapto-pyridine-3,5-dicarbonitrile (7.52) 
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.13-7.00 (m, 3H, phenyl-H), 6.17 (s, 2H, -OCH2O-). 
2-Amino-4-(3,4-dimethoxy-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.53) 
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.17-7.13 (m, 3H, phenyl-H), 3.85 (s, 3H, OCH3), 3.81 (s, 
3H, OCH3). 
2-Amino-4-(4-dimethylamino-phenyl)-6-mercapto-pyridine-3,5-dicarbonitrile (7.54) 
Yellow solid, quantitative yield. 1H-NMR δ(DMSO): 7.41 (d, 2H, J = 8.8 Hz, phenyl-H), 6.83 (d, 2H, J = 8.8 Hz, 
phenyl-H), 3.03 (s, 6H, 2 × CH3). 
 
General Procedure for 2-Amino-4-[(substituted)phenyl]-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-
dicarbonitriles (7.55-7.72) The free thiol (7.37-7.54) (1 mmol) was stirred with 2-bromoethanol 
(84 µL, 1 mmol), NaHCO3 (0.34 g, 1 mmol) in DMF (2 mL) at room temperature for 2 h. Water 
(10 mL) was added to precipitate the crude product, which was collected by filtration. Purification 
by column chromatography on SiO2, eluting with ethylacetate and/or ethylacetate-methanol 
mixtures, followed by recrystallisation gave the desired products. 
 
2-Amino-4-phenyl-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.55) 
White Solid, 54% yield. mp: 211 ºC.  1H-NMR δ(MeOD): 7.56-7.48 (m, 5H, phenyl-H), 3.80 (t, 2H, J = 6.6 Hz, 
OCH2), 3.40 (t, 2H, J = 6.6 Hz, CH2S). 13C-NMR δ(MeOD): 167.1, 159.6, 158.3, 134.0, 130.3, 128.7, 128.4, 
115.4, 115.3, 96.1, 85.7, 59.5, 32.6. MS (ESI): 296.9.  Anal. (C15H12N4OS·0.34H2O.0.3DMF) C, H, N, S. 
2-Amino-4-(3-fluoro-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.56) 
White Solid, 38% yield. mp: 189 ºC. 1H-NMR δ(DMSO): 8.09 (br s, 2H, NH2) 7.70-7.59 (m, 1H, phenyl-H), 
7.52-7.37 (m, 3H, phenyl-H), 5.05 (t, 1H, J= 5.5 Hz, OH), 3.72-3.64 (m, 2H, OCH2), 3.40-3.33 (m, 2H, CH2S). 
13C-NMR δ(DMSO): 167.8, 159.5, 130.3, 130.2, 123.7, 117.1, 116.7, 115.2, 114.8, 114.3, 105.6, 83.3, 59.8, 
31.5. MS (ESI): 314.8 Anal. (C15H11FN4OS·0.3H2O) C, H, N, S. 
2-Amino-4-(4-fluoro-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.57) 
White Solid, 54% yield. mp: 133 ºC. 1H-NMR δ(DMSO): 8.06 (br s, 2H, NH2) 7.68-7.60 (m, 2H, phenyl-H), 
7.49-7.40 (m, 2H, phenyl-H), 5.04 (t, 1H, J= 5.5 Hz, OH), 3.73-3.64 (m, 2H, OCH2), 3.45-3.33 (m, 2H, CH2S). 
13C-NMR δ(DMSO): 167.0, 166.0, 160.0, 157.4, 131.1, 131.0, 130.4, 116.0, 115.6, 115.4, 115.2, 85.8, 83.9, 
59.4, 32.6. MS (ESI): 315.0. Anal. (C15H11FN4OS·0.3MeOH) C, H, N, S.  
2-Amino-4-(3-trifluoromethyl-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.58) 
White Solid, 60% yield. mp: 164 ºC. 1H-NMR δ(DMSO): 8.10 (br s, 2H, NH2), 8.00-7.83 (m, 4H, phenyl-H), 
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159.6, 156.8, 135.1, 132.7, 130.0, 129.8, 129.2, 127.0, 126.6, 125.6, 115.3, 115.1, 93.7, 85.9, 59.5, 32.7. MS 
(ESI): 364.9. Anal. (C16H11F3N4OS·0.07CH2Cl2) C, H, N, S. 
 2-Amino-4-(4-trifluoromethyl-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.59) 
White Solid, 69% yield. mp: 158 ºC. 1H-NMR δ(DMSO): 8.14 (br s, 2H, NH2), 7.99 (d, 2H, J = 8.0 Hz, phenyl-
H), 7.81 (d, 2H, J = 8.0 Hz, phenyl-H), 5.05 (t, 1H, J= 5.5 Hz, OH), 3.74-3.65 (m, 2H, OCH2), 3.45-3.36 (m, 2H, 
CH2S). 13C-NMR δ(DMSO): 178.9, 167.2, 159.5, 157.0, 138.2, 130.8, 130.1, 129.6, 126.6, 125.7, 115.2, 115.0, 
93.4, 85.7, 59.4, 32.7. MS (ESI): 364.6. Anal. (C16H11F3N4OS·0.2CH2Cl2) C, H, N, S. 
2-Amino-4-(3-methyl-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.60) 
White Solid, 74% yield. mp: 178 ºC. 1H-NMR δ(DMSO): 8.02 (br s, 2H, NH2), 7.47-7.30 (m, 4H, phenyl-H), 
5.04 (t, 1H, J= 5.5 Hz, OH), 3.71-3.65 (m, 2H, OCH2), 3.40-3.34 (m, 2H, CH2S), 2.40 (s, 3H, CH3). 13C-NMR 
δ(DMSO): 167.1, 159.6, 158.4, 138.1, 134.0, 131.0, 128.7, 125.5, 115.5, 115.3, 93.6, 85.9, 59.5, 32.7, 20.9. MS 
(ESI): 311.2. Anal. (C16H14N4OS) C, H, N, S.  
2-Amino-4-(4-methyl-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.61) 
White Solid, 81% yield. mp: 206 ºC. 1H-NMR δ(DMSO): 8.00 (br s, 2H, NH2), 7.46-7.36 (m, 4H, phenyl-H), 
5.03 (t, 1H, J = 5.5 Hz, OH), 3.73-3.64 (m, 2H, OCH2), 3.39-3.33 (m, 2H, CH2S), 2.41 (s, 3H, CH3). 13C-NMR 
δ(DMSO): 167.0, 159.6, 158.3, 140.2, 131.1, 129.2, 128.4, 115.5, 115.3, 93.6, 85.7, 59.5, 32.6, 20.9. MS (ESI): 
310.8. Anal. (C16H14N4OS) C, H, N, S.  
2-Amino-4-(3-hydroxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.62) 
White Solid, 70% yield. mp: 227-229 ºC dec. 1H-NMR δ(DMSO): 8.01 (br s, 2H, NH2) 7.41-7.33 (m, 1H, 
phenyl-H), 6.98-6.89 (m, 3H, phenyl-H), 5.05 (t, 1H, J = 5.5 Hz, OH), 3.73-3.64 (m, 2H, OCH2), 3.42-3.33 (m, 
2H, CH2S). 13C-NMR δ(DMSO): 167.1, 135.2, 130.0, 118.9, 117.3, 115.4, 115.3, 115.1, 93.6, 86.0, 59.5, 32.7. 
MS (ESI): 312.8. Anal. (C15H12N4O2S·0.6H2O) C, H, N, S.  
2-Amino-4-(4-hydroxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.63) 
White Solid, 40% yield. mp: 224 ºC dec. 1H-NMR δ(DMSO): 7.95 (br s, 2H, NH2) 7.39 (m, 2H, phenyl-H), 6.93 
(m, 2H, phenyl-H), 5.04 (br s, 1H, OH), 3.70-3.64 (m, 2H, OCH2), 3.32-3.19 (m, 2H, CH2S). 13C-NMR 
δ(DMSO): 167.1, 130.3, 124.3, 115.7, 115.4, 59.5, 32.7. MS (ESI): 312.7. Anal. (C16H14N4O2S·0.1MeOH), C, H, 
N, S.  
2-Amino-4-(3-difluoromethoxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.64) 
White Solid, 36% yield. mp: 140 ºC. 1H-NMR δ(MeOD): 7.60-7.52 (m, 1H, phenyl-H), 7.38-7.31 (m, 3H, 
phenyl-H), 6.86 (t, 1H, 73.4Hz, CF2H), 3.79 (t, 2H, J = 6.6 Hz, OCH2), 3.39 (t, 2H, J = 6.6 Hz, CH2S). 13C-NMR 
δ(DMSO): 169.4, 161.4, 158.5, 152.8, 137.0, 131.7, 126.5, 122.0, 120.4, 117.6, 116.1, 116.0, 95.5, 87.2, 61.4, 
33.5. MS (ESI): 363. Anal. (C16H12F2N4O2S) C, H, N, S.  
2-Amino-4-(4-difluoromethoxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.65) 
White Solid, 44% yield. mp: 156 ºC. 1H-NMR δ(DMSO): 8.04 (br s, 2H, NH2) 7.65 (m, 2H, phenyl-H), 7.38 (m, 
2H, phenyl-H), 7.43 (s, 1H, CF2H), 5.04 (t, 1H, J = 5.5 Hz, OH), 3.73-3.64 (m, 2H, OCH2), 3.38-3.33 (m, 2H, 
CH2S). 13C-NMR δ(DMSO): 167.1, 159.6, 157.4, 152.4, 130.7, 118.4, 115.5, 115.3, 93.4, 85.8, 59.5, 32.7. MS 
(ESI): 363.0. Anal. (C16H12F2N4O2S), C, H, N, S.  
2-Amino-4-(3-trifluoromethoxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.66) 
White Solid, 69% yield. mp: 125 ºC. 1H-NMR δ(DMSO): 8.08 (br s, 2H, NH2) 7.73-7.59 (m, 4H, phenyl-H), 
5.04 (t, 1H, J = 5.5 Hz, OH), 3.73-3.64 (m, 2H, OCH2), 3.38-3.33 (m, 2H, CH2S). 13C-NMR δ(DMSO): 167.1, 
159.5, 156.5, 148.2, 136.1, 131.0, 127.7, 123.3, 122.9, 121.5, 115.2, 115.0, 85.8, 59.5, 32.6. MS (ESI): 380.7. 
Anal. calc. for C16H11F3N4O2S (C 50.53; H 2.92; N 14.73; S 8.43) found (C 50.46; H 2.39; N 15.01; S 8.16) %. 
2-Amino-4-(4-trifluoromethoxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.67) 
White Solid, 75% yield. mp: 144 ºC. 1H-NMR δ(DMSO): 8.08 (br s, 2H, NH2) 7.74-7.58 (m, 4H, phenyl-H), 
5.04 (t, 1H, J = 5.5 Hz, OH), 3.73-3.64 (m, 2H, OCH2), 3.37-3.33 (m, 2H, CH2S). 13C-NMR δ(DMSO): 167.2, 
159.6, 157.1, 149.6, 133.2, 131.0, 121.2, 115.4, 115.2, 93.6, 85.8, 59.5, 32.7. MS (ESI): 380.8. Anal. 
(C16H11F3N4O2S) C, H, N, S.  
2-Amino-4-(3-methoxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.68) 
White Solid, 63% yield. mp: 188 ºC. 1H-NMR δ(DMSO): 8.01 (br s, 2H, NH2) 7.53-7.45 (m, 1H, phenyl-H), 
7.17-7.06 (m, 3H, phenyl-H), 5.06 (t, 1H, J = 5.5 Hz, OH), 3.82 (s, 3H, CH3), 3.73-3.64 (m, 2H, OCH2), 3.39-
3.33 (m, 2H, CH2S). 13C-NMR δ(DMSO): 167.1, 159.7, 159.1, 158.1, 135.3, 130.1, 120.6, 115.9, 115.5, 115.3, 
114.1, 93.7, 85.8, 59.5, 55.4, 32.7. MS (ESI): 326.9. Anal. (C16H14N4O2S·0.2MeOH), C, H, N, S.  
2-Amino-4-(4-methoxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.69) 
White Solid, 54% yield. mp: 188 ºC. 1H-NMR δ(DMSO): 7.96 (br s, 2H, NH2) 7.51 (d, 2H, J = 8.8 Hz, phenyl-
H), 7.13 (d, 2H, J = 8.8 Hz, phenyl-H), 5.03 (t, 1H, J = 5.5 Hz, OH), 3.86 (s, 3H, CH3), 3.73-3.64 (m, 2H, 
OCH2), 3.37-3.33 (m, 2H, CH2S). 13C-NMR δ(DMSO): 167.1, 160.8, 159.8, 158.0, 130.2, 125.9, 115.7, 115.6, 






White Solid, 42% yield. mp: 192 ºC. 1H-NMR δ(DMSO): 7.99 (br s, 2H, NH2) 7.16-7.01 (m, 3H, phenyl-H), 
6.17 (s, 2H, -OCH2O-), 5.02 (t, 1H, J = 5.5 Hz, OH), 3.67 (m, 2H, OCH2), 3.38-3.32 (m, 2H, CH2S). 13C-NMR 
δ(DMSO): 197.7, 167.0, 159.7, 157.9, 148.9, 147.4, 127.4, 123.0, 115.6, 115.4, 108.9, 108.5, 101.8, 93.8, 59.5, 
32.6. MS (ESI): 341.1. Anal. calc. for C16H12N4O3S (C 56.46; H 3.55; N 16.46; S 9.42) found (C 56.31; H 3.11; 
N 16.38; S 9.46) %. 
2-Amino-4-(3,4-dimethoxy-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.71) 
White Solid, 35% yield. mp: 209 ºC. 1H-NMR δ(DMSO): 7.96 (br s, 2H, NH2) 7.19-7.13 (m, 3H, phenyl-H), 
5.02 (m, 1H, OH), 3.86 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.69-3.66 (m, 2H, OCH2), 3.32-3.19 (m, 2H, CH2S). 
13C-NMR δ(DMSO): 167.0, 159.7, 158.0, 150.4, 148.3, 126.0, 121.5, 115.7, 115.6, 112.3, 111.5, 92.7, 85.9, 
59.5, 55.7, 55.6, 32.8. MS (ESI): 356.9. Anal. (C17H16N4O3S), C, H, N, S.  
2-Amino-4-(4-dimethylamino-phenyl)-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile (7.72) 
White Solid, 43% yield. mp: 268 ºC dec. 1H-NMR δ(DMSO): 7.87 (br s, 2H, NH2) 7.39 (d, 2H, J = 8.8 Hz, 
phenyl-H), 6.82 (d, 2H, J = 8.8 Hz, phenyl-H), 4.99 (t, 1H, J = 5.5 Hz, OH), 3.69-3.60 (m, 2H, OCH2), 3.38-3.32 
(m, 2H, CH2S), 3.00 (s, 6H, 2 × CH3). 13C-NMR δ(DMSO): 167.1, 160.0, 158.3, 151.5, 129.9, 120.0, 116.1, 
116.0, 111.3, 93.2, 85.0, 59.6, 39.5, 32.6. MS (ESI): 339.8. Anal. (C17H17N5OS·0.2CH2Cl2) C, H, N, S.  
 
7.4.2 Biology  
Materials and Methods  
[3H]DPCPX and [125I]AB-MECA were purchased from Amersham Biosciences (NL). [3H]ZM 241385 was 
obtained from Tocris Cookson, Ltd. (UK). CHO cells expressing the human adenosine A1 receptor were 
provided by Dr. Andrea Townsend-Nicholson, University College London, UK. HEK 293 cells stably expressing 
the human adenosine A2A and A3 receptor were gifts from Dr. Wang (Biogen, USA) and Dr. K.-N. Klotz 
(University of Würzburg, Germany), respectively.  
All compounds were tested in radioligand binding assays to determine their affinities at the human adenosine A1, 
A2A and the A3 receptors as described previously in Chapter 3, with the exception of non-specific binding on the 
A2A receptor was determined in the presence of 10 µM CGS21680 instead of 100 µM CPA.  The human A1 
receptors were expressed in CHO cells, and [3H]DPCPX used as the radioligand. The A2A and A3 receptors were 
expressed in HEK 293 cells, and [3H]ZM 241385 and [125I]AB-MECA were used as the respective radioligands.  
Compounds for which the affinities were determined (i.e., compounds which showed greater than 50% 
displacement of the radioligand at 1 µM) were tested in functional assays for their ability to influence the levels 
of cAMP in the test system. The compounds were tested at concentrations of mostly 100 × Ki, and at least 20 × 
Ki , where the receptor sites should be almost fully occupied. The behaviour of the compounds was observed 
with reference to known adenosine receptor ligands; CPA (a full agonist), DPCPX (an inverse agonist) and 
N0840 (reported as a neutral antagonist).  
CHO cells expressing the human adenosine A1 receptor were grown overnight as a monolayer in 24 well tissue 
culture plates (400 µL/well; 2 × 105 cells/well). cAMP generation was performed in Dulbecco’s Modified Eagles 
Medium (DMEM)/ N-2-hydroxyethylpiperazin-N'-2-ethansulfonic acid (HEPES) buffer (0.60 g HEPES/ 50 mL 
DMEM pH 7.4). Each well was washed twice with HEPES/DMEM  buffer (250 µL), and the following added, 
adenosine deaminase (0.8 IU/mL), rolipram (50 µM), cilostamide (50 µM). This was then incubated for 30 
minutes at 37 °C, followed by the introduction of the compound of interest. After a further 10 minutes of 
incubation, forskolin was added (10 µM). After a subsequent 15 minutes, incubation was stopped by aspirating 
the assay medium and by adding 200 µL of ice-cold 0.1 M HCl. The amount of cAMP was determined by 
competition with [3H]cAMP for protein kinase A (PKA). Briefly, the sample, approximately 1.8 nM [3H]cAMP, 
and 100 µL PKA solution were incubated on ice for 2.5 hr. The incubations were stopped by rapid dilution with 
2 mL of ice-cold Tris HCl buffer (pH 7.4) and bound radioactive material was then recovered by filtration 
through Whatman GF/C filters. Filters were additionally rinsed with 2 × 2 mL Tris HCl buffer and then the 
radioactivity counted in Packard Emulsifier Safe scintillation fluid (3.5 mL). All data reflect three independent 
experiments performed in duplicate. 
 
Data Analysis 
Ki values were calculated using a non-linear regression curve-fitting program (GraphPad Prism 4, GraphPad 
Software Inc., San Diego, CA, USA). KD values of the radioligands were 1.6 nM, 1.0 nM, and 5.0 nM for 
[3H]DPCPX, [3H]ZM 241385, and [125I]AB-MECA, respectively. The data from the functional assays were also 
analysed with GraphPad Prism. Figure 7.1 and the results shown in Table 7.1 were generated by evaluating the 
data to relate to the known ligands CPA and DPCPX. The first step involved normalising the raw data with 
respect to CPA and DPCPX. CPA was chosen as the baseline value as it has previously been shown to be a full 
agonist, and DPCPX as the highest value, assuming full inversely agonistic behaviour. After normalisation, the 
Y-axis was shifted to present the data as being above or below that of the forskolin-generated levels of cAMP. 
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Finally, the data were again normalised to assume 100% inhibition of cAMP by the agonist CPA and 100% full 
inverse agonism by DPCPX. 
 
7.4.3 Molecular Modelling 
Molecular modelling work was performed with the SPARTAN molecular modelling package Spartan Pro 1.0.2. 
Default values in the Merck Force Field were used in Molecular Mechanics minimisations. The molecular 
electrostatic potential was calculated using the semi-empirical AM1 Hamiltonian. The electrostatic potential was 
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General Conclusions and Perspectives 
The research recorded in this thesis furthers our understanding of the adenosine A1 
receptor. By analysing a series of adenosine A1 receptor antagonists with molecular modelling 
techniques, reoccurring electronic and spatial properties were identified and clustered into a 
new model. This model provided a new perspective from which to design A1 receptor 
antagonists. Despite (or because of) the simplicity of the model, four series of ligands were 
designed and synthesised with extremely promising affinity for the adenosine A1 receptor. 
This illustrates that there are few, though specific, essential features necessary for good 
interaction with the receptor. 
It is vital that the compounds developed in this period of research are further examined 
and investigated, especially in a physiological system. Only in this way can their full potential 
be discovered. It is a step in the right direction that the PSA of a compound is factored into 
the design stage; however this is only an indication of the potential blood-brain barrier (BBB) 
penetration (or otherwise). The confirmation of this will only be certain after more research. 
However, the scope and the resources available to an academic research group may render 
such high aspirations unfeasible. The BBB is a complete area of research in itself and there 
are numerous groups devoted entirely to this subject, be it aspects of the barrier itself,1,2 the 
transporters,3-6 or the penetration and effects of various different pharmaceutical 
preparations.7 In vitro investigations and animal models may shed light on some of the 
questions, but it may be only after in vivo studies in humans (after, of course, the numerous 
lengthy and time-consuming safety and toxicity questions are answered) that the real effects 
of a particular ‘drug’ in the brain are revealed.  
The next step to take in this line of research is perhaps to undertake the same 
procedure for the A2A and A3 receptors, the lack of existing high affinity ligands for the A2B 
receptor may limit this method of development for this particular receptor. Since some 
affinity (albeit much lower than that attained for the A1 receptor) is achieved at the A2A and 
A3 receptors with some of the compounds detailed in this thesis, it may be possible that these 
heterocyclic cores can also be manipulated to enhance the affinity and selectivity for these 
two receptors. On the contrary, it may also be the case that it is only incidental that some 
affinity is shown at the A2A and A3 receptors and that their binding site requirements may be 
only partially satisfied by the heterocycles presented here. The vast expansion in the 
development of A2A8 and A39 ligands over the past few years holds much promise in a 
methodical analysis and development of a ligand-based pharmacophore. 
One discrepancy of adenosine receptor research continues to be the A2B receptor. The 
low affinity nature of this receptor accounts for a lack of good selective ligands and thus 
appropriate radioligands (e.g., [3H]MRS1754 and [3H]MRE2029-F20)10,11 have only just 
recently become available. The inclusion of the A2B receptor as part of the standard 
assessment procedure is still not the norm and although expectations are low for compounds 
designed specifically for another receptor, it is a routine that should be striven to be practised. 
In an attempt to redress this somewhat and to substantiate our general observations that these 
series are (better) A1 receptor ligands, a selection of compounds from each series described in 
this thesis have also been assessed at the A2B receptor. Although the data are not shown in this 
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thesis (due to only the partial evaluation of each series), the indications are that these ligands, 
like many of their predecessors, perform poorly at the adenosine A2B receptor. 
As in many areas of science, no matter how well-trodden the path, there are quite often 
unexpected surprises still waiting to be uncovered. After so many years of adenosine research, 
the notion that the ribose group was necessary for activation of the receptor was a deeply 
embedded belief. The discovery of the pyridine dicarbonitrile series was perhaps by the use of 
screening methods or by chance, nevertheless, this now opens up the potential of exploring 
the bare necessities to achieve activation of the adenosine receptors. That the activation of the 
receptor with the pyridine dicarbonitriles described in Chapter 7 was so dependent upon the 
substituent present (or the lack of) is an extraordinarily interesting area to research further. 
The answer may hold clues to the secrets of activation of GPCRs in general.  
In light of these investigations, cAMP assays have subsequently been performed with 
a selection of the compounds detailed in Chapters 3-6 to determine their effects at the 
adenosine A1 receptor. These experiments have displayed the antagonistic-inverse agonistic 
behaviour typical of most non-ribose compounds. For example, from the compounds in 
Chapter 3, LUF 5767 (3.14) was tested in a whole cell cAMP assays in the presence of 
forskolin and CPA to determine its ability to antagonise the A1 receptor. Due to the adenosine 
A1 receptor’s coupling to an inhibitory G protein, which leads to a decrease in the levels of 
cAMP upon stimulation, forskolin was added to generate a measureable amount of cAMP in 
the system. The amount of cAMP generated by the sole addition of forskolin was thus set at 
100%. CPA, a well-known full agonist of the A1 receptor, reduced the levels of cAMP (set 
thus at 0%). At a concentration of 1 µM, 3.14 displayed antagonistic behaviour in the test 
system, generating cAMP levels at approximately 60% of the forskolin-induced levels. At a 
higher concentration of the compound (10 µM), the effects of CPA were reversed completely 
to such an extent that inverse agonistic behaviour was recorded. 
At the end of Chapter 7, the properties of the pyridine dicarbonitriles were matched to 
the model defined and refined earlier in this thesis. It can clearly be seen that the pyridine 
dicarbonitriles do possess some of the requirements defined by the model, and thus although 
not optimal for A1 binding according to the set criteria, the affinity was in a range to match. 
An interesting line of investigation would be the modification of these pyridine dicarbonitriles 
to be fully compatible with the pharmacophore, e.g., the exchange of the thioethanol group for 
a phenyl ring. The resulting ligand(s) may reveal clues to the activating components in the 
receptor. A systematic dissection of the pyridine dicarbonitriles, examining each section 
(substituent or functional group) methodically may also gauge the importance and influence 
upon activation of the receptor. In combining this with the pharmacophoric model defined 
earlier, more information may be gathered on the orientation of the ligand in the A1 receptor. 
Ensuing mutagenesis studies, in combination with computational work, may further determine 
the exact amino acids involved in receptor-ligand interactions and elicit clues towards the 
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 The adenosine receptors have been a well-explored field of research over the years. 
The therapeutic potential that is on offer by being able to manipulate these receptors is 
immense because the distribution of the receptors is so wide-spread in the physiological 
system. Chapter 1 begins with the introduction of the adenosine receptors and covers some of 
the investigations into potential therapeutic uses. Caffeine, as the archetypical adenosine 
antagonist and its wide consumption, is also given some attention in this introductory chapter. 
The scope and the general outline of this thesis are then detailed. 
The A1 receptor in particular has been investigated thoroughly and many different 
categories of ligands have been specifically synthesised and tested at this receptor. These 
encompass both the variety of different structures and the particular role that the ligand may 
fulfil, as an antagonist, an agonist or even a modulator in an allosteric binding position. 
Caffeine, as detailed in Chapter 1, is a well-known stimulatory ‘drug’ and most of its effects 
are a result of interactions with the adenosine A1 receptor. It is a member of the xanthine 
family of compounds and this class has become the prototypic example of adenosine A1 
receptor antagonists. There are, however, issues arising from the development of xanthines, 
regarding such problems as solubility, bioavailability and specificity for the adenosine 
receptors, and thus the design of non-xanthine antagonists evolved. 
The resulting vast assortment of non-xanthine antagonists is detailed in Chapter 2. 
Despite the large numbers of compounds that have been made, the eventual goal, adenosine 
A1 receptor ligands with the potential to be developed as an eventual medicine, is still a 
distant target. The scope therefore, to create compounds that possess ‘better’ characteristics, 
in terms of affinity, selectivity, activity, solubility, absorption or indeed novelty, to name but 
a few desirable properties, is tremendous. The general restriction to G protein-coupled 
receptor (GPCR) research (i.e., the lack of a fully disclosed binding site) means that 
notwithstanding the many years of investigations, there are still many unknowns in the 
discipline.  
Of the many approaches to understanding the adenosine A1 receptor, computer 
modelling has become one of the mainstays of recent years and has contributed immensely to 
the knowledge-base. These techniques include 3D modelling of the protein itself, 
incorporating the crystal structure of rhodopsin (a very different GPCR) and results from site-
directed mutagenesis studies. Another methodology is the so-called ligand-based approach, 
where the characteristics of the various different ligands that have shown good affinity for the 
receptor are compared and contrasted. The different computational practices have numerous 
advantages and disadvantages. It was the latter method that was chosen as the foundation of 
this thesis. Although the ligand-based approach has its limitations, it has generated 
pharmacophores and subsequent new ligand classes with positive effects at the receptors in 
question. Chapter 3 describes the use of such an approach. After a bout of intense research in 




investigations did not lead to any particular advances in the design and planning processes. 
The general rules for A1 adenosine antagonist design were that the structure should be (i) 
planar, (ii) aromatic and (iii) a nitrogen-containing 6:5 fused heterocycle. This did indeed lead 
to new compounds which displayed good affinity and selectivity for the A1 receptor, but new 
insight into the reasons were not so forthcoming. In the year prior to starting the research 
detailed in this thesis, two new series of compounds were revealed which did not altogether 
abide by these rules. One was the 6:6 naphthyridine series and the other was a series of 
thia(dia)zoles. It was thus a more than appropriate time to update the model and the 
accompanying ingrained mind-set. Molecular modelling of a number of highly active 
compounds revealed a surprisingly simple configuration of hydrogen-bonding aspects and 
lipophilic groups. A series of 4-amido-2,6-diphenyl-pyrimidines were then designed and 
synthesised based on this pharmacophore. The biological results were very encouraging. The 
most effective ligands possessed an affinity of 2 nM at the adenosine A1 receptor with a 
promising selectivity ratio.  
The most well-known effects of caffeine are primarily due to the blockade of receptors 
in the brain. For a compound to be active at the brain, it has to be able to penetrate the blood-
brain barrier (BBB). The BBB has been thoroughly investigated in recent years and 
computational/screening methods to predict its passage have become well-developed. The 
outcome of one such prediction method is to limit the calculated polar surface area (PSA) of a 
compound. Chapter 4 reports on the verification of a method to calculate the PSA and the 
application of it as a first parameter to predict the degree of penetration of adenosine A1 
receptor antagonists to the brain. A series of new ligands incorporating this new criterion were 
made. These 2-amido-4,6-diphenyl-pyrimidines were both within the preset PSA limits and 
were very effective at the adenosine A1 receptor. The best compound in terms of affinity, at 
less than 4 nM, was comparable to that in Chapter 3. However, the selectivity of this ligand 
(and in general, of the whole series) over the A2A and A3 receptors was better than that 
obtained for the 4-amido-2,6-diphenyl-pyrimidines.  
Fixing the hydrogen-bond accepting group corresponding to the oxygen of the amido- 
functionality of the aforementioned 4-amido-pyrimidines (Chapter 3) to the central aromatic 
ring gives rise to purine derivatives. Purines have been thoroughly explored as adenosine 
receptor antagonists, but some features have become almost institutional; namely the presence 
of the N6-amino moiety and the requirement of an N9-substituent. With the aid of the model 
proposed in Chapter 3, a fresh take on the purine ring was explored in Chapter 5. The 
resulting ligands produced some of the lowest Ki values for the A1 receptor in our group to-
date. In particular compound 5.31, LUF 5962, 8-cyclopentyl-2,6-diphenylpurine, at 0.29 nM 
was outstanding. The observations drawn from both this series of purines and the two 
preceding series of pyrimidines led to the refinement of the model described in Chapter 3.  
Analysing the 2-amido-pyrimidines in a similar manner as described in the preceding 




compliant with the criteria of the (refined) model; the extra nitrogen in the central core 
changes the planarity of the ring and is also superfluous to the hydrogen-bonding 
requirements. Exchanging this for a carbon atom generates the 1-deazapurine heterocycle. To 
confirm our observations from Chapter 5 and the subsequently adopted refinements to the 
model, a series of 1-deazapurines were made and tested. These investigations are recounted in 
Chapter 6 and the new refined model substantiated with the observation that five of the 
compounds displayed sub-nanomolar affinity. 
In a slightly different twist to this thesis, Chapter 7 describes the development of a 
series of compounds with a surprisingly different activity at the adenosine A1 receptor. The 
pyridine-3,5-dicarbonitriles were very selective for the A1 receptor and depending on the 
substituent at the 4-position of the pyridine ring, the activity ranged from being fully 
agonistic, comparable to the reference compound CPA, to displaying full inverse agonism in 
our test system.  
Finally, general conclusions about the research described in this thesis are drawn. This 
is also supplemented by an outlook on some potential aspects of research to be pursued, based 





 Adenosinereceptoren zijn al jarenlang het onderwerp van intensief wetenschappelijk 
onderzoek. Het bleek al snel dat deze receptoren wijdverspreid voorkomen in diverse 
fysiologische systemen van het menselijk lichaam en dus een belangrijke therapeutische 
potentie bezitten. Hoofdstuk 1 geeft een introductie over adenosinereceptoren (A1, A2A, A2B 
en A3) en behandelt enkele potentiële therapeutische toepassingen. Verder wordt hier 
aandacht besteed aan cafeïne, het schoolvoorbeeld van een adenosine-antagonist die op zeer 
grote schaal geconsumeerd wordt. Tenslotte wordt de doelstelling en de indeling van dit 
proefschrift aangegeven. 
 Met name aan de adenosine A1 receptor is de afgelopen jaren veel onderzoek verricht 
en diverse categorieën liganden zijn specifiek gesynthetiseerd voor, en getest op, deze 
receptor. Deze grote aantallen van verbindingen staan beschreven in Hoofdstuk 2. 
Desondanks is het uiteindelijke doel om adenosine A1 receptorliganden die een bepaalde rol 
vervullen, zoals die van antagonist, agonist of zelfs modulator/regulator op een allostere 
bindingsplaats, met de potentie om uiteindelijk als geneesmiddel ontwikkeld te kunnen 
worden, nog ver weg. De motivatie om verbindingen te synthetiseren met ‘betere’ 
eigenschappen wat betreft affiniteit, selectiviteit, activiteit, oplosbaarheid en absorptie, om 
maar een aantal wenselijke eigenschappen te noemen, is enorm sterk om deze redenen. De 
voornaamste beperking van het adenosine-onderzoek is het gebrek aan een volledig 
opgehelderde receptorstructuur, hetgeen betekent dat er nog steeds veel onbekende factoren 
zijn in dit onderzoek. 
 Van de vele mogelijke benaderingen om de adenosine A1 receptor te begrijpen is 
computermodellering één van de belangrijkste en het heeft de laatste jaren substantieel 
bijgedragen aan de hoeveelheid vergaarde kennis. De verschillende computertechnieken 
hebben zowel voor- als nadelen. De technieken behelzen 3D modellering van het 
receptoreiwit zelf, gebruikmakend van de kristalstructuur van rhodopsine (een ander GPCR 
eiwit) en de resultaten van sitegerichte mutagenesestudies. Een andere methodologie is de 
benadering die uitgaat van het ligand. Daartoe worden de structuren van verschillende 
liganden, met een bewezen goede affiniteit voor de receptor, driedimensionaal met elkaar 
vergeleken. De laatstgenoemde methode werd gekozen als uitgangspunt voor dit proefschrift. 
Hoewel de benadering uitgaande van het ligand zijn beperkingen kent, heeft deze methode 
modellen opgeleverd van waaruit nieuwe groepen liganden zijn ontwikkeld met de gewenste 
effecten op de bestudeerde receptoren. In Hoofdstuk 3 wordt de toepassing van een dergelijke 
benadering beschreven. Na een intensieve onderzoeksfase in de vroege jaren ’90, die een 
model opleverde voor het ontwerpen van adenosine A1 antagonisten, heeft vervolgonderzoek 
niet geleid tot daadwerkelijke vooruitgang van het ontwerp- en planningsproces. De algemene 
voorwaarden aan het ontwerp van adenosine A1 antagonisten waren dat de structuur (i) vlak, 
(ii) aromatisch en (iii) een stikstofhoudende 6:5 heterobicyclische verbinding diende te zijn. 




receptor, maar ging niet gepaard met nieuwe inzichten en mogelijke verklaringen hiervoor. In 
het jaar voorafgaand aan het in dit proefschrift beschreven onderzoek werden twee nieuwe 
series verbindingen gepresenteerd die niet voldeden aan deze regels. De ene was de 
6:6 nafthiridine serie en de andere was een serie thia(dia)zolen. Het was daarom meer dan 
gerechtvaardigd het model en de bijbehorende denkwijze te herzien. Moleculaire modellering 
van een aantal zeer actieve verbindingen liet een verrassend simpele configuratie van 
waterstofbruggen en lipofiele groepen zien. Een serie 4-amido-2,6-difenylpyrimidines, 
gebaseerd op deze farmacofoor, werd vervolgens ontworpen en gesynthetiseerd. De 
biologische resultaten waren zeer bemoedigend. De effectiefste liganden hadden een affiniteit 
van 2 nM voor de adenosine A1 receptor met een veelbelovende selectiviteit. 
 Cafeïne is een welbekend stimulerend middel en het belangrijkste deel van het effect 
is het gevolg van interacties met de adenosine A1 receptor. Cafeïne behoort tot de familie der 
xanthines, die het schoolvoorbeeld zijn van adenosine A1 antagonisten. De effecten die aan 
deze liganden worden toegeschreven zijn voornamelijk het gevolg van een blokkering van 
receptoren in de hersenen. Echter, een verbinding die effecten veroorzaakt in de hersenen 
moet in staat zijn om de bloed-hersen-barrière (BHB) te passeren. In de afgelopen jaren is aan 
deze BHB uitgebreid onderzoek verricht en de computationele en screeningsmethoden voor 
het voorspellen van de doordringbaarheid zijn sterk verbeterd. De uitkomst van een dergelijke 
methode is het stellen van een limiet aan de grootte van het berekende polaire oppervlak 
(polar surface area, PSA) van een verbinding. In Hoofdstuk 4 wordt verslag gedaan van de 
verificatie van een berekeningsmethode voor de PSA-berekening en de toepassing hiervan als 
de eerste parameter voor het voorspellen van de penetratiegraad van adenosine A1 
antagonisten naar de hersenen. Een serie nieuwe liganden die voldoen aan dit nieuwe 
criterium werd vervolgens bereid. Deze 2-amido-4,6-difenylpyrimidines voldeden aan de 
gestelde PSA-limiet en waren zeer effectief als liganden voor de adenosine A1 receptor. De 
beste verbinding wat betreft affiniteit, met een waarde van minder dan 4 nM, was 
vergelijkbaar met het beste ligand van Hoofdstuk 3. De selectiviteit van dit ligand (en van de 
serie als geheel) ten opzichte van de A2A en A3 receptor was beter dan die van de 
4-amido-2,6-difenylpyrimidines. 
 Het fixeren van de waterstofbrugacceptorgroep overeenkomend met het zuurstofatoom 
van de amidogroep van de eerdergenoemde 4-amidopyrimidines (Hoofdstuk 3) aan de 
centrale aromaatring resulteert in purinederivaten. Purines zijn uitgebreid onderzocht als 
adenosinereceptor antagonisten en enkele eigenschappen worden schier onmisbaar geacht, 
namelijk de aanwezigheid van een N6-aminogroep en de voorwaarde van een N9-substituent. 
In Hoofdstuk 5 werden met behulp van het model, zoals voorgesteld in Hoofdstuk 3, nieuwe 
purinederivaten ontwikkeld en gesynthetiseerd. De resulterende liganden leverden de hoogste 
affiniteit op die tot dusver in onze researchgroep gemeten is voor de A1 receptor. In het 
bijzonder verbinding 5.31, LUF 5962, 8-cyclopentyl-2,6-difenylpurine, met een Ki-waarde 
van 0.29 nM, is uitmuntend. De verkregen informatie van zowel deze serie purines als die van 
Samenvatting 
 137
de voorgaande twee series pyrimidines leidde tot een verfijning van het model uit 
Hoofdstuk 3. 
 Analyse van de 2-amidopyrimidines op eenzelfde manier als beschreven in de 
voorgaande paragraaf resulteerde in een serie triazolopyrimidines. Echter, triazolopyrimidines 
voldoen niet volledig aan de criteria van het (verfijnde) model en bezitten overbodige 
elementen. Het extra stikstofatoom in de centrale ring verandert wellicht de aromaticiteit van 
de ring en is tevens overbodig voor de waterstofbrugeisen. Door uitwisseling van dit 
stikstofatoom voor een koolstofatoom ontstaat 1-deazapurine. Een serie 1-deazapurines werd 
vervolgens gemaakt en getest om de waarnemingen uit Hoofdstuk 5 en de daaropvolgende 
verfijning van het model te bevestigen. Deze resultaten staan in Hoofdstuk 6 beschreven en de 
juistheid van het nieuwe verfijnde model werd bevestigd met de waarneming dat vijf van de 
verbindingen subnanomolaire affiniteit vertoonden. 
 Als een soort zijstap van dit proefschrift staat in Hoofdstuk 7 de ontwikkeling van een 
serie verbindingen met verrassend afwijkende activiteiten ten opzichte van de adenosine A1 
receptor beschreven. De 3,5-dinitrilpyridines blijken zeer selectief te zijn voor de A1 receptor 
en, afhankelijk van de substituent op de 4-positie van de pyridinering, blijkt de activiteit te 
variëren van volledig agonistisch, vergelijkbaar met de referentieverbinding CPA, tot volledig 
invers agonistisch. 
 Tenslotte worden algemene conclusies uit het onderzoek, beschreven in dit 
proefschrift, getrokken. Dit wordt gecompleteerd met enkele toekomstperspectieven inzake 







The morning coffee, the af-
ternoon tea, the mid-day (sugar-
free!) cola drink, these are all 
everyday rituals that many peo-
ple habitually partake in, in the 
name of ‘refreshment’, but 
w h a t  ex a c t l y  a r e  t h e 
‘refreshing’ properties common 
to these beverages? Most peo-
ple would hazard a guess at 
caffeine and they’d be correct. 
Caffeine is the major stimulant 
in some of our most popular 
drinks, with the ‘average’ cup 
of filtered coffee containing 
approximately 100 mg, (UK 
brewed) tea approximately 50 
mg and standard cola drinks 
between 40-50 mg. 
How and why does caffeine 
work? Caffeine acts at recep-
tors in the body. These recep-
tors you can imagine as small 
locks sitting in the surface of a 
cell. The body produces a sub-
stance that activates these re-
ceptors, acting much like a key 
where only the correct teeth or 
grooves fit to open the lock. 
The natural compound that acti-
vates these receptors is called 
adenosine and these receptors 
are called adenosine receptors. 
Caffeine works by blocking the 
receptor, like a key of the right 
size and shape, but with no 
teeth. A substance, like caf-
feine, which is able to block a 
receptor and not activate it, is 
called an antagonist. The 
adenosine receptors are found 
in many different areas of the 
De kop koffie vroeg in de 
morgen, de thee in de middagpauze 
en cola (light!) in de middag, het 
zijn voor veel mensen dagelijks 
terugkerende rituelen wanneer we 
een opkikker nodig hebben. Maar 
wat geeft deze versnaperingen 
eigenlijk precies hun opwekkende 
eigenschappen? De meeste mensen 
zouden waarschijnlijk 'cafeïne' 
gokken, en dat is inderdaad juist. 
Cafeïne is het voornaamste 
stimulerende middel in onze 
favoriete drankjes, met een gehalte 
van rond de 100 mg per kop 
filterkoffie, 50 mg per kop 
(Engelse) thee en tussen 40 en 
50 mg per glas cola. 
Hoe en waarom werkt cafeïne? 
Cafeïne grijpt aan op receptoren in 
het lichaam. Deze receptoren kan 
men opvatten als kleine openingen 
('sleutelgaten') aan de buitenkant 
van een lichaamscel. Het lichaam 
produceert een stofje dat deze 
receptoren activeert, op dezelfde 
manier als waarop een sleutel met 
de juiste groeven en tanden een slot 
kan openen. De stof in het 
menselijk lichaam die deze 
receptoren activeert is adenosine en 
d e  r e c e p t o r e n  w o r d e n 
adenosinereceptoren genoemd. 
C a f e ï n e  b l o k k e e r t  d e 
adenosinereceptor op dezelfde 
manier als een sleutel met de juiste 
afmetingen, maar zonder groeven 
en tanden. Een stofje als cafeïne, 
dat in staat is een receptor te 
blokkeren in plaats van te 
activeren, heet een antagonist. 
Adenosinereceptoren bevinden zich 



































Above – The lock and key analogy 
to adenosine and its receptor. 
 
Below – How adenosine works 
and how caffeine is able to block 
the receptor. 
Boven – De sleutel-slot analogie 
van adenosine en zijn receptor.  
 
Onder – De werking van adeno-
sine en de blokkering van de  
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body and there are four differ-
ent types of adenosine receptor. 
As levels of adenosine rise in 
the brain we become sleepier 
(that mid-afternoon dip). We 
then drink a cup of tea or coffee 
and the caffeine that we take in 
is able to sit in two of the four 
different types of adenosine 
receptors. It has been found that 
the blockade of the so-called A1 
adenosine receptors in the brain 
makes you feel more awake. 
The blockade of the A1 recep-
tors has also been found to be 
potentially useful in the treat-
ment of a range of diverse con-
ditions such as asthma, Alz-
heimer’s disease and kidney 
failure. An illustration of how 
adenosine and caffeine work 
can be found on the previous 
page. 
As a short aside for those 
who may be baffled by some of 
the chemistry terms in this pas-
sage,  ‘Compounds’ and 
‘substances’ are used here in-
terchangeably and refer to a 
chemical material. These com-
pounds are built up of a number 
of different atoms, which is the 
smallest part into which an ele-
ment can be reduced to. In the 
medicinal world, the most com-
mon and important atoms to 
know are C (carbon), H 
(hydrogen), N (nitrogen) and O 
(oxygen). An example is 
paracetamol, the structure of 
which is shown in the figure 
below. 
As mentioned earlier, caf-
het lichaam en er bestaan vier 
verschillende typen van. Als de 
adenosineconcentratie in de 
hersenen stijgt voelen we ons 
slaperig worden (de bekende 'after-
lunch dip'). Wanneer we dan een 
kop koffie of thee drinken kan de 
cafeïne die we binnenkrijgen twee 
van de vier adenosinereceptoren 
blokkeren. Uit onderzoek is 
gebleken dat blokkering van de 
zogenaamde A1 adenosinereceptor 
in de hersenen ons wakker en alert 
houdt. Daarnaast is ook bekend dat 
blokkering van de A1 receptor 
potentie heeft in de behandeling 
van aandoeningen als astma, de 
z iek te  van  Alzhe imer  en 
nierafwijkingen. De werking van 
a d e n o s i n e  e n  c a f e ï n e  i s 
geïllustreerd op de vorige pagina.  
Een korte toelichting voor 
diegenen die niet vertrouwd zijn 
met de chemische terminologie in 
deze samenvatting: 'stofje' en 
'verbinding' worden hier door 
elkaar gebruikt en verwijzen naar 
een chemisch product. Deze 
verbindingen zijn opgebouwd uit 
een reeks verschillende atomen, de 
kleinste ondeelbare onderdelen 
waaruit een element is opgebouwd. 
In de geneesmiddelenwereld zijn de 
m e e s t  v o o r k o m e n d e  e n 
belangrijkste atomen om te 
onthouden C (koolstof), H 
(waterstof), N (stikstof) en O 
(zuurstof). Ter illustratie is 
hieronder de chemische structuur 
van paracetamol weergegeven.  
Zoals eerder gezegd: 
cafeïne blokkeert meer dan één van 
de vier adenosinereceptoren en is 
dus niet selectief. Een ander 
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界 ， 最 常 见 的 原 子 是 C 
(碳 ) ,  H (氢 ) ,  N (氮 )  和  O  
(氧 )。举个例子，化合物
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feine is able to sit at more than 
one of the four adenosine re-
ceptors; another problem with 
caffeine is that it takes a fair 
amount of it to have an effect. 
If we would like to use such a 
substance as a medicine then 
we would like to use a much 
smaller amount of it and make 
sure it acts predominantly at 
one of four different types of 
receptor. Thus this project was 
based on designing and making 
new substances that act in very 
small amounts as antagonists at 
the adenosine A1 receptor. 
This is not a new idea, 
adenosine receptors have been  
well researched a target in me-
dicinal chemistry for more than 
twenty years, and the A1 recep-
tor in particular has had a lot of 
attention. However, although 
many compounds have been 
made aimed at the adenosine A1 
receptor, an actual medicine is 
still lacking despite its great 
potential. These compounds are 
summarised in detail in Chapter 
2, and most notable is the depth 
and variety of different struc-
tures. This collection of many 
years work was the starting 
point for this thesis. The initial 
work was to build up a model 
from which compounds could 
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grote hoeveelheden nodig zijn om 
een effect te genereren. Als we een 
verbinding als cafeïne als 
geneesmiddel zouden willen 
gebruiken zou dat in een veel 
lagere dosering, en met een effect 
op slechts één van de vier 
verschillende typen receptoren 
moeten zijn. Het doel van dit 
project was dan ook het ontwerpen 
en het maken van nieuwe 
verbindingen die zich in kleine 
doseringen gedragen als selectieve 
antagonisten voor de A1 receptor. 
Dit idee is zeker niet nieuw, 
aangezien adenosinereceptoren, 
met name de A1 receptor, al meer 
dan twintig jaar uitgebreid 
o n d e r z o c h t  z i j n  a l s 
a a n g r i j p i n g s p u n t  v o o r 
geneesmiddelen. Hoewel vele 
verbindingen gericht op de 
adenosine A1 receptor zijn gemaakt 
is er nog steeds geen geneesmiddel, 
de grote potentie van deze 
verbindingen ten spijt. Een 
overzicht van al deze verbindingen 
wordt gegeven in Hoofdstuk 2, 
waarbij vooral de grote variëteit 
aan structuren in het oog springt. 
Dit overzicht van jarenlange 
i n s p an n i n ge n  v o rmd e  h e t 
uitgangspunt voor het in dit 
proefschrift beschreven onderzoek. 
De eerste taak was het maken van 
een model met behulp waarvan 
nieuwe verbindingen ontworpen 
konden worden. Dit doel werd 
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the chemical structure of 
paracetamol,showing all the 
carbon, hydrogen, nitrogen 
and oxygen atoms 
paracetamol 
drawn in the 
conventional 
way used by 
scientists 






物性 质（ 如化 合物 的 形
状，大小和原子的分布）
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computerprogramma dat de 
eigenschappen (vorm, afmeting en 
rangschikking der atomen) van 
eerder gemaakte verbindingen kon 
analyseren. 
De analyse van deze eerder 
gemaakte verbindingen resulteerde 
in een model dat een aantal 
randvoorwaarden aangeeft waaraan 
een verbinding die op de A1 
receptor aangrijpt dient te voldoen 
(zie de Figuur hieronder). Na het 
definiëren van het theoretische 
model volgt de fase van het 
bewijzen van de juistheid ervan 
door middel van het ontwerpen, 
maken en testen van nieuwe 
verbindingen. In dit proefschrift 
staan vier series verbindingen 
beschreven die gebaseerd zijn op 
dit model. In Hoofdstuk 3 staat de 
eerste serie, de 4-amido-2,6-difenyl 
pyrimidines (de naamgeving is 
nader toegelicht in de Figuur). De 
serie bleek zeer succesvol en bevat 
enkele zeer actieve verbindingen. 
Aangezien we de eigenschappen 
van cafeïne willen nabootsen, met 
name de stimulerende effecten 
(voor toepassingen zoals tegen de 
ziekte van Alzheimer), dienen we 
er zeker van te zijn dat de 
verbindingen die we maken de 
be designed. This was achieved 
by using a computing package 
to analyse the properties of 
compounds that have been 
made before, in terms of their 
shape and size and actual atom 
distribution. 
Analysing these compounds 
in this way led to a ‘model’ 
being built. This model stipu-
lates a number of different con-
ditions that a compound should 
meet to be good at the A1 re-
ceptor (summarised in the illus-
tration below). Having obtained 
a theoretical model, proof 
comes with the design, synthe-
sis and testing of new struc-
tures. In this thesis, four series 
of substances have been made 
based on this model. The first 
one (Chapter 3) is a series 
called 4-amido-2,6-diphenyl 
pyrimidine (its naming scheme 
can be seen in the figure 
above). This was a very suc-
cessful series with some par-
ticularly potent compounds.  
Since we would like to copy 
some of the actions of caffeine, 
in particular the stimulatory 
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model derived from analysing many 
different compounds 
one compound in the series of 4-
amido-2,6-diphenyl pyrimidines 
central ring system 
e-ve 
e-ve e+ve 
Summary for Non-Scientists/ Samenvatting voor Leken/ 中文 
 
 
tions such as Alzheimer’s), we 
need to know that the com-
pounds we make reach the 
brain. In the body there is a 
physical barrier between the 
brain and the rest of the circula-
tory system. This is called the 
Blood-Brain Barrier (BBB) and 
is there to protect the brain 
from an assortment of different 
substances. It has been found 
that a compound has to hold 
certain assets to be able to cross 
the BBB. One of the ways of 
predicting this was effectively 
incorporated into the design of 
the second series in Chapter 4. 
Chapters 5 and 6 describe 
two more series of compounds 
that were created as adenosine 
A1 receptor antagonists. The 
series in Chapter 5 was made 
based upon a slight modifica-
tion of the series recounted in 
Chapter 3; this led to the most 
potent compound ever discov-
ered in our laboratories. The 
combination of the discoveries 
made in these three series led to 
the re-analysis and the refine-
ment of the model. The last 
series (Chapter 6) was thus syn-
thesised as a result of this, 
proving that the new model is a 
very good summary of the 
properties a compound should 
possess to be effective at the 
adenosine A1 receptor. 
The very last chapter of this 
thesis comes from a slightly 
different angle. Although we 
gain benefit from caffeine 
blocking the effects of adeno-
verbindingen die we maken de 
hersenen kunnen bereiken. Het 
lichaam heeft een fysieke barrière 
tussen de hersenen en de rest van 
d e  b l o e d s o m l o o p .  D e z e 
zogenaamde bloed-hersen-barrière 
(BHB) beschermt de hersenen 
tegen een groot aantal schadelijke 
stoffen. Het is gebleken dat een 
v e r b i n d in g o v e r  b e p a a l d e 
eigenschappen dient te beschikken 
om de BHB te kunnen passeren. 
Eén van de manieren om dit te 
kunnen voorspellen is toegepast om 
een tweede serie verbindingen te 
ontwerpen, dit staat beschreven in 
Hoofdstuk 4. 
In de Hoofdstukken 5 en 6 staan 
tot slot twee series verbindingen 
beschreven die als adenosine A1 
antagonist zijn ontworpen. De 
verbindingen van Hoofdstuk 5 zijn 
het resultaat van een kleine 
modificatie van de serie uit 
Hoofdstuk 3; dit heeft geresulteerd 
in de actiefste verbinding ooit 
gemaakt in ons laboratorium. De 
ontdekkingen die volgden uit deze 
eerste drie series verbindingen 
hebben geleid tot een verdere 
verfijning van het model. De laatste 
serie verbindingen is hierop 
gebaseerd en het bewijs werd 
geleverd dat het verfijnde model 
een nauwkeurige beschrijving is 
van de essentiële eigenschappen 
van een effectieve verbinding voor 
de A1 receptor. 
In het laatste Hoofdstuk van dit 
proefschrift is voor een iets andere 
invalshoek gekozen. Hoewel we 
gebaat zijn bij het blokkerende 
effect van cafeïne op de werking 
van adenosine in de hersenen kan 
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sine in the brain, it can be 
therapeutically beneficial to 
replicate the effects of adeno-
sine in other parts of the body. 
For example, the activation (as 
opposed to the blockade) of 
adenosine A1 receptors has 
been shown to be able to return 
an irregularly high heartbeat to 
normal sinus rhythm. Adeno-
sine can only exist in the body 
for about 1 second, that is to 
say it is very quickly broken 
down by the body. So the use 
of adenosine itself is very lim-
ited – it is used as a direct in-
jection into the heart in emer-
gency situations when patients 
show an irregularly high heart 
rate. Compounds that can 
mimic the effect of adenosine 
are called agonists. Chapter 7 
describes a new series of com-
pounds, which although are 
very similar in size and shape 
have very different effects at 
the adenosine receptor. Some of 
these substances act as agonists 
whilst others as antagonists. 
The most noteworthy factor of 
this chapter is the fact that these 
compounds look nothing like 
adenosine; to date all other sub-
stances that did not resemble 
adenosine could not activate the 
receptor. 
Having conducted four years 
of research in this topic, de-
vised a model and proved its 
worth with a number of differ-
ent series of compounds, does 
this mean that ‘the end’ is in 
sight? I’m afraid the answer is 
therapeutisch wenselijk zijn de 
effecten van adenosine te copiëren. 
Verbindingen die het effect van 
adenosine kunnen nabootsen 
worden agonisten genoemd. De 
ac t ive r ing ( in  p laa t s  van 
blokkering) van adenosine A1 
receptoren, bijvoorbeeld, blijkt een 
ongewoon hoge hartslag terug te 
brengen naar een normaal 
sinusoïdaal ritme. Adenosine kan 
slechts ongeveer één seconde 
bestaan in het lichaam omdat het 
zeer snel wordt afgebroken. De 
toepasbaarheid van adenosine is 
daarom beperkt – het wordt wel 
gebruikt voor directe injectie in het 
hart in noodsituaties bij patiënten 
met een ongewoon hoge hartslag. 
In Hoofdstuk 7 wordt een nieuwe 
serie verbindingen besproken die, 
hoewel erg op elkaar gelijkend wat 
betreft vorm en afmeting, zeer 
uiteenlopende effecten op de 
adenosine A1 receptor hebben. 
Sommige van deze verbindingen 
gedragen zich als agonist en andere 
als antagonist. Het opvallendste 
aspect in dit Hoofdstuk is het feit 
dat deze verbindingen in het geheel 
niet lijken op adenosine; tot dusver 
zijn alle verbindingen die niet op 
adenosine lijken niet in staat 
gebleken om de adenosinereceptor 
te activeren. 
Na vier jaar onderzoek gedaan te 
hebben aan dit onderwerp, een 
model ontworpen te hebben en de 
waarde hiervan bewezen te hebben 
met een groot aantal verbindingen, 
kan nu de vraag gesteld worden of 
‘het einde’ in zicht is. Ik ben bang 
dat het antwoord hierop ‘nee’ is, 
nog niet. Een medicijn tegen de 
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no, not yet. That cure for Alz-
heimer’s is still a long way off. 
This is just one step towards 
such a heady target. We know 
that these compounds have an 
effect at the adenosine A1 re-
ceptor (and not at the other 
adenosine receptors), but we do 
not know the (other) effects it 
may have in a real live system. 
These compounds have to be 
tested further; amongst which, 
the way that it is taken up and 
spread about a bodily system 
has to be investigated, the tox-
icity of the compounds has to 
be assessed, and the speed with 
which this all happens is also a 
matter of research. In all, I hope 
I can summarise my achieve-
ments by saying that I have 
made a good, solid contribution 
to the understanding and ad-
vancement of adenosine recep-
tor research. 
ver weg. Dit proefschrift is een 
stapje in de goede richting van zo’n 
groot doel. We weten nu dat de 
gemaakte verbindingen een effect 
hebben op de adenosine A1 receptor 
( e n  n i e t  o p  d e  a n d e r e 
adenosinereceptoren), maar we 
weten nog niet welke andere 
effecten er zullen zijn in een levend 
organisme. Deze verbindingen 
zullen dus verder getest moeten 
worden; de manier van opname en 
verspreiding door het lichaam dient 
onderzocht te worden, de giftigheid 
van de verbindingen moet 
onderzocht worden en de snelheid 
waarmee  de  versch i l l ende 
processen plaatsvinden is van 
belang.  
Tenslotte, mijn resultaten 
samenvattend, hoop ik te kunnen 
zeggen dat ik een duidelijke 
bijdrage heb kunnen leveren aan 
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List of Abbreviations 
 
Asp  Aspartic acid 
ATP   Adenosine triphosphate 
BBB  Blood-brain barrier 
Bn  Benzyl 
Bu  Butyl 
cAMP  Cyclic adenosine monophosphate  
CHO  Chinese hamster ovary 
CNS  Central nervous system 
CPA  N6-Cyclopentyladenosine 
DMF  Dimethylformamide 
DMSO  Dimethylsulfoxide  
DPCPX 1,3-Dipropyl-8-cyclopentylxanthine 
Et  Ethyl 
GDP  Guanosine diphosphate 
GPCR(s) G(uanylyl-nucleotide-binding) protein-coupled receptor(s) 
GTP  Guanosine triphosphate 
HEK  Human embryonic kidney 
Hex  Hexyl 
His  Histidine 
IC50  Inhibitory concentration (50%)  
Ki  Equilibrium inhibition constant 
Me  Methyl 
NMR  Nuclear magnetic resonance 
Pent  Pentyl 
Ph  Phenyl 
Pr  Propyl 
PSA  Polar surface area 
RT  Room temperature 
SAR  Structure activity relationship  
Ser  Serine 
TCM  Traditional Chinese medicine 
THF  Tetrahydrofuran 
THP  Tetrahydropyran 
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